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I. Summary 
Pharmacoepidemiology studies use and effects of drugs in large numbers of people. It allows 
the investigation and quantification of rare beneficial or adverse events of drugs used by the 
general population under “real-world” conditions. Pharmacoepidemiologic research strongly 
depends on and has been facilitated by the development of large scale health care databases. 
Among these the U.K. Clinical Practice Research Datalink (CPRD) stands as one of the 
largest and best validated medical records databases worldwide. The CPRD was initiated 
more than 25 years ago and contains records on diagnoses, drug prescriptions, demographics, 
lifestyle variables and medical procedures performed from over 12 million patients 
contributing 64 million person-years of prospectively recorded primary healthcare data.  
CPRD data was employed in all studies carried out in this thesis. The goal was set to identify 
and analyze risk factors for new-onset seizures in patients with neuropsychiatric disorders. 
While it has long been suspected that patients suffering from neuropsychiatric disorders 
exhibit an increased risk of new-onset seizures no significant real-world evidence exists on 
risk factors associated with these seizures. 
We first investigated risk factors for new-onset seizures in adult patients with depression. Our 
results suggest that patients suffering from depression were at an increased risk of seizures if 
they abused drugs, suffered from alcoholism, had a history of cerebrovascular disease or 
recent brain injury, comorbid dementia, or comorbid psychiatric disorders. Additionally we 
found current users of cephalosporins or antiarrhythmics to be at an increased risk of seizures 
compared with non-users of these drug classes. 
In a follow-up study we assessed the association between antidepressant drug use and new-
onset seizures in adult patients with depression. Our data suggest that the absolute risk of 
seizures in this population was rare, irrespective of whether patients used antidepressants or 
not. Additionally we found that the use of selective serotonin reuptake inhibitors (SSRIs) or 
serotonin norepinephrine reuptake inhibitors (SNRIs) was associated with a twofold increased 
risk of seizures compared to non-use. However, tricyclic antidepressants (TCAs) at low doses, 
as prescribed in this primary care setting, were not associated with seizures. Among users of 
SSRIs and SNRIs, treatment initiation was associated with a higher risk of seizures compared 
to longer-term treatment. Finally, we could demonstrate that higher doses of antidepressants 
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prescribed were associated with an increased risk of seizures than lower doses, although small 
sample sizes limited conclusiveness. 
In the final study of this thesis, the potential association between antipsychotic drug use and 
new-onset seizures among patients with different underlying neuropsychiatric disorders was 
investigated. The results obtained in this study demonstrate that the association between 
antipsychotic drug use and seizures was strongly modified by the underlying neuropsychiatric 
indication. Our data shows that patients with dementia exhibited a significantly higher risk of 
seizures than patients with affective disorders, irrespective of the use of antipsychotics. 
Additionally, in patients with affective disorders, current use of medium to high potency first-
generation antipsychotics (haloperidol, prochlorperazine, or trifluoperazine) was associated 
with a more than twofold increased risk of seizures compared to non-use of antipsychotics. In 
all of these patients, use of all other antipsychotics was not associated with new-onset 
seizures. In patients with dementia, current use of the second-generation antipsychotics 
amisulpride, aripiprazole, risperidone, or sulpiride, was not associated with seizures, while 
current use of all other antipsychotics was associated with an increased risk of seizures.  
We found that the inability to adjust for confounding by disease severity, the unproven 
validity of the diagnoses of affective disorders and seizures, and the limited sample sizes in 
sub-analyses posed a certain limit to our studies. 
Nevertheless, all studies carried out in this thesis provide new insight into the poorly 
understood relationship between neuropsychiatric disorders and new-onset seizures. Formally 
quantifying the occurrence of seizures and assessing risk factors for seizures among this 
restricted study population was only feasible through access to the large existing data set 
comprising detailed patient information available from the CPRD.  
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II. Abbreviations 
ADHD  Attention deficit hyperactivity disorder 
AMPA   Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
BCE   Before the Christian Era 
BCDSP  Boston Collaborative Drug Surveillance Program 
BMI   Body mass index 
BPU   Basel Pharmacoepidemiology Unit 
CI   Confidence interval 
CNS   Central nervous system 
CPRD   Clinical Practice Research Datalink 
CT   Computed tomography 
DDD   Defined daily dose 
EEG   Electroencephalogram 
FFDCA  Federal Food, Drug and Cosmetic Act 
GP   General Practitioner 
GABA   Gamma-aminobutyric acid 
GPRD   General Practice Research Database 
IR   Incidence rate 
MRI   Magnet resonance imaging  
NA   Not applicable 
NMDA  N-Methyl-D-aspartic acid 
OR   Odds ratio 
PYs   Person-years 
RCT   Randomized Controlled Trial 
SNRI   Serotonin norepinephrine reuptake inhibitor 
SSRI   Selective serotonin reuptake inhibitor 
TCA   Tricyclic antidepressant 
TIA   Transient ischemic attack 
U.S.   United States 
U.K.   United Kingdom 
VAMP   Value Added Medical Products
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1. Introduction 
1.1 Pharmacoepidemiology 
1.1.1 Defining pharmacoepidemiology 
Pharmacoepidemiology, a subdiscipline of epidemiology, investigates use and effects of 
drugs in large numbers of people.1,2 Combining clinical pharmacology (i.e., the study of 
effects of drugs in humans) with epidemiology (i.e., the study of factors that influence or 
determine the occurrence and distribution of health-related states or events in 
populations),2–4 pharmacoepidemiology is primarily used to study large populations of 
individuals, contrary to clinical pharmacology.1 
1.1.2 Historical development of pharmacoepidemiologic studies 
Before the 1950s, little proof was demanded in terms of safety and efficacy prior to 
introducing new drugs to the market.1 Only upon occurrence of harmful events associated 
with drug use, regulatory actions were taken to ensure drug safety. 
One of the most far-reaching drug scandals was the extensive prescription of thalidomide, 
a sedative drug, to pregnant women.5 At the time thalidomide showed no toxic effects in 
animals and was thus assessed and advertised as safe for use in pregnancy.5 Thalidomide 
was introduced to the European market in 1957, and withdrawn only four years later.5 
During this period of time, it caused birth defects in more than 10,000 children who were 
born with missing limbs or limb anomalies.5 
In 1962, the U.S. government thus made amendments to the Federal Food, Drug and 
Cosmetic Act (FFDCA), requiring formal proof of efficacy and relative safety in terms of 
risk-to-benefit ratio for any disease to be treated.6 The 1962 amendments to the FFDCA 
enforced the process leading to the establishment of so-called clinical trials, which are 
nowadays standard procedure prior to placing a new drug on the market.6 
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1.1.3 Clinical trials and the role of pharmacoepidemiology 
Clinical trials are used to investigate pharmacokinetic and pharmacodynamic properties 
of a drug, and to evaluate a drug’s efficacy, safety, and tolerability.6 They are carried out 
in a series of subsequent steps, so-called phases, where each phase is designed to 
investigate a specific aspect of the process of drug development (see Figure 1 for details). 
 
Figure 1: Clinical trials are carried out in a step-wise manner. Each phase of the trial aims to answer a 
specific question. Figure adapted from6. 
1.1.3.1 Clinical trials: phase I to III 
Phases I to III of clinical trials are limited in sample size and observational duration (as 
shown in Figure 1).  
These initial phases of clinical trials are conducted in a well-defined, yet artificial 
environment, where specific patient subgroups (e.g., elderly patients, polymorbid patients 
who use various drugs, women of childbearing age, and children) are excluded from the 
analysis.6 
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1.1.3.2 Clinical trials: phase IV 
As the drug is placed on the marked and thus used by the general population, including all 
patient subgroups, phase IV of clinical trials is initiated. The so-called post-marketing 
surveillance phase studies beneficial and adverse effects of drugs in the general 
population.3 Since drugs are often used over longer periods of time in “real life” than in 
phases I to III of clinical trials, phase IV investigates rare or delayed adverse or beneficial 
effects that were not noticed prior to market introduction.1  
The post-marketing surveillance comprises pharmacovigilance and 
pharmacoepidemiology studies. Pharmacovigilance studies are based on spontaneous 
reporting systems of adverse drug events, and are important to detect signs of adverse 
events not seen in phases I-III of clinical trials.7 Such reports are however difficult to 
interpret; only a small (unknown) proportion of suspected adverse events of drugs are 
reported spontaneously, and adverse events are more likely reported if they are serious, or 
if the drug has received a lot of media attention.3,7,8 
Formal quantification and investigation of adverse drug events is done in 
pharmacoepidemiologic research.1,8 Therefore, it is essential to know the number of 
people exposed and not exposed to the drug under investigation, as well as the number of 
people in each group who developed the outcome in question. In conclusion, the major 
goal of pharmacoepidemiologic research is to describe drug utilization patterns under 
“real life” conditions and to quantitatively investigate previously undetected beneficial or 
adverse drug effects.1 
1.1.4 Association types in pharmacoepidemiology 
Pharmacoepidemiology investigates potential associations between drug exposure and 
beneficial or adverse outcomes. An association is defined as two events (i.e., drug 
exposure and outcome under investigation) occurring together repeatedly, with this 
repeated occurrence taking place more often than a chance occurrence.3 The following 
four scenarios can result from investigating such potential associations: No association, 
artifactual associations, indirect associations, or causal associations.9 
Introduction  Pharmacoepidemiology 
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1.1.4.1 No association 
No association between exposure and outcome is observed when exposure and outcome 
are in fact independent of one another or when the power of the study was too low to 
detect an association. 
The power of a study can be defined as the probability to detect an association between 
exposure and outcome if the association exists.2 The power increases with the precision of 
the outcome variable, the strength of the association, the sample size, and increased α-
level (refer to 1.1.4.2).10 
1.1.4.2 Chance and bias – two types of artifactual associations 
Chance (i.e., random error), is a random variation due to every study being performed on 
only a sample of the entire population while inferring from this subset to the whole 
population. Depending on the analyzed sample results will vary due to irregular 
variations. Random errors associated with the results obtained from analyzing such 
subsets will decrease with increasing sample size.2,4,8 
Whether associations observed between exposures and outcomes are due to chance or not 
can be assessed by statistical testing. First, an (arbitrarily) selected level, the α-level, is 
set. The α-level specifies the probability P that an association is due to chance only when 
in reality no association exists.4 As a standard, an α-level of 0.05 is chosen, referring to 
the P-level reported in most pharmacoepidemiologic studies.4,10A reported association 
between a specific exposure and outcome with a P-value smaller than 0.05 (P<0.05) is 
interpreted as a statistically significant association, thus ruling out the possibility of a 
chance finding with a confidence of greater or equal to 0.95 (≥ 95%).8,9 P-values do not 
convey a message on the strength or the relevance of an association; they simply convey a 
message on how unlikely an observed association would be if in reality there was no 
association.10  
In contrast to chance, bias (i.e., systematic error), is a systematic variation due to treating 
or evaluating two study groups consistently differently. Unlike chance, bias is insensitive 
to sample size and cannot be ruled out by statistical testing.8 
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Bias can cause an apparent association between exposure and an outcome when in reality 
no association exists.9 It is therefore important to prevent bias by selecting a proper study 
design since it cannot be controlled for after study completion. The literature 
distinguishes broadly between two types of bias: selection and information bias. 
Selection bias refers to situations in which the estimated effect of an exposure on an 
outcome is distorted due to procedures used to select subjects for study participation.2,8 
For example, if study participation is voluntary, participators might differ systematically 
in exposure and outcome status from those declining participation; since the association 
between exposure and outcome among nonparticipants is unknown, so is the degree of the 
systematic error introduced.8 
Information bias refers to situations in which the estimated effect of an exposure on an 
outcome is distorted because the information collected on exposure and/or outcome is 
erroneous.8 Common types of information bias are measurement bias (i.e., measurement 
of exposure or outcome is not done in a comparable way in groups to be compared), 
recall bias (i.e., individuals affected by the outcome remember exposures differently than 
individuals not affected by the outcome), or interviewer bias (i.e., interviewers behave 
differently with the groups to be compared).8 
1.1.4.3 Indirect associations 
Indirect (“spurious”) associations result from confounding. Confounding variables are 
variables other than the exposure or outcome under investigation. They are associated 
with the exposure (without being an effect of the exposure) and are risk factors for the 
outcome, creating an apparent association or masking a real association between exposure 
and outcome.8,9  
An example of a confounder is the apparent association between wearing leather shoes in 
bed at night and suffering from a headache the morning after. One could claim that 
wearing leather shoes at night causes headaches, when in reality it is heavy drinking 
associated with forgetting to take off the shoes before going to bed.11  
Confounding in pharmacoepidemiologic studies can be limited if the existence of a 
confounder is known and if the confounder can be measured.8 This can be done by 
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restricting the study population (i.e., exclusion of individuals with potential confounders), 
matching cases and controls (in case-control analyses) or exposed and non-exposed 
individuals (in cohort studies) on potential confounders, stratifying the analyses by the 
potential confounder, or mathematical adjustments in the analysis.8 
1.1.4.4 Causal associations 
The primary aim of pharmacoepidemiologic research is to determine whether a certain 
exposure is causally associated with a specific outcome. However, statistical testing 
cannot assess causality and thus an observed association can, even when statistically 
significant, be simply due to bias or confounding (see previous chapters for a discussion 
of these factors). 
Nevertheless, certain criteria that were developed in 1965 by Sir Austin Bradford Hill,12 
can be applied to assess the likelihood of a causal association. The most important of 
these criteria for pharmacoepidemiologic research, and their respective meanings, are 
summarized in Table 1.  
Table 1: Bradford Hill criteria and their respective meanings used to assess causality in pharmacoepidemiologic studies 
(summarized from12).  
Criterion Meaning 
Strength of the association The stronger the association the more likely a causal link. 
Consistency The association has been observed by different investigators, in different places and 
times, and under different circumstances. 
Temporality The exposure must precede the outcome. 
A typical pitfall: a drug is taken for early signs of a disease which has not yet been 
diagnosed. The temporal sequence suggests that the drug causes the disease, when in 
reality the disease started before the drug exposure. 
Dose-response relationship The higher the exposure (e.g. an increase in drug dose) the greater the effect (e.g. 
adverse event). 
Biological plausibility/Coherence 
with existing information 
Good general theory to explain a causal link.  
The association makes sense taking into account the evidence from the literature; 
however this criterion strongly depends on the available literature.  
This criterion is never absolute, as knowledge changes over time, and so does 
plausibility that something is true. 
Experimental evidence Changing the exposure under controlled conditions causes a change in the outcome. 
Reversibility Removal of exposure leads to decline in outcome. 
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None of these “Bradford Hill criteria” are considered sufficient to prove causality.12 
However, the more criteria are met, the more likely an association is causal.9 Thus, any 
observed association in pharmacoepidemiology has to be interpreted in the context of the 
best evidence available at the time the study is carried out.9 
1.1.5 Study designs in pharmacoepidemiology 
Pharmacoepidemiologic research is frequently categorized into observational studies 
(descriptive studies, analytical studies) and interventional studies (e.g. randomized 
controlled trials).13 Depending on the purpose of the research, some study designs are 
better suited than others (refer to the subsequent chapters for discussion of the different 
study types). 
1.1.5.1 Observational studies 
Observational studies are categorized into descriptive or analytical studies and are used to 
investigate drug utilization patterns and drug safety.13 A major advantage of observational 
studies is that they can be applied if interventional studies are unethical (e.g., if an 
exposure is known to be harmful), unnecessary (e.g., if an intervention is already proven 
to be efficient), or not feasible (e.g., if the outcome is rare or delayed).14 
1.1.5.1.1 Descriptive studies 
Descriptive studies are employed to characterize existing distributions of exposures or 
outcomes without investigating causal inferences.2 Descriptive studies are useful for 
generating hypotheses, although they cannot be applied to determine whether exposure or 
outcome occurred first.15 Additionally, due to the lack of comparison groups, no causal 
associations can be determined.2,13,15 In the following, the different types of descriptive 
studies including case reports, case series, ecologic studies, and cross-sectional studies are 
discussed. 
Case reports describe the experience of one patient while case series describe the 
experience of several patients when using a particular drug (e.g., what clinical features are 
observed after a drug overdose?). Case reports and case series do not provide sufficient 
evidence for making causal inferences, but they often give rise to hypotheses.13 For 
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example, several authors reported seizures as an adverse event in patients using second-
generation antipsychotics such as quetiapine, aripiprazole, or olanzapine, in therapeutic or 
in overdoses.16–20 
Ecologic studies do not investigate data from individual patients, but from groups. These 
studies can be useful to describe differences in the prevalence of certain exposures and 
outcomes between groups or countries.13 However, no conclusions can be drawn at the 
individual level, because confounding factors of the individuals are unknown.13 In a 
recent study the correlation between antidepressant prescribing patterns in Organization 
for Economic Co-operation and development (OECD) countries and the rates of suicide 
was assessed.21 While a weak positive correlation between antidepressant use and suicide 
was observed between countries, no inference could be made at a person’s individual risk 
of suicide associated with the use of antidepressants.21  
In cross-sectional (prevalence) studies, a certain exposure or outcome in a population is 
assessed at a specific point in time, or during a specific time span. The prevalence of an 
exposure or outcome is defined as the total number of individuals who have the exposure 
or outcome under investigation at a particular time (or over a particular time span), 
divided by the population at risk of having this exposure or outcome at that time (or over 
that particular time span).2 The prevalence of an exposure or outcome in a population is 
often reported as a percentage. Examples of cross-sectional studies are investigations on 
lifetime prevalence estimates of major depression across different countries.22,23 
1.1.5.1.2 Analytical studies 
Analytical studies assess and quantify the association between exposures and outcomes.2 
Cohort and case-control studies are two main study types used to test hypotheses on the 
etiology or risk factors for an outcome. 
Cohort studies identify the study population based on exposure status, as described in the 
following two paragraphs summarized from24. The population is followed over time to 
investigate differences in outcomes between the different exposure groups. In their 
simplest form, cohort studies compare exposed individuals (i.e., individuals with the 
alleged risk or protective factor) to unexposed individuals (i.e., individuals not having this 
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factor) with regard to subsequent outcome frequency. In more elaborate settings, different 
exposure groups can be studied simultaneously.  
In cohort-studies, the study population is initially outcome-free and the occurrence of the 
outcome is measured over time. This type of study can be performed prospectively (i.e., 
data on exposure and outcomes is collected while the study is conducted) or 
retrospectively (i.e., data on exposure and outcomes is already available at the time the 
study is conducted) (see Figure 2, upper part). 
 
Figure 2: Settings of cohort and case-control studies (adapted from24,25). 
For example, a British cohort study published in 2011 assessed the association between 
the use of tricyclic and related antidepressants, monoamine oxidase inhibitors, selective 
serotonin reuptake inhibitors, or other antidepressants, and severe adverse events, in 
depressed patients aged 65 or over.26 
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In a case-control study, the study population is identified based on outcome status. Cases 
with an outcome are compared with controls without the outcome, looking for differences 
in antecedent exposures (see Figure 2, lower part).25 
In a case-control study conducted between 1995 and 1999, the cases were all Icelandic 
patients aged 10 years or over who had a first unprovoked seizure; for each case, a 
suitable age-matched control who did not have seizures up to the time the case had a 
seizure was identified.27 The odds ratio of antecedent major depressive disorder was 1.7-
fold increased among cases compared with controls, suggesting that major depressive 
disorder is a risk factor for first unprovoked seizures.27 
Table 2 summarizes advantages and limitations of cohort studies and case-control studies.
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Table 2: Differences between cohort- and case-control studies, and advantages and limitations of both study designs.9,13,24,25,28 
 Cohort study Case-control study Comments 
Sample size Large  Usually smaller than cohort study  
Time Slow  Rapid Not an issue for retrospective database 
research using medical records  
Cost High  Usually smaller Not an issue for retrospective database 
research using medical records  
Analysis Computationally more complex than case-control studies Computationally easier than cohort studies Especially if time-dependent exposures 
are analyzed 
More suited for  Rare exposures: special groups with a high frequency of 
the exposure can be identified and included in the study 
population 
Rare outcomes: a sufficiently large number of cases 
with the outcome can be included  
 
Outcomes to be studied Multiple Just one In case-control studies, it is important to 
ensure that the exposure occurred prior to 
the outcome 
Exposures to be studied Just one Multiple  
Measures All measures, including incidence rates, attributable risks, 
and relative risks 
Only odds ratio: incidence rates cannot be 
calculated as the size of the population at risk is 
unknown 
The odds ratio is a valid estimate of the 
relative risk if: 1) the cases are 
representative of the population at risk, 2) 
the controls are randomly selected from 
the population giving rise to the cases, 3) 
the outcome is rare in the population at 
risk (<5%) 
Validity of exposure data Generally higher than in case-control studies (as 
participants are selected based on their exposure) 
Generally lower than cohort studies: retrospective 
assessment of exposure limits its validity 
Not an issue for retrospective database 
research using medical records  
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Table 2 (cont.)    
 Cohort study Case-control study Comments 
Comparison of exposed and 
unexposed groups/ cases and 
controls  
Exposed and unexposed individuals must be as similar as 
possible at baseline in all aspects except the exposure 
under investigation 
Controls should be selected from the same 
population that gave rise to the cases 
 
Causal relationships More reliable: all subjects are outcome-free at the 
beginning (temporal relationship given), and exposure 
information can be more accurately assessed  
Less reliable: temporal relationship not as easily 
identified, exposure information can be biased  
Not an issue for retrospective database 
research using medical records  
Introduction  Pharmacoepidemiology 
13 
 
Generally one refers to a nested case-control study when the population within which a case-
control study is conducted is well defined.8 Nested-control studies rely on the advantages of 
both cohort and case-control studies.  
The following paragraph represents a summary of28: 
In a nested case-control study a cohort of individuals is followed until they develop the 
outcome under investigation or until their follow-up ends due to other reasons (e.g., death or 
loss to follow-up). The analysis is then conducted as a case-control analysis. The individuals 
who developed the outcome are defined as cases, and the date of their outcome is named 
index date. The individuals who did not develop the outcome up to the index date of the case 
are potential controls. Instead of analyzing the whole original cohort of individuals (as is 
done in cohort studies), only the cases and a defined number of all potential controls are 
analyzed. Thus, nested case-control studies are well suited to investigate time-dependent 
exposures (e.g., drugs in a large cohort of individuals followed over many years). In such 
cases, nested case-control analyses are computationally less complex than analyses of the 
entire cohort. 
Additionally, nested case-control studies are advantageous if exposure information is costly 
(e.g., analyses of blood samples), and when seeking this information for everyone in the 
cohort is too expensive.8 
1.1.5.2 Experimental (interventional) studies 
The following paragraph represents a summary of4: 
Experimental studies are cohort studies in which the exposure status is determined by the 
investigators. This study design allows testing the efficacy or risk of an intervention. In 
randomized control trials (RCTs), the intervention is allocated randomly (i.e. the assignment 
is unpredictable). The major strength of this design is that investigators cannot allocate the 
intervention, thus all patients are as likely to receive it. Thus, in large RCTs the groups with or 
without the intervention are likely to be similar with regard to potential confounding variables 
(e.g., age, sex, severity of disease).  
As selection bias and confounding are avoided, associations demonstrated in RCTs are more 
likely to be causal than those demonstrated in observational studies.9 However, RCTs lack 
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generalizability, since they cannot assess safety issues in large populations of individuals who 
use drugs under everyday conditions in clinical practice.29  
1.1.6 Data sources in pharmacoepidemiology 
The increased availability of large health care databases has facilitated 
pharmacoepidemiologic studies. Thus, drug utilization or safety studies can be conducted in 
subgroups of patients that were excluded from clinical trials. Additionally, if multiple years of 
patient follow-up data are available, assessment of long-term safety of drugs is possible.3  
Available databases can be divided into the two main categories medical records databases 
(data is collected by physicians [usually primary care providers] who enter information on 
patients while providing medical care) and administrative databases (data is collected 
primarily for administrative purposes, such as reimbursement of health care services).29,30 
One of the largest and best validated medical care databases worldwide is the U.K. Clinical 
Practice Research Datalink (CPRD).31 This database was established in 1987 as ‘Value Added 
Medical Products (VAMP)’ database, and was long known as ‘General Practice Research 
Database (GPRD)’.32 In 2011, the CPRD contained records from more than 12 million 
patients contributing 64 million person-years of prospectively recorded primary healthcare 
data.33 
The U.K. health care system is particularly suitable for establishing primary care research 
databases such as the CPRD, as almost every person in the U.K. is registered with a general 
practitioner (GP) who functions as a ‘gate-keeper’ in the healthcare system. Secondary care 
(specialist care, hospital care, etc.) is either provided at the request of the GP, or if directly 
assessed, full disclosure from secondary care is reported back to the GP.33 Through this 
prospective recording by the GPs and the nearly complete medical histories of patients, this 
database is especially valuable for pharmacoepidemiology.  
While prescription data is nearly completely documented as the GPs use the computer to 
generate prescriptions, diagnoses must be manually recorded and can therefore be incomplete 
or wrongly coded.34 Although the validity of the diagnoses recorded in the CPRD is high 
(with an average positive predictive value of almost 90%), records of acute disorders may be 
less valid than records of chronic disorders.34,35  
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Today, researchers can access through a linkage system data from secondary care hospital 
episode statistics, death certification data, socioeconomic classification data, and disease 
registry data including the National Cancer Intelligence Network and the Myocardial 
Infarction National Audit Program register.33 
Table 3 summarizes different data types available to researchers from the CPRD. 
Table 3: Overview of the different data types available to researchers from the CPRD.32 
Data Details 
Patient characteristics Gender, birth year, weight, height, body mass index, occupation, ethnicity, 
marital status etc. 
Patient demographics Practice attended, U.K. region the patient lives in 
Medical diagnoses Recorded as “Read codes” 
Drug prescriptions Including quantity of the prescribed drug, and dose instructions 
Lifestyle variables Smoking status, alcohol consumption 
Referrals to hospitals or specialists With diagnoses, drug prescriptions 
Laboratory tests E.g. blood and urine tests  
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1.2 Seizures and Epilepsy 
1.2.1 Defining seizures and epilepsy 
Seizures are transient disruptions of brain function resulting from excessive neuronal 
activity.36 Depending on location and extent of the affected brain regions, seizures result in 
alterations of muscle tone, sensations, consciousness, or behavior.36 Seizures are clinical 
events that can occur in all people for example after sleep withdrawal, overdoses or 
withdrawal from certain drugs, or hypoxia.37 
Epilepsy is a chronic condition of repeated spontaneous seizures.36 Spontaneous seizures are 
defined as seizures without a direct precipitating cause. A diagnosis of epilepsy requires either 
at least two spontaneous seizures occurring more than 24h apart, one spontaneous seizure 
with a high risk of recurrence, or the diagnosis of an epilepsy syndrome (defined by a cluster 
of symptoms occurring together including seizure type, etiology, age of onset, and other 
factors).38,39 Epilepsy is a disorder of the brain that is characterized by an enduring 
predisposition to generate seizures.37 
1.2.2 History of seizures and epilepsy 
Seizures and epilepsy have been studied by medical scholars throughout time. One of the 
earliest publication on epilepsy, “the Sacred Disease”, part of the Hippocratic Collection, was 
written in 400 BCE, potentially by Hippocrates himself.40 It was suggested that epilepsy is a 
hereditary disorder of the brain, and thus contemporary beliefs that seizures and epilepsy were 
a sign from the gods were refused40: 
“My own view is that those who first attributed a sacred character to this malady [i.e., 
epilepsy] were like the magicians, purifiers, charlatans and quacks of our own day, men who 
claim great piety and superior knowledge. Being at a loss, and having no treatment which 
would help, they concealed and sheltered themselves behind superstition, and called this 
illness sacred, in order that their utter ignorance might not be manifest.” 
While this early report showed profound knowledge of the human body, it was not until very 
recently that the findings of Hippocrates were acknowledged. For example, throughout the 
Middle Ages and the Renaissance, patients with epilepsy were thought to be possessed by the 
devil and women with epilepsy were persecuted as witches.41 
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It was not until the mid-19th century, when John Hughlings Jackson recognized that seizures 
were caused by “occasional, sudden, excessive discharges of gray matter”.39 Jackson 
discovered that seizures could spread from a single focus with localized motor symptoms to 
generalized seizures accompanied by loss of consciousness.36,39 
Following these findings, bromide, the first antiepileptic drug, became available, followed by 
phenobarbital (1912) and phenytoin (1937).36,39 With the development of new techniques, 
such as the electroencephalogram (EEG) in 1929, neuroscientists were able to show that 
seizures are associated with neuronal hyperexcitability in the brain.39 
1.2.3 Epidemiology of seizures and epilepsy 
Worldwide, it has been estimated that up to 10% of people have at least one seizure at some 
point in their life, and 0.4 - 1% of people suffer from epilepsy.42,43  
In developed countries the overall incidence rate of spontaneous seizures was estimated 55 
per 100,000 person-years.44,45 These data are not conclusive with regard to potential gender 
differences in seizure risk.44–46 Spontaneous seizures occur most frequently in neonates and 
infants (incidence rate 100 to 130 per 100,000 person-years) and people aged 65 years or over 
(incidence rate 110 to 180 per 100,000 person-years).44,46  
Focal seizures with or without generalization are assumed to be more common than 
generalized-onset seizures; however, in most studies misclassification of seizure types is 
difficult to estimate (see chapter 1.2.6).44,45,47 
Estimates of the overall incidence rate of epilepsy range from 30 to 50 per 100,000 person-
years in high income countries to 120 per 100,000 person-years in low-income 
countries.42,43,47 The higher incidence of epilepsy in low-income countries compared to high-
income countries is presumably caused by parasitic diseases associated with seizures, such as 
malaria or neurocysticercosis, as well as lower standards in medical infrastructure.47 It was 
shown that incidence rates of epilepsy exhibit similar age-related trends as incidence rates of 
spontaneous seizures, with peaks in the first year of life and at ages 65 or over.44,45  
Focal epilepsies, commonly caused by localized tumors, developmental malformations, or 
damages after head trauma or stroke, account for about 60% of all epilepsies. Generalized 
epilepsies, mostly based on genetic mutations, account for the remaining 40% of epilepsies.39 
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1.2.4 Risk factors for seizures and epilepsy 
Risk factors for seizures and epilepsy vary by age groups, as Table 4 displays. Across all age 
groups however, the causes of seizures remain unknown in most cases.   
Table 4: Causes of seizures overall (%) and by age group (: frequent cause in this age group). 
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Age group 
U
n
id
en
ti
fi
ed
 c
au
se
 4
4
 
C
er
eb
ro
v
as
cu
la
r 
d
is
ea
se
 4
4
 
N
eo
p
la
sm
s 
4
4
 
T
ra
u
m
at
ic
 b
ra
in
 i
n
ju
ry
 4
6
,4
8
,4
9
 
C
er
eb
ra
l 
p
al
sy
/i
n
te
ll
ec
tu
al
 d
is
ab
il
it
y
 4
4
 
In
fe
ct
io
n
 4
6
,4
8
,4
9
  
N
eu
ro
d
eg
en
er
at
iv
e 
d
is
ea
se
s 
4
4
,4
6
 
O
th
er
 4
6
,4
8
,4
9
  
All ages 68% 9% 6% 5% 4% 1% 7% 1% 
Neonates and children         
Middle aged         
Adults aged 65         
Numerous additional risk factors for seizures have been identified (see Table 5). 
Table 5: Additional risk factors for seizures  
Category Risk Factor References 
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Heavy alcohol consumption or alcohol withdrawal 50–53 
Illicit drug use 54 
Medication use or withdrawal 55–60 
Metabolic or electrolyte imbalances 61 
Fever 61 
Severe dehydration 62 
Sleep deprivation 63,64 
Anoxic encephalopathy 60 
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Depression and suicidality 27,65,66 
Other psychiatric disorders 66,67 
Migraine with aura 68,69 
Severe hypertension 70,71 
Attention deficit (hyperactivity) disorder 72 
Multiple sclerosis 73,74 
Systemic lupus erythematosus 74 
Preeclampsia 60 
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1.2.5 Mechanism of seizures 
Little is known about the physiological processes underlying seizures. The following 
paragraphs summarize the current knowledge about how seizures may be generated by the 
brain36,39,75: 
Glutamate is the major excitatory transmitter while GABA (-Aminobutyric acid) is the main 
inhibitory transmitter in the brain. It is currently believed that excessive synaptic activity 
during seizure results from an imbalance between these two antagonistic neurotransmitters. 
Depolarization and thus neural excitation is triggered by two types of glutamate regulated 
channels, AMPA (-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-
Methyl-D-aspartic acid), in combination with voltage gated sodium and calcium channels. 
Hyperpolarization and therefore neural inhibition is caused by activation of GABA receptor-
mediated chloride channels and different types of potassium channels.  
Under normal conditions, post-hyperpolarization following an action potential prevents 
immediate generation of a new action potential and thus neuron hyperexcitation. However, 
during a seizure, neurons located in the seizure focus exhibit a prolonged depolarization 
phase (depolarization shift), which can be identified as a sharp waveform in the EEG of 
patients. The observed depolarization shift is followed by rapid firing of action potentials in 
affected neurons. During such an event GABAergic inhibition of regulatory signals appears to 
be suppressed, enabling the spread of neural hyperexcitability to surrounding areas in the 
brain. 
1.2.6 Seizure types 
Focal seizures start within networks of one brain hemisphere, and are classified based on 
whether they affect consciousness or awareness.76 Focal seizures can evolve to generalized 
seizures affecting both hemispheres.76 
Generalized seizures begin at some point within, and rapidly engage networks distributed in 
both brain hemispheres.76 
Classification and features of focal and generalized seizures are summarized in Table 6.43,76–78
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Table 6: Classification and key features of focal and generalized seizures. Summarized from43,76–78. 
  
Typical manifestations Consciousness Duration 
F
o
ca
l 
se
iz
u
re
s Without impairment of 
consciousness or awareness 
Motor symptoms: jerking, spasms, posturing, reversible weakness in one side of the body 
(Todd’s paralysis) 
Sensory- or psychic symptoms (i.e. aura): tingling, numbness, pain, feeling of heat, 
hallucinations (flashing lights), sudden intense emotions (fear, depression, anger, irritability), 
dysphasia, disturbance of memory, sensations of unreality or depersonalization, hallucination 
of vision, taste, or smell 
Preserved Mostly only a few seconds 
With impairment of consciousness 
or awareness 
Altered consciousness (confusion, unresponsiveness, motor arrest) 
Automatisms (repetitive movements such as chewing, lip smacking, fiddling, tapping, 
whistling, humming, uncoordinated violent behavior) 
Impaired or lost Few seconds to minutes 
G
en
er
a
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d
 s
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re
s 
Tonic Stiffening of muscles (e.g. contraction of facial or respiration muscles, rising up of arms)  
Falling over, usually backward 
Impaired or lost 
Less than 60 s, person recovers 
quickly 
Clonic Jerking or twitching of limbs or body About 2 min 
Myoclonic Brief contraction of muscles, resulting in sudden irregular jerking or twitching of trunk or one 
or more limbs 
Sometimes caused by drugs (antidepressants, antipsychotics), drug toxicity or withdrawal, 
post-hypoxic brain damage 
Presentation varies from subtle jerk to violent jolt 
Fraction of a second 
Atonic Sudden relaxation of muscles 
Person often falls over, usually forward (also called “drop attacks”) 
Less than 60 s, 
person recovers quickly 
Tonic-clonic (“grand mal”) Loss of consciousness, tonic phase with flexion and rigidity  
Clonic phase with convulsions of usually all four limbs 
Stertorous breathing, froth of saliva from mouth, loss of bladder control, cyanosis 
Tonic phase: 10-30 s 
Clonic phase: 30-60 s 
Confusion after: > 10 min 
Absence (“petit mal”) Abrupt loss of consciousness and cessation of motor activity, staring vacantly into space 
Mostly in children or adolescents, continue into adulthood in 7-80% of cases 
EEG diagnostic in more than 90% of cases 
Mostly less than 10 s 
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1.2.7 Diagnosis of seizures 
Diagnosis of an epileptic seizure mainly relies on the patient’s clinical history, rendering eye 
witness reports of seizures crucial in establishing a correct diagnosis.78  
Although no features exclusively correlated with epileptic seizures are known, a handful of 
strong seizure markers have been identified to this point: postictal confusion,78,79 occurrence 
out of sleep,79 cyanosis,78,79 lateral tongue biting,78,79 preceding “déjà vu” or “jamais vu”,78,79 
confirmed unresponsiveness, head or eye turning to one side,78,79 rhythmic limb shaking,78 
and unusual posturing.78,79 
Following an initial seizure event, an EEG recording is done to detect potential abnormalities 
in electrical activity. However, less than half of patients undergoing epileptic seizures show 
detectable EEG abnormalities within 24h after seizure occurrence.80 Additionally, magnet 
resonance imaging (MRI) or computed tomography (CT) are used to detect direct causes of 
seizures, such as brain injuries, brain tumors, or stroke.61 
A variety of medical conditions imitate symptoms of epileptic seizures leading to one third of 
false epileptic seizure diagnoses.78 For example, about 20% of patients referred to epilepsy 
centers have psychogenic nonepileptic seizures, by definition a psychiatric, not a neurologic 
disorder.79 This type of seizures is characterized by a resistance to antiepileptic drugs, unusual 
triggers, a tendency to occur in the presence of an audience, a history of psychiatric 
diagnoses, and the presence of a normal EEG during video monitoring of the seizure.79 
Differential diagnosis of epileptic seizures should therefore include the following seizure 
imitators61,80,81: 
i. Neurological disorders such as transient ischemic attacks, transient global amnesia, 
migraine, restless legs syndrome.  
ii. Cardiovascular disorders such as vasovagal syncopes, orthostatic hypotension, cardiac 
arrhythmias, or structural heart disease.  
iii. Sleep disorders such as obstructive sleep apnea, hypnic jerks, or narcolepsy.  
iv. Movement disorders such as paroxysmal dyskinesia.  
v. Psychological disorders such as night terror, panic attacks, or psychogenic 
nonepileptic seizures.  
Introduction  Seizures and Epilepsy 
22 
 
From the seizure imitators listed above syncopes and psychogenic nonepileptic seizures are 
most frequently misdiagnosed as epileptic seizures.79 It has been reported that the occurrence 
of syncopes is more likely compared to epileptic seizures when nausea, sweating, 
lightheadedness, or prolonged standing or sitting precede the event.78,80 Motor symptoms 
associated with syncopes are clonic or myoclonic but stop once the patient lies horizontally.79 
Additionally, bradycardia and hypotension are more common in patients with syncopes, while 
tachycardia and hypertension are more common in patients with epileptic seizures.61 
1.2.8 Therapy of seizures 
Currently, no cure for epilepsy exists. However, available therapies reduce seizure occurrence 
in 70-80% of patients and thus strongly improve quality of life.39,82  
While first-time seizures are treated pharmacologically only under certain circumstances, 
recurrent seizures in patients with epilepsy are treated with antiepileptic drugs to reduce 
morbidity and mortality associated with further seizures.82  
Anti-seizure drugs can be categorized according to different types of mechanism:  
1) Sodium channel blockers inhibit Na+-channels to recover from inactivation und 
reduce the ability of neurons to fire action potentials at high frequency (e.g., 
carbamazepine, lamotrigine, phenytoin, topiramate, valproic acid, and zonisamide). 
2) GABAA receptor agonists inhibit the postsynaptic cell by increasing the inflow of 
chloride ions into the cell, thus hyperpolarizing the neuron (e.g., benzodiazepines and 
barbiturates) 
3) Inhibitors of the presynaptic GABA transporter promote GABA release into the 
synaptic cleft (e.g. tiagabine). 
4) Calcium channel blockers inhibit opening of voltage-gated T-type Ca2+-channels 
thus reducing Ca2+ ion inflow and postsynaptic neuron depolarization (e.g., 
ethosuximide, valproic acid). 
5) NMDA-type and AMPA-type glutamate receptor antagonists reduce Na+ ion 
inflow into the postsynaptic neuron, thus inhibiting postsynaptic depolarization (e.g. 
felbamate, topiramate, phenobarbital, tiagabine). 
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2. Aims of the thesis 
Neuropsychiatric disorders have repeatedly been reported to increase the risk of seizures.27,65–
67,83–86 The overall aim of this thesis was to study the occurrence and the determinants of new-
onset seizures among patients with neuropsychiatric disorders under real-world conditions. 
An initial project aimed to explore risk factors for new-onset seizures among adult patients 
with depression. Although several observational studies have reported a correlation between 
depression and seizures,27,65–67 risk factors for new-onset seizures in patients with depression 
have not been investigated. Thus, this project assessed the association between lifestyle 
factors (e.g., drug abuse, alcoholism, and smoking), neurologic or psychiatric comorbidities, 
and concomitantly used drugs, and new-onset seizures in adult patients with depression. 
Two subsequent studies aimed at investigating the association between psychotropic drug use 
and seizures, thereby discriminating between potential drug effects and effects of the 
underlying neuropsychiatric disorders. 
The purpose of the second project was to explore the association between antidepressant drug 
use and new-onset seizures among adult patients with depression. Since antidepressants are 
used for numerous disorders (i.e., depression, anxiety disorders, bipolar disorder, obsessive-
compulsive disorders, post-traumatic stress disorder, and chronic pain),87 and since seizure 
risk might be affected differently by these disorders, the study population was set to users of 
antidepressants for unipolar depression. As seizure risk is increased when applying 
antidepressants in overdose,57,88–90 this study aimed to explore dose-dependent effects within 
therapeutic dose ranges of antidepressants.  
The third project studied the association between antipsychotic drug use in adults with 
neuropsychiatric disorders and new-onset seizures. Little evidence on antipsychotic-induced 
seizures can be found and to this day the role of the underlying indication has not been 
investigated.91–94 This project thus aimed to explore the risk of seizures associated with 
antipsychotic drug use for patients with underlying schizophrenia, affective disorders, or 
dementia.
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3. Seizure projects 
3.1 Project 1: Risk factors for seizures in adult patients with depression 
Unabbreviated title: Lifestyle factors, psychiatric and neurologic comorbidities, and 
drug use associated with incident seizures among adult patients with depression: a 
population-based nested case-control study 
Marlene Bloechliger1, MSc, Alessandro Ceschi2,3, MD, Stephan Rüegg4, MD, Susan S Jick5, 
DSc, Christoph R Meier1,5,6, PhD, and Michael Bodmer1,7, MD, MSc 
1 Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, 
Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland;  
2 National Poisons Centre, Tox Info Suisse, Associated Institute of the University of Zurich, 
Zurich, Switzerland 
3 Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, Ente 
Ospedaliero Cantonale, Lugano 
4 Division of Clinical Neurophysiology, Department of Neurology, University Hospital Basel, 
Basel, Switzerland 
5 Boston Collaborative Drug Surveillance Program, Boston University School of Public 
Health, Lexington, Massachusetts, USA 
6 Hospital Pharmacy, University Hospital Basel, Basel, Switzerland 
7 Medical Department, Zuger Kantonsspital, Zug, Switzerland 
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3.1.1 Abstract 
Objective 
To investigate risk factors for incident seizures among adult patients with depression. 
Methods 
We conducted a nested case-control analysis in adult patients with newly diagnosed 
depression, using data from the U.K.-based Clinical Practice Research Datalink (CPRD). 
Among cases with incident seizures and matched controls, we estimated odds ratios (ORs) 
with 95% confidence intervals (CIs) of potential risk factors for seizures as reported from data 
of the general population: underweight (body mass index <18.5 kg/m2), smoking, alcoholism, 
drug abuse, psychiatric or neurologic comorbidities, and concomitant use of drugs. 
Results 
Of 186,540 patients with depression, 1,489 developed a seizure during follow-up. Being 
underweight (OR, 1.67 [95% CI, 1.23-2.26]), a current smoker (OR, 1.45 [95% CI, 1.26-
1.67]), having alcoholism (OR, 2.98 [95% CI, 2.56-3.47]), and drug abuse (OR, 2.51 [95% 
CI, 1.94-3.24]), were associated with increased risks of seizures compared to normal weight, 
non-smoking, no alcoholism, and no drug abuse, respectively. Previous stroke/transient 
ischemic attack (OR 6.07 [95% CI, 4.71-7.83]) or intracerebral bleeding (OR 8.19 [95% CI, 
4.80-13.96]), and comorbid dementia (OR 6.83 [95% CI, 4.81-9.69]), were strongly 
associated with seizures. Current use of cephalosporins (OR, 2.47 [95% CI, 1.61-3.78]) and 
antiarrhythmics (OR, 1.59 [95% CI, 1.26-2.01]) was associated with an increased risk of 
seizures compared to non-use.  
Conclusion 
Among adult patients with depression, being underweight, smoking, alcoholism, and drug 
abuse, were associated with seizures. Remote stroke and comorbid dementia were strong risk 
factors for seizures. Current use of cephalosporins or antiarrhytmics was associated with an 
increased risk of seizures compared to non-use.  
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3.1.2 Introduction 
Depression is a common and disabling disorder. Lifetime prevalence estimates of major 
depression range between about 7% in some Asian countries to about 20% in certain 
European countries and the United States.22 Patients with depression develop seizures more 
frequently than individuals without depression,27,65,67 and it has been suggested that common 
neurobiological abnormalities increase the risk for both disorders.84 Apart from depression, 
suicidal ideation/attempt, psychiatric disorders including schizophrenia, bipolar disorder, and 
obsessive-compulsive disorders, and neurologic disorders including dementia, Parkinson’s 
disease, multiple sclerosis, ischemic or hemorrhagic stroke, transient ischemic attack (TIA), 
brain infections, brain tumors, severe brain trauma, or migraine with aura, have been 
associated with seizures.27,61,62,66,69,78 Use of antidepressants, antipsychotics, antimalarials, 
antibiotics, antivirals, immunosuppressants, stimulants, sedatives, or opioids, has also been 
associated with the occurrence of seizures.55,56,58,95 Alcohol intoxication, withdrawal or 
dependence, or abuse of recreational drugs, are recognized risk factors for seizures.50,54,78 
No observational study has yet explored risk factors for new-onset seizures among patients 
with depression. This study aimed to investigate in detail which lifestyle factors, 
comorbidities, and co-medications are associated with seizures among adult patients with 
depression. 
3.1.3 Methods 
Study design and data source 
We conducted a retrospective population-based nested case-control study using data from the 
U.K.-based Clinical Practice Research Datalink (CPRD). The CPRD encompasses 
approximately 10,000,000 patient records provided by general practitioners (GPs) throughout 
England, Wales, Scotland and Northern Ireland.31 The patients enrolled in participating 
practices are representative of the U.K. with regard to age, sex, and geographic distribution. 
Researchers have access to anonymized data of patients which encompass demographics, 
lifestyle factors, medical diagnoses (recorded as ‘Read codes’), and drug prescriptions. The 
recording of diagnoses and drug prescriptions has been validated and proven to be of high 
quality.34,35 Data from the CPRD have repeatedly been used to conduct observational studies 
on depression 96–98 and seizures.86,99,100 This study was approved by the Independent Scientific 
Advisory Committee for Medicines and Healthcare products Regulatory Agency research. 
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Study population 
We identified all patients aged 18 to 89 years with an incident depression diagnosis followed 
by an antidepressant drug treatment, or a first prescription for an antidepressant drug followed 
by an incident depression diagnosis within one year thereafter, between January 1998 and 
December 2012. Incident depression was defined by Read codes corresponding to the 
International Classification of Diseases version 10 (ICD-10) codes for depression. The date of 
the incident depression diagnosis or the first prescription for an antidepressant drug, 
whichever came first, will subsequently be called ‘start date’. We excluded patients with a 
recorded history of epilepsy or seizures, any antiepileptic drug therapy, HIV, non-cerebral 
malignancy, or benign or malignant brain tumors prior to the start date. Patients had to have 
had at least three years of active history in the database prior to the start date to minimize 
inclusion of patients with prevalent rather than incident depression.  
Definition of cases 
Cases were patients in the study population who had at some point after the start date (1) an 
incident diagnosis of seizures or epilepsy defined by recorded Read codes corresponding to 
ICD-10 codes for seizures or epilepsy, (2) a first prescription for an antiepileptic drug 
followed by an incident diagnosis of seizures or epilepsy (as defined under [1]) within three 
months thereafter, or (3) a first prescription for an antiepileptic drug preceded or followed by 
a Read code record of a suspected seizure within three months before or after, provided that 
an incident diagnosis of seizures or epilepsy (as defined under [1]) followed at any time 
thereafter. The date of (1), (2), or (3), whichever came first, will be referred to as ‘index date’. 
Cases older than 90 years were excluded as were those with a record of HIV, non-cerebral 
malignancy, or benign or malignant brain tumors diagnosed between the start date and the 
index date, or within one month after the index date.  
Control selection 
For each case we identified up to four controls from the study population who had no 
diagnoses for seizures during the study period. We matched controls to cases on index date, 
age (+/- 2 years), sex, GP practice, number of years of history in the CPRD prior to the index 
date (+/- 2 years), and - to match on a proxy for depression severity - antidepressant exposure 
at the index date, defined by the quantity and type of antidepressant prescribed by the GP at 
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the closest visit prior to the index date and the daily dose instructions recorded. If no dose 
instruction was available, we used default values in the following order: (1) the dose 
instruction given for the same drug at any time prior to the index date, (2) the defined daily 
dose if no dose instruction was recorded at any time prior to the index date, or (3) the dose of 
one unit (i.e. tablet or capsule) of sustained release forms. We matched cases and controls on 
the following types of antidepressant exposure at the index date: (1) ‘No antidepressant 
treatment’: the patient had been diagnosed with depression, but had not yet received a 
prescription for an antidepressant; (2) ‘Mono use’ of antidepressants: the patient was 
prescribed only one of the following antidepressants at the index date: (a) selective serotonin 
reuptake inhibitors (SSRIs) [citalopram, escitalopram, fluoxetine, paroxetine, sertraline, or 
fluvoxamine], (b) serotonin norepinephrine reuptake inhibitors (SNRIs) [venlafaxine and 
duloxetine], (c) tricyclic antidepressants (TCAs) [amitriptyline, clomipramine, doxepin, 
imipramine, trimipramine, nortriptyline, lofepramine, and dosulepin], or (d) ‘other 
antidepressants’ (reboxetin, mirtazapine, bupropion, trazodone, viloxazine, nefazodone, St. 
John’s wort, tryptophan, or agomelatine); (3) ‘Mixed use’ of antidepressants: the patient was 
prescribed concomitantly at least two of the antidepressants listed above at the index date; (4) 
‘Past use’ of antidepressants: the patient had been prescribed antidepressants in the past, but 
the treatment had elapsed. We applied the same exclusion criteria to controls as to cases. 
Exposure variables 
We assessed information on body mass index (BMI) [<18.5, 18.5-24.9, 25.0-29.9, ≥30 kg/m2, 
or unknown], lifestyle factors including smoking status (non, current, former, or unknown), 
alcohol consumption (none, 1-14, 15-28, 29-42, >42 units/week, or unknown), alcoholism 
(based on Read codes), and drug abuse (based on Read codes) recorded at any time prior to 
the index date.51,54,101,102 
We assessed the prevalence of any of the following comorbidities based on Read codes 
recorded at any time prior to until three months after the index date: schizophrenia, manic 
episodes/bipolar disorder, obsessive-compulsive disorder, anxiety disorders, suicidal 
ideation/suicide attempt, dementia, Parkinson’s disease, multiple sclerosis, intracerebral 
bleeding, ischemic stroke/TIA, major head trauma (head trauma with intracranial injury), 
meningitis or encephalitis, brain abscess, migraine, attention deficit hyperactivity disorder 
(ADHD), and sinus vein thrombosis.27,61,62,67,69,72,78  
Project 1: Risk factors for seizures in adult patients with depression 
34 
 
Lastly, we assessed the use of drugs that have been reported to alter the risk of seizures: 
atypical or typical antipsychotics, benzodiazepines or non-benzodiazepine hypnotics, 
barbiturates, penicillins, cephalosporins, fluoroquinolones, carbapenems, antimalarials, 
antivirals, immunosuppressants, opioids, anticonvulsants, antiarrhythmics, and stimulants.55–58 
‘Non-users’ of such drugs were those with no prescriptions prior to the index date, ‘current 
users’ and ‘past users’ received the last prescription ≤90 days or >90 days prior to the index 
date, respectively. 
Data analysis 
Analyses were conducted with SAS statistical software (version 9.4; SAS Institute, Cary, NC, 
USA), using conditional logistic regression methods for matched case-controls studies.  
We calculated crude odds ratios (ORs) with 95% confidence intervals (CIs) for each exposure 
variable and exposure level for which numbers of observations were sufficient to conduct 
meaningful analyses. All estimated odds ratios were conditional on the matching factors. We 
calculated odds ratios for all comorbidities (yes/no). Additionally, for psychiatric 
comorbidities and acute neurologic comorbidities (intracerebral bleeding, ischemic 
stroke/TIA, major head trauma, meningitis or encephalitis, and brain abscess), we categorized 
diagnoses by the timing (within 12 months prior to until 3 months after the index date, >12 
months prior to the index date). We calculated odds ratios for drugs categorized by timing of 
use (current, past use), and for current use by the number of recorded prescriptions prior to the 
index date (1-3, ≥3). 
3.1.4 Results 
Of 186,540 patients with depression, there were 1,489 cases with a diagnosis of an incident 
seizure or epilepsy. The mean age of cases (+/- standard deviation) was 47.2 (+/- 18.9) years 
and 51.2% of patients were female. 
Approximately 40% of cases were aged 18-39 years, 30% 40-59 years, and 30% 60-90 years 
at the index date (Table 7). More than 50% were past users of antidepressants while almost 
30% were current mono users of an SSRI. Being underweight (BMI <18.5 kg/m2) was 
associated with an increased risk of seizures compared to normal weight (BMI between 18.5 
and 25.0 kg/m2). Current smoking, drinking more than 42 units of alcohol per week, 
alcoholism, and drug abuse (mainly unspecified drug abuse, abuse of opioids, cannabis, or 
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anxiolytics/hypnotics) were associated with increased risks of seizures compared to non-
smoking, non-drinking, no alcoholism, and no drug abuse, respectively (Table 7). 
Anxiety disorders and suicidal ideation/suicide attempt were most frequently observed among 
cases and controls (Table 8). People with depression and one of the following comorbidities, 
schizophrenia, manic episodes or bipolar disorder, anxiety disorders, and suicidal 
ideation/suicide attempt, were at increased risk of seizures compared to people with 
depression alone (Table 8).  
Psychiatric comorbidities diagnosed within 12 months prior to until 3 months after the index 
date were associated with higher risks of seizures than psychiatric comorbidities diagnosed 
>12 months prior to the index date, although most differences were not significant (Table 9). 
Having comorbid dementia (OR 6.83 [95% CI, 4.81-9.69]), previous intracerebral bleeding 
(OR 8.19 [95% CI, 4.80-13.96]) or ischemic stroke/TIA (OR 6.07 [95% CI, 4.71-7.83] was 
strongly associated with the risk of seizures (Table 10). The associations with intracerebral 
bleeding, ischemic stroke/TIA, and major head trauma, were stronger when the diagnosis was 
recorded within 12 months prior to until 3 months after the index date compared to those with 
a diagnosis recorded >12 months prior to the index date (Table 11). Overall, prevalent 
migraine was not associated with seizures (OR 1.13 [95% CI, 0.94-1.36]) [Table 10], while 
migraine with aura tended to be associated with an increased risk of seizures (OR 2.00 [95% 
CI, 0.81-4.96]) [data not shown].  
Current use of antiarrhythmics (mainly propranolol) or cephalosporins was associated with 
1.6- and 2.5-fold increased risks of seizures compared to non-use, respectively (Table 12). 
Past use of these drug classes was not associated with seizures. Treatment initiation was more 
strongly associated with seizures in users of antiarrhythmics and cephalosporins than longer-
term treatment. 
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Table 7: Characteristics and lifestyle factors of cases with seizures and matched controlsa 
Characteristics No. Cases (%)b  
(n=1,489) 
No. Controls 
(%)b (n=5,932) 
Crude OR 95% CI 
Sex     
Male 726 (48.8) 2,886 (48.7) NA NA 
Female 763 (51.2) 3,046 (51.4) NA NA 
Age, years     
18-29 310 (20.8) 1,230 (20.7) NA NA 
30-39 295 (19.8) 1,167 (19.7) NA NA 
40-49 292 (19.6) 1,188 (20.0) NA NA 
50-59 193 (13.0) 775 (13.1) NA NA 
60-69 150 (10.1) 587 (9.9) NA NA 
70-79 132 (8.9) 515 (8.7) NA NA 
80-90 117 (7.9) 470 (7.9) NA NA 
Exposure to antidepressants     
No use 79 (5.3) 313 (5.3) NA NA 
Past use 776 (52.1) 3,104 (52.3) NA NA 
Mono use of SSRIs 399 (26.8) 1,596 (26.9) NA NA 
Mono use of SNRIs 49 (3.3) 186 (3.1) NA NA 
Mono use of TCAs 62 (4.2) 244 (4.1) NA NA 
Mono use of other 
antidepressants 
48 (3.2) 189 (3.2) NA 
NA 
Mixed use of antidepressants 76 (5.1) 300 (5.1) NA NA 
Body mass index, kg/m2   
 
 
<18.5 68 (4.6) 145 (2.4) 1.67 1.23-2.26 
18.5-24.9 571 (38.4) 1,989 (33.5) 1 reference 
25.0-29.9 339 (22.8) 1,602 (27.0) 0.73 0.63-0.85 
≥30.0 256 (17.2) 1,199 (20.2) 0.73 0.62-0.87 
Unknown 255 (17.1) 997 (16.8) 0.91 0.76-1.09 
Smoking status   
 
 
Nonsmoker 511 (34.3) 2,320 (39.1) 1 reference 
Current smoker 584 (39.2) 1,887 (31.8) 1.45 1.26-1.67 
Former smoker 325 (21.8) 1,476 (24.9) 0.98 0.84-1.15 
Unknown 69 (4.6) 249 (4.2) 1.33 0.98-1.80 
Alcohol consumptionc (in 
units/week) 
   
 
Nondrinker 652 (43.8) 2,499 (42.1) 1 reference 
1-14  439 (29.5) 1,954 (32.9) 0.86 0.75-0.99 
15-28 89 (6.0) 405 (6.8) 0.86 0.67-1.11 
29-42 49 (3.3) 172 (2.9) 1.12 0.80-1.56 
>42 102 (6.9) 136 (2.3) 2.97 2.25-3.93 
Unknown 158 (10.6) 766 (12.9) 0.78 0.64-0.96 
Project 1: Risk factors for seizures in adult patients with depression 
37 
 
Table 7 (cont.)     
Characteristics No. Cases (%)b  
(n=1,489) 
No. Controls 
(%)b (n=5,932) 
Crude OR 95% CI 
Alcoholismd     
No 1,121 (75.3) 5,295 (89.3) 1 reference 
yes 368 (24.7) 637 (10.7) 2.98 2.56-3.47 
Drug abused     
no 1,383 (92.9) 5,748 (96.9) 1 reference 
yese 106 (7.1) 184 (3.1) 2.51 1.94-3.24 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable; SSRIs, selective serotonin reuptake inhibitors; 
SNRIs, serotonin norepinephrine reuptake inhibitors; TCAs, tricyclic antidepressants. 
a Controls were matched to cases on age, sex, index date, GP practice, duration of history in the CPRD, and exposure to 
antidepressants at the index date (as described in the methods section). All ORs presented are conditional on the matching 
factors. 
b Due to rounding, percentages may not total 100. 
c Based on Read code records at any time prior to the index date.  
d Based on Read code records at any time prior to the index date until 3 months after the index date. 
e Read code records mainly corresponding to unspecified drug abuse (50.3%), abuse of opioids (14.1%) , cannabis (12.4%), 
anxiolytics/hypnotics (12.4%), and psychostimulants (4.8%). 
Table 8: Odds ratios of psychiatric comorbidities among cases with seizures and matched controlsa 
Psychiatric comorbidity No. Cases (%)b  
(n=1,489) 
No. Controls (%)b  
(n= n=5,932) 
Crude OR 95% CI 
Schizophrenia 
   
 
Noc  1,457 (97.9) 5,865 (98.9) 1 reference 
Yesd  32 (2.2) 67 (1.1) 1.93 1.25-2.98 
Manic episodes/bipolar disorder    
 
 
Noc  1,474 (99.0) 5,905 (99.5) 1 reference 
Yesd  15 (1.0) 27 (0.5) 2.25 1.19-4.26 
Obsessive-compulsive disorder   
 
 
Noc  1,473 (98.9) 5,874 (99.0) 1 reference 
Yesd  16 (1.1) 58 (1.0) 1.09 0.63-1.90 
Anxiety disorders     
Noc  1,087 (73.0) 4,526 (76.3) 1 reference 
Yesd  402 (27.0) 1,406 (23.7) 1.20 1.05-1.37 
Suicidal ideation/suicide attempt   
 
 
Noc  1,231 (82.7) 5,376 (90.6) 1 reference 
Yesd  258 (17.3) 556 (9.4) 2.13 1.80-2.52 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable. 
a Controls were matched to cases on age, sex, index date, GP practice, duration of history in the CPRD, and exposure to 
antidepressants at the index date (as described in the methods). All ORs presented are conditional on the matching factors. 
b Due to rounding, percentages may not total 100. 
c Defined as no Read code record of the respective disorder at any time prior to until 3 months after the index date. 
d Defined as a Read code record of the respective disorder at any time prior to until 3 months after the index date. 
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Table 9: Odds ratios of psychiatric comorbidities among cases with seizures and matched controlsa, by timing of the 
diagnosis 
Psychiatric comorbidity No. Cases (%)b  
(n=1,489) 
No. Controls (%)b 
(n= n=5,932) 
Crude OR 95% CI 
Schizophrenia 
   
 
No diagnosisc  1,457 (97.9) 5,865 (98.9) 1 reference 
Diagnosis by timing     
Within 12 months prior to until 3 months 
after the ID 
12 (0.8) 19 (0.3) 2.50 1.20-5.24 
>12 months prior to the ID 20 (1.3) 48 (0.8) 1.71 1.01-2.90 
Manic episodes/bipolar disorder    
 
 
No diagnosisc  1,474 (99.0) 5,905 (99.5) 1 reference 
Diagnosis by timing     
Within 12 months prior to until 3 months 
after the ID 
9 (0.6) 10 (0.2) 3.80 1.50-9.63 
>12 months prior to the ID 6 (0.4) 17 (0.3) 1.41 0.56-3.58 
Obsessive-compulsive disorder   
 
 
No diagnosisc  1,473 (98.9) 5,874 (99.0) 1 reference 
Diagnosis by timing     
Within 12 months prior to until 3 months 
after the ID 
5 (0.3) 12 (0.2) 1.67 0.59-4.74 
>12 months prior to the ID 11 (0.7) 46 (0.8) 0.94 0.49-1.83 
Anxiety disorders     
No diagnosisc  1,087 (73.0) 4,526 (76.3) 1 reference 
Diagnosis by timing     
Within 12 months prior to until 3 months 
after the ID 
112 (7.5) 295 (5.0) 1.60 1.27-2.02 
>12 months prior to the ID 290 (19.5) 1,111 (18.7) 1.09 0.94-1.27 
Suicidal ideation/suicide attempt   
 
 
No diagnosisc  1,231 (82.7) 5,376 (90.6) 1 reference 
Diagnosis by timing     
Within 12 months prior to until 3 months 
after the ID 
64 (4.3) 86 (1.5) 3.48 2.48-4.88 
>12 months prior to the ID 194 (13.0) 470 (7.9) 1.89 1.57-2.27 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable; ID, index date. 
a Controls were matched to cases on age, sex, index date, GP practice, duration of history in the CPRD, and exposure to 
antidepressants at the index date (as described in the methods section). All ORs presented are conditional on the matching 
factors. 
b Due to rounding, percentages may not total 100. 
c Defined as no Read code record at any time prior to until 3 months after the index date. 
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Table 10: Odds ratios of neurologic comorbidities among cases with seizures and matched controlsa 
Neurologic comorbidity No. Cases (%)b  
(n=1,489) 
No. Controls (%)b 
(n=5,932) 
Crude 
OR 
95% CI 
Dementia     
Noc  1,389 (93.3) 5,845 (98.5) 1 reference 
Yesd  100 (6.7) 87 (1.5) 6.83 4.81-9.69 
Parkinson’s disease     
Noc  1,470 (98.7) 5,901 (99.5) 1 reference 
Yesd  19 (1.3) 31 (0.5) 2.43 1.35-4.39 
Multiple sclerosis   
 
 
Noc  1,479 (99.3) 5,910 (99.6) 1 reference 
Yesd  10 (0.7) 22 (0.4) 1.82 0.86-3.84 
Intracerebral bleeding   
 
 
Noc  1,447 (97.2) 5,910 (99.6) 1 reference 
Yesd  42 (2.8) 22 (0.4) 8.19 4.80-13.96 
Ischemic stroke/ Transient ischemic attack 
  
 
Noc  1,306 (87.7) 5,753 (97.0) 1 reference 
Yesd  183 (12.3) 179 (3.0) 6.07 4.71-7.83 
Major head traumae   
 
 
Noc  1,260 (84.6) 5,484 (92.5) 1 reference 
Yesd  229 (15.4) 448 (7.6) 2.36 1.97-2.82 
Meningitis or encephalitis   
 
 
Noc  1,469 (98.7) 5,889 (99.3) 1 reference 
Yesd  20 (1.3) 43 (0.7) 1.86 1.10-3.16 
Migraine   
 
 
Noc  1,320 (88.7) 5,322 (89.7) 1 reference 
Yesd  169 (11.4) 610 (10.3) 1.13 0.94-1.36 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable. 
a Controls were matched to cases on age, sex, index date, GP practice, duration of history in the CPRD, and exposure to 
antidepressants at the index date (as described in the methods section). All ORs presented are conditional on the 
matching factors. 
b Due to rounding, percentages may not total 100. 
c Defined as no Read code record of the respective disorder at any time prior to until 3 months after the index date. 
d Defined as a Read code record of the respective disorder at any time prior to until 3 months after the index date. 
e Defined as head trauma with intracranial injury. 
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Table 11: Odds ratios of neurological comorbidities among cases with seizures and matched controlsa, by timing of the 
diagnosis 
Neurological comorbidity No. Cases (%)b  
(n=1,489) 
No. Controls (%)b 
(n= n=5,932) 
Crude 
OR 
95% CI 
Intracerebral bleeding 
   
 
No diagnosisc  1,447 (97.7) 5,910 (99.6) 1 reference 
Diagnosis by timing     
Within 12 months prior to until 3 months after 
the ID 
18 (1.2) 5 (0.1) 15.03 5.56-40.63 
>12 months prior to the ID 24 (1.6) 17 (0.3) 6.10 3.22-11.54 
Ischemic stroke/ Transient ischemic attack 
  
 
No diagnosisc  1,306 (87.7) 5,753 (97.0) 1 reference 
Diagnosis by timing     
Within 12 months prior to until 3 months after 
the ID 
90 (6.0) 24 (0.4) 20.27 12.40-33.13 
>12 months prior to the ID 93 (6.3) 155 (2.6) 3.53 2.61-4.77 
Major head trauma   
 
 
No diagnosisc  1,260 (84.6) 5,484 (92.5) 1 reference 
Diagnosis by timing     
Within 12 months prior to until 3 months after 
the ID 
61 (4.1) 30 (0.5) 9.14 5.82-14.34 
>12 months prior to the ID 168 (11.3) 418 (7.1) 1.85 1.52-2.25 
Meningitis or encephalitis   
 
 
No diagnosisc  1,469 (98.7) 5,889 (99.3) 1 reference 
Diagnosis by timing     
Within 12 months prior to until 3 months after 
the ID 
X X NA NA 
>12 months prior to the ID 19 (1.3) 42 (0.7) 1.81 1.05-3.11 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable: numbers in the contingency table were not 
adequate to calculate odds ratios; X, cell contains <5 observations (due to ethics regulations to preserve confidentiality, 
the exact count is not displayed); ID, index date. 
a Controls were matched to cases on age, sex, index date, GP practice, duration of history in the CPRD, and exposure to 
antidepressants at the index date (as described in the methods section). All ORs presented are conditional on the 
matching factors. 
b Due to rounding, percentages may not total 100.  
c Defined as no Read code record of the respective disorder at any time prior to until 3 months after the index date. 
  
Project 1: Risk factors for seizures in adult patients with depression 
41 
 
Table 12: Odds ratios of selected drug groups among cases with seizures and matched controlsa, by currentb or pastc use, and 
by current use and number of prescriptions 
Drug group No. Cases (%)d  
(n=1,489) 
No. Controls (%)d 
(n= n=5,932) 
Crude OR 95% CI 
Atypical antipsychoticse 
   
 
No use 1,380 (92.7) 5,695 (96.0) 1 reference 
Current use  63 (4.2) 130 (2.2) 2.11 1.53-2.92 
Current use by nr. of presc.     
1-3 11 (0.7) 20 (0.3) 2.42 1.15-5.09 
>3 52 (3.5) 110 (1.9) 2.06 1.45-2.92 
Past use  46 (3.1) 107 (1.8) 1.85 1.30-2.65 
Typical antipsychoticsf   
 
 
No use 1,011 (67.9) 4,497 (75.8) 1 reference 
Current use  70 (4.7) 121 (2.0) 2.71 1.99-3.70 
Current use by nr. of presc.     
1-3 38 (2.6) 52 (0.9) 3.35 2.18-5.14 
>3 32 (2.2) 69 (1.2) 2.20 1.42-3.40 
Past use  408 (27.4) 1,314 (22.2) 1.43 1.25-1.64 
Benzodiazepines or non-
benzodiazepine hypnoticsg 
   
 
No use 687 (46.1) 3,260 (55.0) 1 reference 
Current use  254 (17.1) 482 (8.1) 2.76 2.29-3.32 
Current use by nr. of presc.     
1-3 50 (3.4) 97 (1.6) 2.60 1.81-3.74 
>3 204 (13.7) 385 (6.5) 2.80 2.29-3.43 
Past use  548 (36.8) 2,190 (36.9) 1.22 1.07-1.39 
Penicillinsh     
No use 249 (16.7) 1,024 (17.3) 1 reference 
Current use  150 (10.1) 510 (8.6) 1.23 0.97-1.55 
Current use by nr. of presc.     
1-3 25 (1.7) 114 (1.9) 0.91 0.58-1.44 
>3 125 (8.4) 396 (6.7) 1.32 1.03-1.70 
Past use  1,090 (73.2) 4,398 (74.1) 1.03 0.88-1.21 
Cephalosporinsi     
No use 1,013 (68.0) 4,223 (71.2) 1 reference 
Current use  34 (2.3) 58 (1.0) 2.47 1.61-3.78 
Current use by nr. of presc.     
1-3 24 (1.6) 33 (0.6) 3.05 1.80-5.17 
>3 10 (0.7) 25 (0.4) 1.69 0.81-3.54 
Past use  442 (29.7) 1,651 (27.8) 1.14 1.00-1.30 
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Table 12 (cont.)     
Drug group No. Cases (%)d  
(n=1,489) 
No. Controls (%)d 
(n= n=5,932) 
Crude OR 95% CI 
Fluoroquinolonesj     
No use 1,262 (84.8) 5,102 (86.0) 1 reference 
Current use  11 (0.7) 36 (0.6) 1.20 0.61-2.37 
Current use by nr. of presc.     
1-3 9 (0.6) 25 (0.4) 1.40 0.65-3.02 
>3 X 11 (0.2) NA NA 
Past use  216 (14.5) 794 (13.4) 1.11 0.94-1.31 
Antimalarialsk     
No use 1,398 (93.9) 5,490 (92.6) 1 reference 
Current use  23 (1.5) 86 (1.5) 1.04 0.65-1.65 
Current use by nr. of presc.     
1-3 X 16 (0.3) NA NA 
>3 21 (1.4) 70 (1.2) 1.16 0.71-1.90 
Past use  68 (4.6) 356 (6.0) 0.75 0.57-0.98 
Immunosuppressantsl     
No use 1,471 (98.8) 5,867 (98.9) 1 reference 
Current use  10 (0.7) 39 (0.7) 1.03 0.51-2.06 
Current use by nr. of presc.     
1-3 X X NA NA 
>3 9 (0.6) 39 (0.7) 0.93 0.45-1.91 
Past use  8 (0.5) 26 (0.4) 1.22 0.55-2.70 
Opioidsm     
No use 457 (30.7) 2,165 (36.5) 1 reference 
Current use  301 (20.2) 812 (13.7) 1.89 1.59-2.26 
Current use by nr. of presc.     
1-3 46 (3.1) 102 (1.7) 2.15 1.50-3.09 
>3 255 (17.1) 710 (12.0) 1.84 1.53-2.23 
Past use  731 (49.1) 2,955 (49.8) 1.22 1.06-1.40 
Anticonvulsantsn     
No use 1,371 (92.1) 5,695 (96.0) 1 reference 
Current use  68 (4.6) 103 (1.7) 2.85 2.07-3.92 
Current use by nr. of presc.     
1-3 20 (1.3) 27 (0.5) 3.11 1.74-5.54 
>3 48 (3.2) 76 (1.3) 2.75 1.89-4.01 
Past use  50 (3.4) 134 (2.3) 1.59 1.14-2.21 
Antiarrhythmicso     
No use 1,134 (76.2) 4,745 (80.0) 1 reference 
Current use  114 (7.7) 309 (5.2) 1.59 1.26-2.01 
Current use by nr. of presc.     
1-3 25 (1.7) 32 (0.5) 3.27 1.93-5.52 
>3 89 (6.0) 277 (4.7) 1.38 1.06-1.78 
Past use  241 (16.2) 878 (14.8) 1.16 0.99-1.37 
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Table 12 (cont.) 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable; nr., number; presc., prescriptions; X, cell contains 
<5 observations (due to ethics regulations to preserve confidentiality, the exact count is not displayed). 
a Controls were matched to cases on age, sex, index date, GP practice, duration of history in the CPRD, and exposure to 
antidepressants at the index date (as described in the methods section). All ORs presented are conditional on the matching 
factors. 
b Defined as last prescription ≤90 days ago 
c Defined as last prescription >90 days ago 
d Due to rounding, percentages may not total 100. 
e Mainly consisting of olanzapine (35.5%), risperidone (30.1%), quetiapine (21.4%), and amisulpride (6.1%). 
f Mainly consisting of prochlorperazine (76.2%), flupentixol (5.3%), chlorpromazine (4.5%), and thioridazine (4.3%) 
g Mainly consisting of diazepam (39.0%), zopiclone (26.0%), temazepam (19.1%), and chlordiazepoxide (4.4%) 
h Mainly consisting of amoxicillin (64.2%), flucloxacillin (19.2%), penicillin (12.5%), and phenoxymethylpenicillin (2.1%).  
i Mainly consisting of cefalexin (67.7%), cefaclor (18.5%), and cefradine (8.5%). 
j Mainly consisting of ciprofloxacin (85.5%), ofloxacin (9.6%) 
k Mainly consisting of quinine (62.9%), atovaquone and proguanil (13.1%), mefloquine (11.1%), and chloroquine (9.4%). 
l Mainly consisting of methotrexate (44.6%), and azathioprine (38.6%). 
m Mainly consisting of codeine (56.0%), dihydrocodeine (19.6%), dextropropoxyphene (12.0%), and tramadol (9.1%). 
n Mainly consisting of gabapentin (38.6%), pregabalin (18.0%), carbamazepine (14.1%), and sodium valproate (10.4%) 
o Mainly consisting of propranolol (68.2%), diltiazem (10.5%), and digoxin (8.0%).  
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3.1.5 Discussion 
This large population-based nested case-control study revealed that underweight, current 
smoking, high alcohol consumption, alcoholism, and drug abuse were associated with 
increased risks of seizures in adult patients with depression. Patients with comorbid dementia 
or a history of intracerebral bleeding, ischemic stroke/TIA, or major head trauma, had 
considerably higher risks of seizures than patients without these comorbidities. Current use of 
cephalosporins or antiarrhythmics was also associated with an increased risk of seizures 
compared to non-use of these drug groups. 
These results on the association between BMI and lifestyle factors and the risk of seizures 
among patients with depression are consistent with reports from the general 
population.51,101,102 Being an underweight (BMI≤18.5kg/m2) adult was associated with a non-
significantly increased risk of seizures (adjusted relative risk 1.6 [95% CI, 0.7 to 3.8]) in a 
study using a different U.K. population-based database.102 Additionally, while we observed a 
crude 1.5-fold (95% CI, 1.3- to 1.7-fold) increased risk of seizures with current smoking 
compared to non-smoking, a study based on data from the Nurses’ Health Study II reported an 
adjusted 2.6-fold (95% CI, 1.5- to 4.4-fold) increased risk of seizures among women who 
currently smoked compared to women who did not smoke.101 In accordance with our results, 
ex-smoking was not associated with seizures in that study.101 Our results concur with a meta-
analysis reporting a dose-dependent association between alcohol consumption and the risk of 
seizures, with a risk curve rising steeply after a threshold of approximately 28 units of alcohol 
consumption per week.51 Lastly, drug abuse has repeatedly been associated with increased 
risk of seizures in the general population, either through direct toxicity or withdrawal.54 
Our results further suggest that depressed patients with comorbid schizophrenia, manic 
episodes or bipolar disorder, or suicidal ideation/suicide attempt were approximately twice as 
likely to experience an incident seizure as depressed patients without these psychiatric 
comorbidities. While depression, schizophrenia, bipolar disorder, and suicidal ideation/suicide 
attempt have been reported to be individual risk factors for seizures,27,65–67,85 our study 
suggests that schizophrenia, bipolar disorder, and suicidal ideation/suicide attempt represent 
additional risk factors for seizures among patients with depression. Psychiatric comorbidities 
diagnosed close to the index date tended to be associated with increased risks of seizures 
compared to psychiatric comorbidities diagnosed further in the past, a finding which is 
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supported by a Swedish observational study on the association between psychiatric disorders 
and seizures.67  
Depressed patients with comorbid dementia or a history of intracerebral bleeding, ischemic 
stroke/TIA, or recent major head trauma, were at a substantially increased risk of developing 
seizures compared to depressed patients without these comorbidities. The risk increases 
ranged from approximately 7-fold for comorbid dementia to approximately 20-fold for 
recently diagnosed ischemic stroke/TIA. These results are consistent with the epidemiologic 
literature on these neurologic disorders and their strong individual association with acute 
symptomatic or progressive seizures in the general population. In an observational study 
among patients aged 65 or over, a diagnosis of dementia was associated with a 7- to 11-fold 
increased risk of incident seizures compared with no such diagnosis.86 Additionally, several 
population-based studies reported a 23- to 35-fold increased risk of seizures in patients with 
stroke in the first year after their stroke diagnosis, compared to the general population.103–105 
In our study, depression with comorbid migraine was overall not associated with an increased 
risk of seizures compared with depression alone, but depression with comorbid migraine with 
aura was. These results are in line with the results of an observational study by Hesdorffer et 
al. (2007) among an Icelandic population aged 10 years or over.69  
We observed increased risks of seizures associated with current, but not past use of 
cephalosporins and antiarrhythmics (mainly propranolol). As these effects were not adjusted 
for confounding factors other than the matching variables, these associations might either 
represent true adverse drug effects, or they could alternatively be related to underlying 
disorders for which the drugs were prescribed. The finding that current and past users of 
antipsychotics, benzodiazepines, opioids, and anticonvulsants, had increased odds ratios of 
seizures compared to non-users, might suggest that underlying disease or disease severity 
leading to these drug prescriptions - rather than the drug itself - was associated with the 
occurrence of seizures.  
We investigated the association between lifestyle factors, comorbidities, and co-medication 
and the risk of incident seizures among a large population of patients with incident depression 
who were followed for up to 16 years. The study was based on one of the largest and best 
validated medical records databases worldwide. However, it is a limitation that depression and 
seizure diagnoses were not formally validated in the CPRD. Thus, to ascertain the validity of 
the depression diagnosis, we only included patients in our base population if they received at 
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least one antidepressant prescription within a year prior to or at any time after the depression 
diagnosis. As only selected patients receive antiepileptic therapy after the first seizure,82 we 
decided to include patients with recorded seizure codes even if they did not receive any 
antiepileptic therapy afterwards. However, we developed the algorithm used to define a first-
time seizure by reviewing a random sample of 150 profiles of patients with a record of 
seizure/epilepsy at some time after the depression diagnosis to assess the likelihood of the 
seizure diagnosis.  
Through matching, our analyses were adjusted for sex, age, calendar time, number of years of 
history in the database, GP practice, and antidepressant exposure status at the index date (a 
potential proxy for depression severity). As this study aimed to crudely describe the features 
that distinguish depressed patients who develop seizures from depressed patients who do not 
develop seizures rather than test formal hypotheses, we did not adjust our multivariate 
analyses for other potential confounders. Our estimated odds ratios should therefore be 
interpreted as crude descriptive associations rather than unbiased risk estimates.  
In conclusion, our study suggests that among adult patients with depression, current smoking, 
drinking of more than five to six units of alcohol a day, alcoholism, and drug abuse were 
potential risk factors for seizures. Patients with psychiatric comorbidities, dementia, or 
recorded histories of ischemic stroke and/or TIA, intracerebral bleeding, or major head 
trauma, had substantially higher risks of seizures compared to patients without these 
comorbidities. Lastly, current use of cephalosporins or antiarrhythmics was associated with an 
increased risk of seizures compared to non-use in patients with depression. 
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3.2.1 Abstract 
Objective 
To assess the risk of first-time seizures in association with exposure to antidepressants in 
patients with depressive disorders. 
Methods 
We conducted a retrospective follow-up study with a nested case-control analysis using data 
from the U.K.-based Clinical Practice Research Datalink (CPRD). We estimated crude 
incidence rates with 95% confidence intervals (CIs) of seizures in depressed patients who 
used selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake 
inhibitors (SNRIs), tricyclic antidepressants (TCAs), ‘other antidepressants’, no 
antidepressants, or who had used antidepressants in the past. To adjust for potential 
confounding, we estimated odds ratios of antidepressant drug use among cases with seizures 
and matched controls in a nested case-control analysis. 
Results 
Of 151,005 depressed patients, 619 had an incident seizure during follow-up. Incidence rates 
per 10,000 person-years were 12.44 (95% CI, 10.67-14.21) in SSRI users, 15.44 (95% CI, 
8.99-21.89) in SNRI users, 8.33 (95% CI, 4.68-11.98) in TCA users, 9.33 (95% CI, 6.19-
12.46) in non-users of antidepressants, and 5.05 (95% CI, 4.49-5.62) in past users of 
antidepressants. In the case-control analysis, relative risk estimates for seizures were 
increased in current users of SSRIs (adjusted odds ratio 1.98, 95% CI 1.48-2.66) and SNRIs 
(adjusted odds ratio 1.99, 95% CI 1.20-3.29), but not TCAs (adjusted odds ratio 1.36, 95% CI 
0.86-2.14), compared with non-use.  
Conclusion 
Current use of SSRIs or SNRIs was associated with a twofold increased risk of first-time 
seizures compared to non-use, while current use of TCAs (mostly low dose) was not 
associated with seizures. Treatment initiation in SSRI and SNRI users was associated with the 
highest risk of seizures.  
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3.2.2 Introduction 
Depression is among the top three leading causes of disease burden in terms of disability-
adjusted life years in high-income countries.
106
 In the U.K. about 25% of adults suffer from an 
episode of major depression at least once in their lifetime.
23
 Patients with moderate to severe 
depression should receive treatment including pharmacotherapy.
107
 Second-generation 
antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), or ‘other antidepressants’ (such as trazodone, 
reboxetine, bupropion or mirtazapine), are preferred to older tri- or tetracyclic antidepressants 
as first-line antidepressants.
108
 
Most antidepressants induce seizures in overdose,
57,88,89
 but the seizure risk at therapeutic 
dose ranges remains unclear. Clinical trials suggested higher seizure incidence in patients 
assigned to placebo than to most second-generation antidepressants.
93
 Therapeutic use of 
tricyclic antidepressants (TCAs) has been associated with an increased risk of seizures, a risk 
reported to be higher than the risk for therapeutic use of SSRIs.
55,57,58,109,110
 Conversely, a 
recent British observational study found that use of SSRIs, venlafaxine, or mirtazapine, was 
associated with an increased risk of seizures compared to use of TCAs in depressed patients 
aged 65 or older.
26
 
Evidence to date mainly comes from trials that were limited to few patients and focused on 
efficacy and short-term safety.
57,58,93,109,111
 To analyze seizure risk in a large ‘real life setting’ 
we estimated absolute and relative risk estimates of seizures in 151,005 adult patients with 
depression who used various types of antidepressants and were followed over a period of up 
to 14 years. 
3.2.3 Methods 
Study design and data source 
We conducted a retrospective population-based follow-up study with a nested case-control 
analysis, using data from the U.K.-based Clinical Practice Research Datalink (CPRD). The 
CPRD encompasses some 10,000,000 patient records provided by some 600 participating 
general practitioner (GP) practices.31 Patients are representative of the U.K. with regard to 
age, sex, and geographic distribution. GPs provide data on patient characteristics, medical 
diagnoses (recorded as ‘Read codes’), and drug prescriptions in a standardized and 
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anonymous form. The records of diagnoses and drug prescriptions have been validated and 
proven to be of high quality.34,35 Data from the CPRD have been used to conduct 
observational studies on depression or antidepressant use98,112–115 and on seizures.86,99,100,115 
This study was approved by the Independent Scientific Advisory Committee for Medicines 
and Healthcare products Regulatory Agency research. 
Study population 
Between 1998 and 2010, we identified all patients aged 18 to 89 years with an incident 
depression diagnosis followed by an antidepressant drug treatment or a first prescription for 
an antidepressant followed by an incident depression diagnosis within one year thereafter. 
Depression was defined by Read codes corresponding to the International Classification of 
Diseases version 10 (ICD-10) codes. The date of the incident depression diagnosis or the first 
prescription for an antidepressant, whichever came first, will subsequently be called ‘start 
date’. We excluded patients with a diagnosis of epilepsy or any antiepileptic therapy prior to 
the start date, and patients with important risk factors for seizures such as a recorded history 
of alcoholism, drug abuse, head trauma, intracerebral bleeding, brain tumor, brain abscess, 
sinus vein thrombosis, meningitis, encephalitis, HIV, or cancer prior to the start date. We did 
not exclude patients with dementia or a history of stroke and/or TIA even though they are risk 
factors for seizures86,105 because we aimed to investigate the potential effect modification by 
these comorbidities on our results. Patients had to have had at least three years of active 
history in the database prior to the start date to avoid inclusion of patients with prevalent 
depression.  
Follow-up and definition of seizure cases 
We followed all patients from the start date until they had (1) an incident record of seizure or 
epilepsy (corresponding to ICD-10 codes; as shown in, (2) a first prescription of antiepileptic 
therapy for reasons other than epilepsy, (3) until they turned 90 years old, (4) died, (5) left the 
database, (6) reached the end of data drawdown (December 2012), or (7) until one month 
prior to a first record of an important risk factor for seizures (as described under ‘study 
population’), whichever came first. Patients whose follow-up ended due to (1) will 
subsequently be called ‘cases’, and the date of the seizure will be referred to as ‘index date’.  
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Person-time analysis 
We assessed person-time for four antidepressant classes and corresponding single drugs 
between the start date and the end of follow-up: (1) SSRIs (citalopram, escitalopram, 
fluoxetine, paroxetine, sertraline, and fluvoxamine), (2) SNRIs (venlafaxine and duloxetine), 
(3) TCAs (amitriptyline, clomipramine, doxepin, imipramine, trimipramine, nortriptyline, 
lofepramine, and dosulepin), or (4) other antidepressants (mirtazapine, bupropion, reboxetine, 
and trazodone).  
We included patients who used solely one antidepressant, who switched antidepressants, or 
who concomitantly used different antidepressants during follow-up, and accumulated person-
time as follows: (1) no exposure to antidepressants (‘no antidepressant treatment’), defined as 
the period between the first diagnosis of depression and the first prescription for an 
antidepressant, provided that the diagnosis occurred prior to the prescription; (2) current 
exposure to solely one antidepressant (‘mono use’), defined as use from the day of the 
prescription through the expected end of treatment plus 7 days, provided that no other 
antidepressant was prescribed in this period. Patients who switched between different 
antidepressants but had no period of overlapping treatment contributed person-time to mono 
use of these different antidepressants; (3) current exposure to more than one antidepressant 
drug concomitantly (‘mixed use’), defined as use from the day when at least two 
antidepressants were prescribed concomitantly through the expected end of treatment of all or 
all but one antidepressant plus 90 days (to ascertain that if a person switched from mixed use 
to mono use and developed a subsequent seizure, the discontinued drug was most likely not 
associated with the seizure). Patients who remained treated with one antidepressant after the 
period of mixed use plus 90 days contributed person-time to mono use for the remaining drug 
thereafter; and (4) past exposure after the stop of antidepressant treatment (‘past use’), defined 
as the time after 7 or 90 days (depending on whether use was mono or mixed) after treatment 
had elapsed. The duration of treatment was derived from the recorded number of tablets or 
volume of liquids and the daily dose instructions.  
Nested case-control analysis 
For each case we identified four controls from the study population who did not develop 
seizures during follow-up. Controls were matched to cases on age (±2 years), sex, GP, index 
date, duration of history in the database prior to the index date (±2 years), and duration of 
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depression (±1 year). Case and control exposure was classified according to the timing of 
antidepressant use prior to the index date; ‘non-users’ were those who had no antidepressant 
prescriptions prior to the index date; ‘current users’ and ‘past users’ were those who had 
received the last prescription ≤90 days or >90 days prior to the index date, respectively. We 
further classified current users by number of prescriptions prior to the index date (1, 2-3, 4-5, 
>5 for SSRIs; 1-3, >3 for SNRIs, TCAs, and other antidepressants). We additionally stratified 
current users by sex. We evaluated antidepressant single drugs if they were used by at least 30 
patients at the index date. Users of antidepressant single drugs were classified by daily dose 
intake (≤1 defined daily dose (DDD)116, >1 defined daily dose) if the expected observations 
per cell of the contingency table were larger than 5. We assessed daily dose intake at the index 
date based on the quantity of drug prescribed by the GP at the previous visit and the daily 
dose instructions. If no dose instruction was available, we used default values in following 
order: (1) the dose instruction given for the same drug at the closest visit prior to the previous 
visit, (2) the defined daily dose if no dose instruction was recorded at any time prior, or (3) the 
dose of one unit (i.e. tablet or capsule) of sustained release forms.  
Statistical analysis 
We conducted a crude person-time analysis to estimate incidence rates with 95% confidence 
intervals (95% CIs) of seizures in patients with no antidepressant treatment, with any mono 
use, with mono use of different antidepressant classes and corresponding single drugs, and 
with past use of antidepressants. We stratified incidence rates by sex and age (18-49 vs. 50-89 
years).  
In the nested case-control analysis, we used SAS statistical software (version 9.3; SAS 
Institute, Cary, NC, USA) to conduct conditional logistic regression analyses. Relative risk 
estimates of antidepressant use among cases and controls were calculated as odds ratios with 
95% CIs. Odds ratios in this study were a valid relative risk estimate because the incidence 
rates of seizures were low (< 5%) in patients with no antidepressant treatment and in patients 
using antidepressants.25 We defined the reference group as patients who never used the 
respective antidepressant class in a given analysis (for analyses of drug classes) or 
antidepressant single drug (for analyses of single drugs) prior to the index date, and adjusted 
multivariate models for all other antidepressants used. We calculated odds ratios for 
antidepressant classes categorized by timing of antidepressant use (current/past use), and for 
current use by sex and number of prescriptions prior. In addition, we calculated odds ratios of 
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antidepressant single drug use, and where appropriate, categorized by dose used at the index 
date. Based on preexisting literature, we a priori adjusted our main multivariate models for 
alcohol consumption (none, 1-14 units/week, >14 units/week, unknown), history of other 
psychiatric disorders (schizophrenia, compulsive disorders, or affective disorders other than 
depression), dementia, Parkinson’s disease, transient ischemic attack [TIA], stroke, suicidal 
ideation, and current or past use of antipsychotics, opioids, benzodiazepines, or other 
antidepressants than those studied.27,55,62 We tested additional potential confounders 
(cardiovascular diseases, diabetes, hypertension, hyperlipidemia, hypothyroidism, sleep 
disorders, migraine, or multiple sclerosis; use of lithium, monoamine oxidase inhibitors, 
antibiotics, antimalarials, or antiarrhythmic drugs) but did not include them in the final model 
as they did not alter the risk estimates by >5%.  
To assess potential effect modification, we conducted additional analyses comparing risk 
estimates between patients with depression with or without comorbid dementia, and patients 
with depression with or without a history of stroke and/or TIA.  
In sensitivity analyses, we explored whether risk estimates differed if we defined the 
reference group as patients with no antidepressant treatment prior to the index date, and if we 
distinguished between patients who used solely one antidepressant vs. those who switched 
antidepressants during follow-up, as switching of antidepressants has been associated with 
more severe depression.117 
3.2.4 Results 
We identified 151,005 patients with incident depression who met our inclusion criteria. 
Among those, we identified 619 seizure cases and 2,476 controls in the nested case-control 
analysis. Mean age (± standard deviation) at the index date was 48.6 (± 20.6) years and 57.2% 
of patients were female.  
Incidence rates 
The estimated incidence rates of seizures per 10,000 person-years (PYs) were 12.58 (95% CI, 
11.03-14.13), 9.33 (95% CI, 6.19-12.46), and 5.05 (95% CI, 4.49-5.62) in patients with 
current mono use, no antidepressant treatment, and past use of antidepressants, respectively 
(Table 13). Estimated incidence rates per 10,000 PYs for current mono use of SSRIs, SNRIs, 
and TCAs were 12.44 (95% CI, 10.67-14.21), 15.44 (95% CI, 8.99-21.89), and 8.33 (95% CI, 
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4.68-11.98), respectively. Among patients treated with SSRIs or SNRIs, incidence rates 
tended to be higher in older (50-89 years) than in younger patients (18-49 years). 
Current users of escitalopram and paroxetine were as likely to develop seizures as non-users 
of antidepressants. Current users of sertraline, venlafaxine, or mirtazapine developed seizures 
almost twice as likely as non-users of antidepressants, although these differences were not 
statistically significant (Table 14). 
Nested case-control analysis 
Prevalent diagnoses of TIA, stroke, dementia, Parkinson’s disease, schizophrenia and 
concurrent use of antipsychotic drugs or cephalosporin antibiotics were associated with 
increased odds of seizures (Table 15).  
Current use of SSRIs (adjusted odds ratio 1.98 [95% CI, 1.48-2.66]) and SNRIs (adjusted 
odds ratio 1.99 [95% CI, 1.20-3.29]) was associated with increased odds of seizures in both 
sexes compared to non-use of the respective drug classes, while current use of TCAs was 
associated with slightly increased odds of seizures in men, but not in women (Table 16). The 
odds of seizures were highest at treatment initiation with SSRIs and SNRIs.  
Among single antidepressants, use of citalopram (adjusted odds ratio 1.69 [95% CI, 1.25-
2.28]), sertraline (adjusted odds ratio 2.53 [95% CI, 1.49-4.30]), fluoxetine (adjusted odds 
ratio 1.51 [95% CI, 1.06-2.16]), and venlafaxine (adjusted odds ratio 2.52 [95% CI, 1.44-
4.42]), was associated with significantly increased odds of seizures compared to non-use 
(Table 17). We observed trends toward higher odds of seizures with increasing dose for 
fluoxetine, venlafaxine, and mirtazapine.  
Due to low numbers of patients with dementia or stroke/TIA, we could not explore effect 
modification by these disorders in users of all antidepressant drug classes. Current use of 
SSRIs tended to be more strongly associated with seizures in patients with dementia (adjusted 
odds ratio 6.74 [95% CI, 1.53-29.62]) than those without dementia (adjusted odds ratio 1.90 
[95% CI, 1.41-2.55]) (as shown in Table 18). We observed no effect modification by history 
of stroke/TIA in users of SSRIs or TCAs (as shown in Table 19).  
Odds ratios did not change considerably when we compared antidepressant users to patients 
with depression who did not yet take any antidepressant medication (as shown in Table 20). 
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Additionally, switching antidepressants was not associated with substantially different odds 
ratios of seizures compared to using the same antidepressant during follow-up (as shown in 
Table 21).  
Table 13: Incidence rates of seizures in patients with depression with no antidepressant treatment, with current and past use 
of antidepressants, and with current use of different antidepressant drug classes, by age or sex 
Antidepressant drug class Person-years 
No. of cases with 
outcome 
IR per 10,000 
person-years 
95% CI 
No antidepressant 
treatment 
    
Overall 36,457 34 9.33 6.19-12.46 
Stratified by age      
18-49 years 25,885 29 11.20 7.13-15.28 
50-90 years 10,573 5 4.73 0.58-8.87 
Stratified by sex     
men  10,400 12 11.54 5.01-18.07 
women  26,057 22 8.44 4.91-11.97 
Antidepressant treatment 
(overall) 
    
Overall 200,331 252 12.58 11.03-14.13 
Stratified by age      
18-49 years 113,055 126 11.15 9.20-13.09 
50-90 years 87,276 126 14.44 11.92-16.96 
Stratified by sex     
men  62,805 107 17.04 13.81-20.27 
women  137,526 145 10.54 8.83-12.26 
Past use of antidepressants     
Overall 609,764 308 5.05 4.49-5.62 
Stratified by age  
    
18-49 years 391,520 183 4.67 4.00-5.35 
50-90 years 218,244 125 5.73 4.72-6.73 
Stratified by sex     
men  199,125 133 6.68 5.54-7.81 
women  410,639 175 4.26 3.63-4.89 
SSRIs     
Overall 152,758 190 12.44 10.67-14.21 
Stratified by age  
    
18-49 years 91,036 97 10.66 8.53-12.78 
50-90 years 61,722 93 15.07 12.01-18.13 
Stratified by sex     
men  46,664 76 16.29 12.63-19.95 
women  106,094 114 10.75 8.77-12.72 
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Table 13 (cont.)     
Antidepressant drug class Person-years 
No. of cases with 
outcome 
IR per 10,000 
person-years 
95% CI 
SNRIs     
Overall 14,253 22 15.44 8.99-21.89 
Stratification by age      
18-49 years 8,025 10 12.46 4.74-20.18 
50-90 years 6,228 12 19.27 8.37-30.17 
Stratification by sex 
    
men  5,343 10 18.72 7.12-30.32 
women  8,910 12 13.47 5.85-21.09 
TCAs     
Overall 24,004 20 8.33 4.68-11.98 
Stratified by age      
18-49 years 9,983 11 11.02 4.51-17.53 
50-90 years 14,021 9 6.42 2.23-10.61 
Stratified by sex 
    
men  6,918 12 17.35 7.53-27.16 
women  17,086 8 4.68 1.44-7.93 
Other Antidepressantsa     
Overall 9,316 20 21.47 12.06-30.88 
Stratified by age      
18-49 years 4,010 8 19.95 6.13-33.78 
50-90 years 5,306 12 22.62 9.82-35.42 
Stratified by sex 
    
men  3,880 9 23.20 8.04-38.36 
women  5,436 11 20.24 8.28-32.19 
Abbreviations: IR, incidence rate; CI, confidence interval; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin 
norepinephrine reuptake inhibitors; TCAs, tricyclic antidepressants. 
a This group consisted of the drugs mirtazapine, bupropion, reboxetine, and trazodone 
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Table 14: Incidence rates of seizures in current users of most frequently used single antidepressants, by age or sex 
Antidepressant drug Person-years No. of cases with outcome 
IR per 10,000 
person-years 
95% CI 
Citalopram  
    
Overall 61,677 87 14.11 11.14-17.07 
Stratified by age      
18-49 years 35,286 44 12.47 8.78-16.15 
50-90 years 26,391 43 16.29 11.42-21.16 
Stratified by sex 
    
men  18,551 36 19.41 13.07-25.75 
women  43,127 51 11.83 8.58-15.07 
Escitalopram     
Overall 8,080 8 9.90 3.04-16.76 
Stratified by age      
18-49 years 4,940 4 8.10 0.16-16.03 
50-90 years 3,139 4 12.74 0.25-25.23 
Stratified by sex     
men  2,545 2 7.86 NA 
women  5,535 6 10.84 2.17-19.51 
Fluoxetine 
    
Overall 49,488 52 10.51 7.65-13.36 
Stratified by age      
18-49 years 31,847 31 9.73 6.31-13.16 
50-90 years 17,640 21 11.90 6.81-17.00 
Stratified by sex 
    
men  14,434 23 15.93 9.42-22.45 
women  35,054 29 8.27 5.26-11.28 
Paroxetine 
    
Overall 17,537 16 9.12 4.65-13.59 
Stratified by age      
18-49 years 9,807 8 8.16 2.50-13.81 
50-90 years 7,730 8 10.35 3.18-17.52 
Stratified by sex 
    
men  5,955 4 6.72 0.13-13.30 
women  11,582 12 10.36 4.50-16.22 
Sertraline 
    
Overall 15,912 27 16.97 10.57-23.37 
Stratified by age  
    
18-49 years 9,119 10 10.97 4.17-17.76 
50-90 years 6,793 17 25.03 13.13-36.92 
Stratified by sex     
men  5,155 11 21.34 8.73-33.95 
women  10,758 16 14.87 7.59-22.16 
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Table 14 (cont.)     
Antidepressant drug Person-years No. of cases with outcome 
IR per 10,000 
person-years 
95% CI 
Venlafaxine 
    
Overall 13,153 22 16.73 9.74-23.71 
Stratified by age      
18-49 years 7,444 10 13.43 5.11-21.76 
50-90 years 5,709 12 21.02 9.13-32.91 
Stratified by sex 
    
men  4,993 10 20.03 7.61-32.44 
women  8,160 12 14.71 6.39-23.03 
Amitriptyline 
    
Overall 9,854 12 12.18 5.29-19.07 
Stratified by age  
    
18-49 years 3,845 8 20.81 6.39-35.23 
50-90 years 6,010 4 6.66 0.13-13.18 
Stratified by sex     
men  2,723 8 29.38 9.02-49.74 
women  7,131 4 5.61 0.11-11.11 
Mirtazapine 
    
Overall 7,032 12 17.06 7.41-26.72 
Stratified by age  
    
18-49 years 2,971 5 16.83 2.08-31.58 
50-90 years 4,061 7 17.24 4.47-30.00 
Stratified by sex 
    
men  3,061 7 22.87 5.93-39.81 
women  3,971 5 12.59 1.55-23.63 
Abbreviations: IRs, incidence rates; CI, confidence interval; NA, not applicable. 
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Table 15: Characteristics of cases with seizures and matched controlsa 
Characteristics 
No. Cases 
(n=619) (%)b 
No. Controls 
(n=2,476) (%)b 
ORc 95% CI 
Sex 
   
 
Male 265 (42.8) 1,060 (42.8) NA NA 
Female 354 (57.2) 1,416 (57.2) NA NA 
Age, years 
   
 
18-29 153 (24.7) 604 (24.4) NA NA 
30-39 101 (16.3) 400 (16.2) NA NA 
40-49 95 (15.4) 383 (15.5) NA NA 
50-59 70 (11.3) 293 (11.8) NA NA 
60-69 66 (10.7) 279 (11.3) NA NA 
70-79 66 (10.7) 246 (9.9) NA NA 
80-90 68 (11.0) 271 (11.0) NA NA 
Body mass index, kg/m2 
   
 
<18.5 18 (2.9) 54 (2.2) 1.32 0.75-2.32 
18.5-24.9 221 (35.7) 868 (35.1) 1 reference 
25.0-29.9 137 (22.1) 641 (25.9) 0.82 0.65-1.05 
≥30.0 112 (18.1) 452 (18.3) 0.95 0.73-1.23 
Unknown 131 (21.2) 461 (18.6) 1.15 0.86-1.53 
Smoking status 
 
 
 
 
Nonsmoker 251 (40.6) 1,027 (41.5) 1 reference 
Current smoker 175 (28.3) 687 (27.8) 1.05 0.84-1.32 
Former smoker 147 (23.8) 597 (24.1) 1.02 0.80-1.29 
Unknown 46 (7.4) 165 (6.7) 1.07 0.70-1.65 
Alcohol consumption (in 
units/week, any time prior to 
the index date) 
   
 
Nondrinker 257 (41.5) 946 (38.2) 1 reference 
1-14  211 (34.1) 900 (36.4) 0.85 0.69-1.05 
>14 52 (8.4) 247 (10.0) 0.75 0.53-1.06 
Unknown 99 (16.0) 383 (15.5) 0.85 0.63-1.17 
Comorbidities at any time 
prior to the index date 
   
 
Transient ischemic attack 40 (6.5) 51 (2.1) 3.76 2.37-5.96 
Ischemic stroke 72 (11.6) 71 (2.9) 5.36 3.67-7.84 
Dementia 51 (8.2) 38 (1.5) 6.72 4.20-10.77 
Parkinson's disease 10 (1.6) 14 (0.6) 3.05 1.31-7.13 
Compulsive disorders and/or 
affective disordersd  
31 (5.0) 101 (4.1) 1.25 0.82-1.91 
Schizophrenia  16 (2.6) 15 (0.6) 4.27 2.11-8.63 
Suicide attempt and/or suicidal 
ideation 
65 (10.5) 125 (5.1) 2.28 1.65-3.15 
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Table 15 (cont.)     
Characteristics 
No. Cases 
(n=619) (%)b 
No. Controls 
(n=2,476) (%)b 
ORc 95% CI 
Migraine 70 (11.3) 251 (10.1) 1.14 0.85-1.51 
Concurrent drug usee     
Antipsychotic drugsf 54 (8.7) 64 (2.6) 4.07 2.74-6.05 
Benzodiazepines 79 (12.8) 167 (6.7) 2.05 1.52-2.77 
Penicillins 48 (7.8) 204 (8.2) 0.92 0.63-1.35 
Cephalosporinsg 17 (2.8) 30 (1.2) 2.42 1.32-4.43 
Antimalarials 9 (1.5) 32 (1.3) 1.12 0.52-2.38 
Opioidsh 97 (15.7) 290 (11.7) 1.50 1.14-1.99 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable. 
a Controls were matched to cases on age, sex, index date, GP practice, duration of history in the CPRD, and duration of 
depression. All ORs presented are conditional on the matching factors.  
b Due to rounding, percentages may not total 100. 
c ORs for different categories of body mass index, smoking status, and alcohol consumption were adjusted for each other. 
ORs for comorbidities and concomitant drug use were not adjusted. 
d Affective disorders excluding depression. 
e Last prescription within 90 days prior to index date.  
f This group consisted mainly of phenothiazines such as prochlorperazine (76.4%) or chlorpromazine/promazine (3.8%). 
g This group consisted mainly of first-generation cephalosporins such as cephalexin (66.3%) or cefadrine (9.0%).  
h This group consisted mainly of codeine/dihydrocodeine (74.8%), dextropropoxyphene (17.7%), and tramadol (6.5%). 
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Table 16: Odds ratios for seizures in users of different antidepressant drug classes, by current or past use, by current use and sex, or by current use and number of prescriptions prior to 
the index date 
Antidepressant drug class 
No. Cases 
(n=619) (%)a 
No. Controls 
(n=2,476) (%)a 
OR crude 95% CI OR adj.b 95% CI 
SSRIs       
No use 105 (17.0) 557 (22.5) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  243 (39.3) 629 (25.4) 2.03 1.57-2.63 1.98 1.48-2.66 
Current use stratified by sexc       
men 100 (16.2) 286 (11.6) 1.62 1.12-2.36 1.84 1.19-2.85 
women 143 (23.1) 343 (13.8) 2.46 1.72-3.52 2.22 1.47-3.37 
Current use by number of prescriptions        
1 27 (4.4) 48 (1.9) 2.99 1.79-5.02 3.35 1.89-5.92 
2-3  37 (6.0) 105 (4.2) 1.97 1.25-3.09 2.37 1.46-3.87 
4-5 28 (4.5) 89 (3.6) 1.70 1.06-2.72 1.51 0.90-2.52 
>5 151 (24.4) 387 (15.6) 1.97 1.46-2.65 1.77 1.26-2.48 
Past use (last presc. >90 days ago) 271 (43.8) 1,290 (52.1) 1.07 0.82-1.39 1.16 0.87-1.56 
SNRIs       
No use 551 (89.0) 2,290 (92.5) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  31 (5.0) 64 (2.6) 2.07 1.32-3.24 1.99 1.20-3.29 
Current use stratified by sexc       
men 14 (2.3) 33 (1.3) 1.77 0.92-3.42 1.86 0.87-3.97 
women 17 (2.7) 31 (1.3) 2.38 1.29-4.41 2.15 1.06-4.37 
Current use by number of prescriptions       
1-3 12 (1.9) 12 (0.5) 4.27 1.88-9.72 4.03 1.70-9.56 
>3 19 (3.1) 52 (2.1) 1.56 0.91-2.69 1.24 0.67-2.29 
Past use (last presc. >90 days ago) 37 (6.0) 122 (4.9) 1.29 0.87-1.89 1.17 0.76-1.79 
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Table 16 (cont.)       
Antidepressant drug class 
No. Cases 
(n=619) (%)a 
No. Controls 
(n=2,476) (%)a 
OR crude 95% CI OR adj.b 95% CI 
TCAs       
No use 475 (76.7) 1,896 (76.6) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  35 (5.7) 147 (5.9) 0.95 0.64-1.40 0.99 0.63-1.53 
Current use stratified by sexc       
men 20 (3.3) 66 (2.6) 1.25 0.73-2.14 1.58 0.85-2.96 
women 15 (2.4) 81 (3.3) 0.72 0.41-1.28 0.58 0.30-1.13 
Current use by number of prescriptions       
1-3 11 (1.8) 48 (1.9) 0.91 0.45-1.82 0.80 0.36-1.77 
>3 24 (3.9) 99 (4.0) 0.97 0.61-1.54 0.86 0.52-1.43 
Past use (last presc. >90 days ago) 109 (17.6) 433 (17.5) 1.01 0.79-1.29 1.09 0.82-1.43 
Other antidepressantsd       
No use 552 (89.2) 2,299 (92.9) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  34 (5.5) 51 (2.1) 2.88 1.83-4.54 2.30 1.34-3.96 
Current use stratified by sexc       
men 20 (3.2) 25 (1.0) 3.46 1.86-6.42 3.78 1.87-7.61 
women 14 (2.3) 26 (1.1) 2.31 1.17-4.56 0.97 0.38-2.50 
Current use by number of prescriptions       
1-3 10 (1.6) 13 (0.5) 3.21 1.41-7.34 3.28 1.31-8.20 
>3 24 (3.9) 38 (1.5) 2.76 1.61-4.71 1.63 0.84-3.16 
Past use (last presc. >90 days ago) 33 (5.3) 126 (5.1) 1.08 0.73-1.61 0.92 0.59-1.43 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin norepinephrine reuptake inhibitors; TCAs, 
tricyclic antidepressants. 
a Due to rounding, percentages may not total 100. 
b Adjusted for alcohol consumption, other antidepressant drugs, benzodiazepines, antipsychotics, opioids, schizophrenia, affective disorders other than depression, compulsive 
disorders, suicidal ideation, dementia, Parkinson’s disease, TIA, and stroke. 
c Reference groups: Male non-users (for men), female non-users (for women).  
d This group consisted of the drugs mirtazapine, bupropion, reboxetine, and trazodone. 
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Table 17: Odds ratios for seizures in users of different antidepressant single drugs, by use and by dose used at the index datea 
Antidepressant drug No. Cases (n=619) (%)b No. Controls (n=2,476) (%)b OR crude 95% CI OR adj.c 95% CI 
Citalopram       
No use at the ID 527 (85.1) 2,267 (91.6) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
Use at the ID 92 (14.9) 209 (8.4) 1.94 1.48-2.54 1.69 1.25-2.28 
Use at the ID by dose       
≤20mg (≤DDD) 65 (10.5) 155 (6.3) 1.84 1.35-2.51 1.68 1.19-2.37 
>20mg (>DDD) 27 (4.4) 54 (2.2) 2.22 1.37-3.59 1.72 1.01-2.93 
Escitalopram       
No use at the ID 611 (98.7) 2,455 (99.2) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
Use at the ID 8 (1.3) 21 (0.9) 1.54 0.68-3.50 1.28 0.48-3.40 
Fluoxetine       
No use at the ID 569 (91.9) 2,336 (94.4) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
Use at the ID 50 (8.1) 140 (5.7) 1.47 1.05-2.06 1.51 1.06-2.16 
Use at the ID by dose       
≤20mg (≤DDD) 38 (6.1) 120 (4.9) 1.30 0.89-1.90 1.41 0.94-2.10 
>20mg (>DDD) 12 (1.9) 20 (0.8) 2.42 1.18-4.94 1.99 0.92-4.29 
Paroxetine       
No use at the ID 602 (97.3) 2,422 (97.8) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
Use at the ID 17 (2.8) 54 (2.2) 1.27 0.73-2.21 1.04 0.56-1.92 
Sertraline       
No use at the ID 589 (95.2) 2,434 (98.3) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
Use at the ID 30 (4.9) 42 (1.7) 2.92 1.81-4.69 2.53 1.49-4.30 
Use at the ID by dose       
≤50mg (≤DDD) 14 (2.3) 21 (0.9) 2.75 1.39-5.46 2.42 1.15-5.11 
>50mg (>DDD) 16 (2.6) 21 (0.9) 3.08 1.61-5.90 2.64 1.26-5.54 
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Table 17 (cont.)       
Antidepressant drug No. Cases (n=619) (%)b No. Controls (n=2,476) (%)b OR crude 95% CI OR adj.c 95% CI 
Venlafaxine       
No use at the ID 592 (95.6) 2,429 (98.1) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
Use at the ID 27 (4.4) 47 (1.9) 2.49 1.51-4.10 2.52 1.44-4.42 
Use at the ID by dose       
≤100mg (≤DDD) 13 (2.1) 32 (1.3) 1.76 0.89-3.50 1.86 0.88-3.95 
>100mg (>DDD) 14 (2.3) 15 (0.6) 3.78 1.82-7.83 3.73 1.63-8.55 
Amitriptylined       
No use at the ID 603 (97.4) 2,435 (98.3) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
Use at the ID 16 (2.6) 41 (1.7) 1.60 0.88-2.90 1.48 0.75-2.92 
Mirtazapine       
No use at the ID 604 (97.6) 2,443 (98.7) 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
Use at the ID 15 (2.4) 33 (1.3) 1.86 1.00-3.48 1.53 0.73-3.20 
Use at the ID by dose       
≤30mg (≤DDD) 10 (1.6) 26 (1.1) 1.58 0.75-3.32 1.19 0.50-2.84 
>30mg (>DDD) 5 (0.8) 7 (0.3) 2.89 0.92-9.11 3.16 0.79-12.69 
Abbreviations: ID, index date; OR, odds ratio; CI, confidence interval; adj., adjusted; DDD, defined daily dose (as described in the methods section). 
a We assessed use and dose used at the index date from the quantity of drug prescribed at the previous visit and the daily dose instruction given. If no information on daily dose 
instruction was available, we used default values as described in the methods section. These default values were used in 27 (9.0%), 5 (17.2%), 25 (13.2%), 10 (14.1%), 11 (15.3%), 25 
(33.8%), 25 (43.9%), or 8 (16.7%) patients who at the index date used citalopram, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine, amitriptyline, or mirtazapine, 
respectively. 
b Due to rounding, percentages may not total 100. 
c Adjusted for alcohol consumption, other antidepressant drugs, benzodiazepines, antipsychotics, opioids, schizophrenia, affective disorders other than depression, compulsive 
disorders, suicidal ideation, dementia, Parkinson’s disease, TIA, and stroke. 
d Of 57 users, only 10 (17.5%) used doses >75mg (>DDD) at the ID
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Table 18: Odds ratios for seizures in users of different antidepressant drug classes compared to non-users of antidepressants, by current or past use, and by dementia  
Analysis restricted to patients with dementia       
Antidepressant drug class 
No. Cases  
(n=51) (%)a 
No. Controls 
(n=38) (%)a 
OR crude 95% CI OR adj.b 95% CI 
SSRIs       
No use 7 (1.1) 9 (0.4) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  29 (4.7) 11 (0.4) 4.48 1.26-15.87 6.74 1.53-29.62 
Past use (last presc. >90 days ago) 15 (2.4) 18 (0.7) 1.20 0.35-4.13 1.44 0.33-6.27 
SNRIs       
No use 44 (7.1) 34 (1.4) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  X X NA NA NA NA 
Past use (last presc. >90 days ago) 5 (0.8) X NA NA NA NA 
TCAs       
No use 43 (7.0) 29 (1.2) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  X X NA NA NA NA 
Past use (last presc. >90 days ago) 8 (1.3) 5 (0.2) 0.97 0.28-3.33 0.64 0.14-2.96 
Other antidepressantsc       
No use 39 (6.3) 31 (1.3) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  9 (1.5) 6 (0.2) 2.64 1.59-4.38 1.41 0.37-5.36 
Past use (last presc. >90 days ago) X X NA NA NA NA 
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Table 18 (cont.) 
Analysis restricted to patients without dementia 
Antidepressant drug class 
No. Cases 
(n=568) (%)a 
No. Controls 
(n=2,438) (%)a 
OR crude 95% CI OR adj.b 95% CI 
SSRIs       
No use 98 (15.8) 548 (22.1) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  214 (34.6) 618 (25.0) 1.95 1.49-2.55 1.90 1.41-2.55 
Past use (last presc. >90 days ago) 256 (41.4) 1,272 (51.4) 1.07 0.82-1.41 1.15 0.86-1.55 
SNRIs       
No use 507 (81.9) 2,256 (91.1) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  29 (4.7) 61 (2.5) 2.16 1.36-3.43 2.11 1.27-3.52 
Past use (last presc. >90 days ago) 32 (5.2) 121 (4.9) 1.19 0.79-1.80 1.11 0.72-1.73 
TCAs       
No use 432 (69.8) 1,867 (75.4) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  35 (5.7) 143 (5.8) 1.10 0.74-1.63 1.06 0.68-1.64 
Past use (last presc. >90 days ago) 101 (16.3) 428 (17.3) 1.05 0.82-1.36 1.10 0.83-1.46 
Other antidepressantsc       
No use 513 (82.9) 2,268 (91.6) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  25 (4.0) 45 (1.8) 2.64 1.59-4.38 2.50 1.41-4.42 
Past use (last presc. >90 days ago) 30 (4.9) 125 (5.1) 1.11 0.74-1.68 0.88 0.56-1.39 
Abbreviations: OR, odds ratio; CI, confidence interval; adj., adjusted; NA, not applicable; X, cell contains <5 observations (due to ethics regulations to preserve  
confidentiality, the exact count is not displayed). 
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Table 19: Odds ratios for seizures in users of different antidepressant drug classes compared to non-users of antidepressants, by current or past use, and by a history of stroke/TIA  
Analysis restricted to patients with a history of stroke/TIA 
Antidepressant drug class 
No. Cases 
(n=90) (%)a 
No. Controls  
(n=103) (%)a 
OR crude 95% CI OR adj.b 95% CI 
SSRIs       
No use 15 (2.4) 24 (1.0) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  50 (8.1) 31 (1.3) 1.93 0.87-4.27 2.35 0.98-5.61 
Past use (last presc. >90 days ago) 25 (4.0) 48 (1.9) 0.71 0.31-1.67 0.85 0.34-2.14 
SNRIs       
No use 85 (13.7) 96 (3.9) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  X 5 (0.2) NA NA NA NA 
Past use (last presc. >90 days ago) X X NA NA NA NA 
TCAs       
No use 65 (10.5) 70 (2.8) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  8 (1.3) 16 (0.7) 0.58 0.22-1.52 0.82 0.27-2.45 
Past use (last presc. >90 days ago) 17 (2.8) 17 (0.7) 1.17 0.53-2.57 1.01 0.42-2.42 
Other antidepressantsc       
No use 77 (12.4) 98 (4.0) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  6 (1.0) X NA NA NA NA 
Past use (last presc. >90 days ago) 7 (1.1) X NA NA NA NA 
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Table 19 (cont.) 
Analysis restricted to patients without a history of stroke/TIA 
Antidepressant drug class 
No. Cases 
(n=90) (%)a 
No. Controls  
(n=103) (%)a 
OR crude 95% CI OR adj.b 95% CI 
SSRIs       
No use 90 (14.5) 533 (21.5) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  193 (31.2) 598 (24.2) 1.88 1.42-2.48 1.94 1.42-2.63 
Past use (last presc. >90 days ago) 246 (39.7) 1,242 (50.2) 1.09 0.82-1.44 1.18 0.87-1.60 
SNRIs       
No use 466 (75.3) 2,194 (88.6) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  27 (4.4) 59 (2.4) 2.36 1.46-3.80 2.08 1.24-3.51 
Past use (last presc. >90 days ago) 36 (5.8) 120 (4.9) 1.44 0.97-2.14 1.20 0.78-1.84 
TCAs       
No use 410 (66.2) 1,826 (73.8) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  27 (4.4) 131 (5.3) 0.97 0.63-1.50 1.03 0.65-1.65 
Past use (last presc. >90 days ago) 92 (14.9) 416 (16.8) 0.97 0.77-1.30 1.08 0.80-1.44 
Other antidepressantsc       
No use 475 (76.7) 2,201 (88.9) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  28 (4.5) 49 (2.0) 3.10 1.89-5.10 2.03 1.12-3.68 
Past use (last presc. >90 days ago) 26 (4.2) 123 (5.0) 1.01 0.65-1.56 0.82 0.51-1.31 
Abbreviations: OR, odds ratio; CI, confidence interval; adj., adjusted; NA, not applicable; X, cell contains <5 observations (due to ethics regulations to preserve confidentiality, the 
exact count is not displayed). 
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Table 20: Odds ratios for seizures in users of different antidepressant drug classes compared to non-users of antidepressants, by current or past use 
Antidepressant drug class 
No. Cases (n=619) 
(%)a 
No. Controls 
(n=2,476) (%)a 
OR crude 95% CI OR adj.b 95% CI 
No use of antidepressants 34 (5.5) 228 (9.2) 1 reference 1 reference 
SSRIs       
Current use (last presc. ≤ 90 days ago)  243 (39.3) 629 (25.4) 2.56 1.70-3.86 2.06 1.35-3.16 
Past use (last presc. >90 days ago) 271 (43.8) 1,290 (52.1) 1.37 0.89-2.09 1.21 0.78-1.89 
SNRIs       
Current use (last presc. ≤ 90 days ago)  31 (5.0) 64 (2.6) 3.71 2.06-6.67 2.11 1.06-4.20 
Past use (last presc. >90 days ago) 37 (6.0) 122 (4.9) 2.39 1.37-4.17 1.25 0.64-2.45 
TCAs       
Current use (last presc. ≤ 90 days ago)  35 (5.7) 147 (5.9) 1.75 1.02-3.01 1.04 0.56-1.92 
Past use (last presc. >90 days ago) 109 (17.6) 433 (17.5) 1.91 1.21-3.03 1.15 0.68-1.94 
Other antidepressantsc       
Current use (last presc. ≤ 90 days ago)  34 (5.5) 51 (2.1) 5.22 2.87-9.48 2.44 1.19-4.98 
Past use (last presc. >90 days ago) 33 (5.3) 126 (5.1) 2.00 1.14-3.49 0.99 0.50-1.96 
Abbreviations: OR, odds ratio; CI, confidence interval; adj., adjusted; NA, not applicable; presc., prescription; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin-
norepinephrine reuptake inhibitors; TCAs, tricyclic antidepressants. 
a Cases and controls could be users of more than one antidepressant group and thus be listed more than once in the table (thus percentages do not total 100%). 
b Adjusted for alcohol consumption, other antidepressant drug classes, benzodiazepines, antipsychotics, opioids, schizophrenia, affective disorders other than depression, 
compulsive disorders, suicide attempt or suicidal ideation, dementia, Parkinson’s disease, TIA, and stroke.  
c This group consisted of the drugs mirtazapine, bupropion, reboxetine, and trazodone.  
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Table 21: Odds ratios for seizures in users of different antidepressant drug classes compared to non-users of antidepressants, by current or past use, and by switching of antidepressants during 
follow-up, compared to non-users of antidepressants 
Antidepressant drug class 
No. Cases  
(n=619) (%)a 
No. Controls  
(n=2,476) (%)a 
OR crude 95% CI OR adj.b 95% CI 
No use 34 (5.5) 228 (9.2) 1 reference 1 reference 
Analyses restricted to patients who did not switch antidepressants 
SSRIs       
Current use (last presc. ≤ 90 days ago)  150 (24.2) 396 (16.0) 2.56 1.68-3.91 2.13 1.37-3.30 
Past use (last presc. >90 days ago) 148 (23.9) 800 (32.3) 1.22 0.78-1.90 1.19 0.75-1.88 
SNRIs       
Current use (last presc. ≤ 90 days ago)  6 (1.0) 16 (0.7) 2.79 0.99-7.88 2.21 0.74-6.57 
Past use (last presc. >90 days ago) X 26 (1.1) NA NA NA NA 
TCAs       
Current use (last presc. ≤ 90 days ago)  15 (2.4) 63 (2.5) 1.70 0.85-3.37 1.51 0.74-3.11 
Past use (last presc. >90 days ago) 27 (4.4) 157 (6.3) 1.30 0.73-2.31 1.07 0.59-1.95 
Other antidepressantsc       
Current use (last presc. ≤ 90 days ago)  9 (1.5) 13 (0.5) 5.19 2.02-13.33 2.17 0.72-6.48 
Past use (last presc. >90 days ago) X 18 (0.7) NA NA NA NA 
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Table 21 (cont.) 
Antidepressant drug class 
No. Cases  
(n=619) (%)a 
No. Controls  
(n=2,476) (%)a 
OR crude 95% CI OR adj.b 95% CI 
No use 34 (5.5) 228 (9.2) 1 reference 1 reference 
Analyses restricted to patients who switched antidepressants 
SSRIs       
Current use (last presc. ≤ 90 days ago)  93 (15.0) 233 (9.4) 2.59 1.63-1.14 1.87 1.11-3.15 
Past use (last presc. >90 days ago) 123 (19.9) 490 (19.8) 1.65 1.04-2.61 1.15 0.68-1.96 
SNRIs       
Current use (last presc. ≤ 90 days ago)  25 (4.0) 48 (1.9) 4.04 2.15-7.59 2.31 1.05-5.08 
Past use (last presc. >90 days ago) 34 (5.5) 96 (3.9) 2.84 1.60-5.05 1.58 0.75-3.37 
TCAs       
Current use (last presc. ≤ 90 days ago)  20 (3.2) 84 (3.4) 1.77 0.94-3.34 0.66 0.28-1.57 
Past use (last presc. >90 days ago) 82 (13.3) 276 (11.2) 2.29 1.42-3.70 0.96 0.47-2.00 
Other antidepressantsc       
Current use (last presc. ≤ 90 days ago)  25 (4.0) 38 (1.5) 5.23 2.72-10.08 2.57 1.13-5.88 
Past use (last presc. >90 days ago) 31 (5.0) 108 (4.4) 2.20 1.24-3.90 0.99 0.48-2.06 
Abbreviations: OR, odds ratio; CI, confidence interval; adj., adjusted; NA, not applicable; presc., prescription; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin-norepinephrine 
reuptake inhibitors; TCAs, tricyclic antidepressants; X, cell contains <5 observations (due to ethics regulations to preserve confidentiality, the exact count is not displayed). 
a Cases and controls could be users of more than one antidepressant group and thus be listed more than once in the table (thus percentages do not total 100%). 
b Adjusted for alcohol consumption, other antidepressant drug classes, benzodiazepines, antipsychotics, opioids, schizophrenia, affective disorders other than depression, compulsive 
disorders, suicide attempt or suicidal ideation, dementia, Parkinson’s disease, TIA, and stroke.  
c This group consisted of the drugs mirtazapine, bupropion, reboxetine, and trazodone. 
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3.2.5 Discussion 
The findings of this observational study suggest that patients with depressive disorder who are 
treated with SSRIs and SNRIs are at a higher risk of developing seizures than untreated 
patients or patients who received antidepressant drug treatment in the past. Our estimated 
incidence rates tended to be higher in SSRI and SNRI users and lower in TCA users than in 
non-users of antidepressants, especially in patients aged 50 or over. Estimated incidence rates 
of seizures were low irrespective of any antidepressant treatment. Adjusted relative risk 
estimates suggested that SSRI and SNRI users were at a twofold increased risk of developing 
seizures than non-users, and that the period of treatment initiation was associated with the 
highest risk of seizures. In addition, effect modification by underlying dementia, but not 
stroke/TIA, may be important in users of SSRIs.  
Alper et al. found significantly lower incidence rates of seizures among depressed patients 
who used second-generation antidepressants than those who used placebo.93 However, these 
findings were based on a very limited number of patients with seizures in the placebo groups, 
and this missing information about seizure occurrence in the placebo groups questions the 
validity of their findings.93 Conversely, our incidence rate estimates which were based on 4.5 
times as many cases with seizures observed and a considerably longer follow-up period were 
higher in users of second-generation antidepressants than in patients with no antidepressant 
treatment. Our incidence rate estimate in past users was closely similar to incidence rates of 
unprovoked seizures in the non-depressed European populations.44,45 Of interest, this 
incidence rate in past users was significantly lower than the incidence rate in depressed 
patients who did not yet use antidepressants. This finding supports the theory that untreated 
depression is a risk factor for seizures.27,65,66,84  
Our results of the nested case-control analysis are in line with a recent British observational 
study on severe adverse events related to antidepressants in depressed patients aged over 65 
years, which reported increased hazard ratios of seizures among SSRI users (adjusted hazard 
ratio 1.83, 95% CI 1.49-2.26) and users of other antidepressants (adjusted hazard ratio 2.24, 
95% CI 1.60-3.15), but not TCA users (adjusted hazard ratio 1.02, 95% CI 0.76-1.38), 
compared to non-users.26 Our results in patients aged between 18 and 90 suggested that 
current use of SSRIs or SNRIs was associated with an increased risk of seizures compared to 
non-use, in particular at treatment initiation. Overall, current use of TCAs was not associated 
with seizures compared to non-use, although we observed a potential slight risk difference 
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between men and women. TCAs were generally prescribed at low doses among our study 
population: the most frequently used TCA amitriptyline was rarely prescribed at doses higher 
than 75-100 mg, the minimum daily dose considered by some authors to be effective 
compared to placebo for treatment of depression.118 
In this study we provide absolute and relative risk estimates of developing seizures in a large 
population of adult depressed patients who were followed over a long period of time and 
under ‘real-life’ conditions. To our knowledge, no other study thus far has provided detailed 
information on the role of timing, duration, and dose of antidepressant use on the risk of 
seizures. Our results suggest that treatment initiation and for some substances increasing dose 
are important risk factors for developing seizures among users of SSRIs and SNRIs. We 
addressed potential confounding by excluding patients with major risk factors for seizures, 
matching controls to cases on age, gender, GP practice, and duration of depression, and 
adjusting multivariate models for other potential confounders reported in the literature. 
There are limitations to this study. First of all, the ascertainment of a first epileptic seizure is 
not guaranteed through the Read code record; other medical conditions could wrongly have 
been classified as seizures. As antiepileptic drugs are usually only prescribed to selected 
patients after the first seizure,82 we did not want to consider patients with subsequent 
antiepileptic treatment only. Also, potential misclassification of seizures was likely to be 
similarly distributed across users of different antidepressants. Second, the limited number of 
cases with seizures (especially in the analyses of single drugs) resulted in imprecise risk 
estimates. Although point estimates revealed trends toward higher or lower risk associated 
with different antidepressants and doses prescribed, the differences were not statistically 
significant. Third, we could not adjust our analyses for depression severity based on rating 
scales, as this information is not available in the CPRD. Depression has been associated with 
an increased risk of seizures in a review of clinical trials,93 in epidemiological studies,27,65,66 
and in reviews of neurobiological studies,84,119 and depression severity may be associated with 
the choice of antidepressant drug and dose prescribed. However, we aimed to minimize 
confounding by depression severity on our results by including patients with an ICD-10 coded 
depression diagnosis only if they received an antidepressant treatment at some point after the 
diagnosis to exclude patients with mild and transient depression. To avoid comparing patients 
with more severe depression to patients with less severe depression, we matched controls to 
cases on duration of depression and included users of other antidepressants than the ones 
studied in the reference group of the nested case-control analysis. A sensitivity analysis in 
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which we compared patients with antidepressant treatment to patients with no treatment 
yielded closely similar relative risk estimates and thus argued against substantial confounding 
by indication. Last, to further assess the influence of depression severity on the relative risk 
estimates, we explored the association of interest in patients who did or did not switch 
between drug treatments,117 and observed no substantial differences in relative risk estimates.  
In conclusion, our study suggested that depressed patients who currently used SSRIs and 
SNRIs were at a higher risk of developing incident seizures than untreated patients. Current 
use of TCAs was not associated with the occurrence of seizures, a finding that may be 
explained by low dosages of TCAs prescribed. Treatment initiation rather than longer-term 
treatment was an important risk factor for the development of seizures. Our findings on the 
risk of seizures associated with single antidepressants were based on a limited number of 
cases and controls; further studies, preferably taking into account underlying depression 
severity and drug doses taken, are needed to confirm them. Also, further research is required 
on the association between antidepressant use and seizure frequency in patients with 
diagnosed epilepsy and comorbid depression. 
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3.3.1 Abstract 
Objective 
To investigate the association between antipsychotic drug use and the development of first-
time seizures in patients with schizophrenia, affective disorders, or dementia. 
Methods 
We used data from the U.K.-based Clinical Practice Research Datalink database to conduct a 
follow-up study with a nested case-control analysis between 1998 and 2013. We identified 
patients with schizophrenia, affective disorders, or dementia, and estimated incidence rates of 
seizures among users of four antipsychotic subclasses, defined according to existing 
hypotheses on their seizure-inducing potential (1. olanzapine or quetiapine; 2. amisulpride, 
aripiprazole, risperidone, or sulpiride; 3. low to medium potency first-generation 
antipsychotics [chlorpromazine, zuclopenthixol, flupenthixol, pericyazine, promazine, 
thioridazine]; 4. medium to high potency first-generation antipsychotics [haloperidol, 
prochlorperazine, trifluoperazine]), and among those who did not use antipsychotics. To 
adjust for confounding, we estimated odds ratios for seizures separately among patients with 
affective disorders or dementia, stratified by antipsychotic use and timing of use. 
Results 
In the total cohort of 60,121 patients (who had schizophrenia, affective disorders, or 
dementia), the incidence rate of seizures per 10,000 person-years was 32.6 (95% confidence 
interval [CI] 22.6-42.6) in users of olanzapine or quetiapine, 24.1 (95% CI 13.2-34.9) in users 
of amisulpride, aripiprazole, risperidone, or sulpiride, 49.4 (95% CI 27.7-71.0) in users of low 
to medium potency antipsychotics, 59.1 (95% CI 40.1-78.2) in users of medium to high 
potency antipsychotics, and 11.7 (95% CI 10.0-13.4) in non-users of antipsychotics. Patients 
with dementia had significantly higher incidence rates of first-time seizures compared with 
patients with affective disorders, irrespective of antipsychotic drug use. In patients with 
affective disorders, current use of medium to high potency first-generation antipsychotics was 
associated with an increased risk of seizures (adjusted odds ratio 2.51 [95% CI 1.51-4.18]) 
compared with non-use, while use of other antipsychotics was not associated with seizures. In 
patients with dementia, current use of olanzapine or quetiapine (adjusted odds ratio 2.37 [95% 
CI 1.35-4.15]), low to medium potency first-generation antipsychotics (adjusted odds ratio 
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3.08 [95% CI 1.34-7.08]), and medium to high potency first-generation antipsychotics 
(adjusted odds ratio 2.24 [95% CI 1.05-4.81]) was associated with an increased risk of 
seizures compared with non-use, but current use of amisulpride, aripiprazole, risperidone, or 
sulpiride (adjusted odds ratio 0.92 [95% CI 0.48-1.75]) was not. Use of antipsychotics in 
patients with schizophrenia could not be investigated due to small numbers. 
Conclusions 
Current use of medium to high potency first-generation antipsychotics was associated with a 
2.5-fold increased risk of seizures compared to non-use of antipsychotics in patients with 
affective disorders. In these patients, current use of all other antipsychotic subclasses was not 
associated with seizures. In patients with dementia, current and past use of all antipsychotic 
subclasses, except amisulpride, aripiprazole, risperidone or sulpiride, was associated with an 
increased risk of seizures. 
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3.3.2 Introduction 
Antipsychotics are commonly used in patients with schizophrenia, affective disorders, or 
dementia.120 These drugs have been associated with seizures, especially if high doses are 
applied, if a rapid dose increase occurs, or if other risk factors for seizures are present.55,57  
Across first-generation antipsychotics, low potency drugs with strong sedation (particularly 
aliphatic phenothiazines) have been associated with a higher risk of seizures than high 
potency drugs.[3–6] The evidence on this association is scarce and is mainly based on one 
observational study in hospitalized psychiatric patients published almost 50 years ago.91 In 
this study, the overall incidence of seizures over 4.5 years was 1.2% among 859 phenothiazine 
users, while no seizures occurred among 669 non-users of phenothiazines.91  
Among second-generation antipsychotics clozapine has repeatedly been associated with the 
highest risk of seizures.93,122–124 In a meta-analysis of clinical trials including a limited number 
of patients observed over a short time period, the incidence rate of seizures was higher in 
users of clozapine, olanzapine, and quetiapine compared to placebo, but not in users of 
risperidone or ziprasidone.93 Also, users of clozapine, olanzapine, and quetiapine more 
frequently reported seizures than users of other second-generation antipsychotics (such as 
risperidone, amisulpride, or aripiprazole) in two studies based on pharmacovigilance data 
susceptible to reporting bias and confounding.92,94 
Using primary care observational data collected in the U.K. over a time span of 15 years, we 
aimed to explore the association between antipsychotic drug use and the development of first-
time seizures in a large population of adult patients with schizophrenia, affective disorders, or 
dementia. We further aimed to investigate the role of the underlying indication on the risk of 
seizures in antipsychotic drug users. 
3.3.3 Methods 
Study design and data source 
We used data from the U.K.-based Clinical Practice Research Datalink (CPRD) database to 
conduct a retrospective population-based follow-up study with a nested case-control analysis. 
The CPRD was established more than 25 years ago and encompasses data on some eight 
million people who are registered with approximately 700 general practitioners (GPs), as 
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described in detail elsewhere.31,32,125,126 The GPs record information on demographics, 
lifestyle variables, medical diagnoses (recorded as ‘Read codes’), hospitalizations, and drug 
prescriptions in a standardized anonymous form. The records on drug exposure and diagnoses 
have repeatedly been validated and proven to be of high quality 34,35. The CPRD has been the 
data source for several observational studies on antipsychotic drug use 127–129 and on 
seizures.86,99,100,115 This study was approved by the Independent Scientific Advisory 
Committee for Medicines and Healthcare products Regulatory Agency research (London, 
U.K.). 
Study population 
We identified all patients aged 18 to 89 years between January 1998 and December 2011, who 
(1) had a first-time diagnosis of schizophrenia, affective disorders, or dementia, followed by 
an antipsychotic prescription at any time thereafter, or (2) a first-time prescription for an 
antipsychotic drug, provided that a first-time diagnosis of schizophrenia, affective disorders, 
or dementia followed within one year. Schizophrenia, affective disorders, and dementia were 
defined by codes corresponding to the International Classification of Diseases version 10 
(ICD-10) codes F20-29 ‘Schizophrenia, schizotypal and delusional disorders’, F30-39 ‘Mood 
[affective] disorders’, and F00-F03 ‘Dementia in Alzheimer’s disease’, ‘Vascular dementia’, 
‘Dementia in other diseases classified elsewhere’, and ‘Unspecified dementia’. The date of (1) 
or (2), whichever came first, will subsequently be called the ‘start date’. We excluded patients 
with a diagnosis of seizures or epilepsy, or any records of antiepileptic prescriptions, prior to 
the start date. Additionally, we excluded patients with recorded major risk factors for seizures 
such as a history of alcoholism, drug abuse, head trauma, intracerebral bleeding, brain tumor, 
brain abscess, sinus vein thrombosis, meningitis, encephalitis, HIV, or cancer prior to the start 
date. Patients were required to have had at least one year of active history in the database 
prior to the start date and those with codes suggesting a history of schizophrenia, affective 
disorders, or dementia prior to the start date were excluded.  
Follow-up and definition of seizure cases 
We followed all patients from the start date until they had (1) a first-time diagnosis of seizure 
or epilepsy (corresponding to ICD-10 codes G40 ‘Epilepsy’, G41 ‘Status epilepticus’, or 
R56.8 ‘Other and unspecified convulsions’), (2) a first-time prescription for an antiepileptic 
drug followed by a first-time diagnosis of seizure or epilepsy (as defined under [1]) within 
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three months thereafter, (3) a first-time prescription for an antiepileptic drug preceded or 
followed by a code of a suspected seizure within three months before or after, provided that a 
first-time diagnosis of seizure of epilepsy (as defined under [1]) followed at any time 
thereafter, (4) until they turned 90 years old, (5) died, (6) left the database, (7) reached the end 
of last data collection (December 2013), or (8) until one month prior to a first-time record of a 
major risk factor for seizures (as described under ‘study population’), whichever came first. 
Patients whose follow-up ended due to (1), (2), or (3) will subsequently be called ‘cases’, and 
their date of follow-up end will be referred to as ‘index date’.  
Person-time analysis 
We assessed person-time for four antipsychotic subclasses according to existing hypotheses 
on their seizure-inducing potential (as described in the ‘Introduction’). We included individual 
drugs in these subclasses if they encompassed at least 100 person-years of accumulated use. 
Subclasses included: (1) second-generation drugs associated with a high risk of seizures 
(olanzapine or quetiapine), (2) other second-generation drugs (amisulpride, aripiprazole, 
risperidone, and sulpiride), (3) low to medium potency first-generation drugs 
(chlorpromazine, zuclopenthixol, flupenthixol, pericyazine, promazine, thioridazine), and (4) 
medium to high potency first-generation drugs (haloperidol, prochlorperazine, 
trifluoperazine). We classified first-generation drugs into low to medium or medium to high 
potency according to ‘The American Psychiatric Publishing Textbook of 
Psychopharmacology’.130 
Person time was accumulated as follows: (1) no exposure to antipsychotics (‘no antipsychotic 
treatment’) was defined as the period between the first diagnosis of affective disorders, 
schizophrenia, or dementia, and the first prescription for an antipsychotic, provided that the 
diagnosis occurred prior to the prescription; (2) current exposure to only one antipsychotic 
(‘mono use’) was defined as use from the day of the prescription through the expected end of 
treatment plus 7 days, provided that no other antipsychotic was prescribed in this period. 
Patients who switched between different antipsychotics but had no period of overlapping 
treatment contributed person-time to mono use of these different antipsychotics; (3) current 
exposure to more than one antipsychotic concomitantly (‘mixed use’) was defined as use from 
the day when at least two antipsychotics were prescribed concomitantly through the expected 
end of treatment of all or all but one antipsychotic plus 90 days. Patients who remained 
treated with one antipsychotic after the period of mixed use contributed person-time to mono 
Project 3: Antipsychotic drug use and the risk of seizures 
81 
 
use for the remaining drug thereafter; and (4) past exposure after stopping antipsychotic 
treatment (‘past use’) was defined as the time after mono- or mixed use had elapsed. The 
duration of treatment was derived from the recorded quantity of tablets, injections, or oral 
liquids, and the dose instructions. If no quantity or dose instruction was recorded, we used 
default values in the following order: (1) the quantity and/or dose instruction recorded for the 
same drug at the closest visit prior to the previous visit, or, if no information was available at 
any time before, (2) the quantity and/or dose instruction most frequently recorded among our 
study population for the same drug.  
Nested case-control analysis 
For each case we identified up to four controls from the study population with no seizures 
during the study period. Controls were matched to cases on age (year of birth ± 2 years), sex, 
index date, and duration of history in the database prior to the index date (± 2 years). 
Additionally, controls were matched to cases on underlying schizophrenia, affective disorders, 
or dementia. If patients had diagnoses for more than one of these disorders prior to the index 
date, they were matched according to the following order based on smallest chance of 
remission/recovery and strongest association with seizures: (1) dementia, (2) schizophrenia, 
and (3) affective disorders.66,85,86 
Case and control exposure to antipsychotics was classified according to the timing of 
antipsychotic use prior to the index date; ‘non-users’ were those who had no antipsychotic 
prescriptions prior to the index date; ‘current users’ and ‘past users’ were those who had 
received the last prescription ≤90 days or >90 days prior to the index date, respectively. 
Additionally, current users were stratified by exposure duration (‘short-term users’ and ‘long-
term users’ were those who had received the first prescription ≤90 days or >90 days prior to 
the index date, respectively). Because incidence rates of seizures differed significantly 
between patients with affective disorders and patients with dementia in the follow-up part of 
the study, we conducted the nested case-control analysis among cases and controls with 
underlying affective disorders or dementia separately (number of patients with schizophrenia 
was too low for a separate analysis). We evaluated individual antipsychotic drugs if there 
were at least 5 exposed subjects in each exposure level. Where possible we classified each 
antipsychotic drug by the dose prescribed at the index date (≤1 defined daily dose, > 1 defined 
daily dose).116 
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Statistical analysis 
We conducted a crude person-time analysis to estimate incidence rates of seizures, with 95% 
confidence intervals (95% CIs), for the following exposures: any mono use, mono use of 
different antipsychotic subclasses, mono use of individual drugs, past use of antipsychotics, 
and no use of antipsychotics. Incidence rates were estimated among the whole cohort of 
patients with schizophrenia, affective disorders, or dementia, and separately among patients 
who had diagnoses of affective disorders or dementia only. 
In the nested case-control analysis, we used SAS statistical software (version 9.4; SAS 
Institute, Cary, NC, USA) to conduct conditional logistic regression analyses. Relative risk 
estimates of antipsychotic use among cases and controls were calculated as odds ratios with 
95% CIs. Our reference group comprised patients with no antipsychotic treatment prior to the 
index date. Based on preexisting literature, we a priori adjusted multivariate models for 
alcohol consumption (none, 1-14 units/week, >14 units/week, unknown), compulsive 
disorders, Parkinson’s disease, stroke and/or transient ischemic attack (TIA), suicidal 
ideation/attempts, and current or past use of antidepressants, anticonvulsants, opioids, 
benzodiazepines, or antipsychotics other than those studied.55,62,66,131 We tested as additional 
potential confounders a history of cardiovascular diseases, diabetes, hypertension, 
hyperlipidemia, hypothyroidism, sleep disorders, renal diseases, or migraine, and concurrent 
use of antibiotics, anti-malarial drugs, stimulants, and immunosuppressant or antiarrhythmic 
drugs, but we did not include them in the final model as they did not alter the risk estimates 
by more than 5%.  
To assess potential effect modification we stratified cases and controls by history of stroke 
and/or TIA, or of underlying disorders (affective disorders, dementia) and age (18-59 years, 
60-90 years). 
In sensitivity analyses we explored whether risk estimates of seizures associated with the use 
of antipsychotic subclasses differed if the reference group included non-users of the 
respective antipsychotic subclass (who potentially used other subclasses) prior to the index 
date. Additionally, we excluded users of prochlorperazine from the exposed group, to explore 
whether the risk of seizures associated with the use of medium to high potency first-
generation antipsychotics changed since this drug is often used to treat nausea rather than 
psychotic symptoms. 
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3.3.4 Results 
We identified 60,121 patients who met our inclusion criteria, of whom 79.6% were diagnosed 
with affective disorders, 11.2% with dementia, 3.0% with schizophrenia, and 6.2% with more 
than one disorder. Of these patients, 583 had a first-time diagnosis of seizure during follow-
up. We also conducted a nested case-control analysis of 334 cases and 1,336 controls all of 
whom had an affective disorder, and 202 cases and 773 controls all of whom had dementia. 
Mean age (± standard deviation) at the index date of patients with affective disorders or 
dementia was 47.7 (±18.5) years and 76.7 (±8.1) years, respectively. 
Incidence rates 
Among the entire study population, the estimated incidence rates of seizures per 10,000 
person-years (PYs) were 38.0 (95% CI, 31.1-44.9), 11.7 (95% CI, 10.0-13.4), and 12.4 (95% 
CI, 10.9-13.8) in current mono users, non-users, or past users of antipsychotics, respectively 
(Table 22). The highest incidence rate of seizures was among users of medium to high 
potency first-generation drugs (59.1 per 10,000 person-years [95% CI, 40.1-78.2]), and lowest 
for users of the second-generation drugs amisulpride, aripiprazole, risperidone, or sulpiride 
(24.1 per 10,000 person-years [95% CI, 13.2-34.9]). Among individual drugs, use of 
haloperidol was associated with the highest incidence rate of seizures (115.4 per 10,000 
person-years [95% CI, 50.1-180.7]). Incidence rates of seizures were significantly higher in 
patients with dementia than in patients with affective disorders, irrespective of antipsychotic 
treatment (Table 22). Incidence rates of seizure were similar in non-use and past use of 
antipsychotics among patients with affective disorders, while in patients with dementia, past 
use of antipsychotics was associated with significantly higher incidence rate of seizures than 
non-use.  
Nested case-control analysis 
In the nested case-control analysis history of suicide attempt and/or suicidal ideation, 
migraine, or stroke/TIA, and concurrent use of opioids, benzodiazepines, anticonvulsants, or 
antidepressants were associated with an increased risk of seizures in patients with affective 
disorders (Table 23). History of stroke/TIA and concurrent use of benzodiazepines, were 
associated with an increased risk of seizures in patients with dementia.  
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Current use of first-generation medium to high potency antipsychotics (adjusted odds ratio 
2.51 [95% CI, 1.51-4.18]) was associated with an increased risk of seizures compared to non-
use of antipsychotics in patients with affective disorders (Table 24). In these patients, current 
use of all other antipsychotic subclasses was not associated with seizures. In patients with 
dementia, current and past use of all first-generation antipsychotics and olanzapine and 
quetiapine, was associated with an increased risk of seizures compared to non-use of 
antipsychotics, while use of amisulpride, aripiprazole, risperidone, or sulpiride was not 
associated with seizures (Table 24). Due do small numbers of patients with current 
antipsychotic use, we could not calculate meaningful odds ratios for current use stratified by 
exposure duration. 
Table 25 displays odds ratios of seizures associated with the most frequently prescribed 
antipsychotic individual drugs in patients with affective disorders or dementia, respectively. 
Current use of prochlorperazine was associated with an increased risk of seizures compared to 
non-use of antipsychotics in patients with affective disorders (Table 25). Current use of all 
antipsychotic individual drugs except risperidone and past use of all antipsychotic individual 
drugs were associated with increased risks of seizures compared to non-use of antipsychotics 
in patients with dementia (Table 25). Most users of antipsychotic drugs were prescribed doses 
that were lower than or equal to the defined daily dose at the index date (88.0% of olanzapine 
or quetiapine users, 92.4% of amisulpride, aripiprazole, risperidone, or sulpiride users, 97.8% 
of low to medium potency first-generation antipsychotic users, and 100% of medium to high 
potency first-generation antipsychotic users). Thus, we were unable to assess a potential dose-
effect relationship of antipsychotic drug use in relation to the risk of seizures. 
Due to low numbers of patients with a history of stroke/TIA, potential effect modification by 
indication (affective disorders or dementia) could not be assessed in this subgroup. However, 
in the whole study population, the effects of antipsychotic use on the risk of seizures did not 
differ materially between those with and without a history of stroke/TIA (Table 26). 
Current use of medium to high potency first-generation antipsychotics was associated with 
increased risks of seizures in all age groups (adjusted odds ratios 2.20 [95% CI, 1.18-4.09] 
and 4.97 [95% CI, 1.68-14.67] in patients less than 60 years or 60 years or over, respectively) 
[data not shown]. Most patients with dementia (94.6%) were aged 60 years or over while 
1,233 (73.2%) patients with affective disorders were aged less than 60 years, and 447 (26.8%) 
were aged 60 years or over at the index date.  
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When the reference group was defined as non-use of the respective subclass of antipsychotics 
the results were closely similar (Table 27) to those of the main analysis (Table 24). Excluding 
prochlorperazine from the subclass of first-generation medium to high potency antipsychotics 
yielded a higher odds ratio of seizures in patients with affective disorders (adjusted odds ratio 
12.56 [95% CI, 3.31-47.67]) compared to the estimate from the main analysis (Table 24), 
although the difference was not statistically significant.  
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Table 22: Incidence rates of seizures in patients with no antipsychotic treatment, with current and past use of antipsychotics, 
and with current use of different antipsychotic subclasses or single drugs, by underlying disorder  
 
PYs 
No. of patients 
with seizures 
IR  
[per 10,000 PYs] 
95% CI 
Whole study population     
No antipsychotic treatment 156,386 183 11.7 10.0-13.4 
Past use 218,623 270 12.4 10.9-13.8 
Any mono use 30,779 117 38.0 31.1-44.9 
Olanzapine or quetiapine 12,577 41 32.6 22.6-42.6 
Olanzapine 6,839 13 19.0 8.7-29.3 
Quetiapine 5,738 28 48.8 30.7-66.9 
Amisulpride, aripiprazole, risperidone, or 
sulpiride 
7,895 19 24.1 13.2-34.9 
Amisulpride 1,256 5 39.8 4.9-74.7 
Risperidone 5,012 13 25.9 11.8-40.0 
Low to medium potency antipsychoticsa 4,051 20 49.4 27.7-71.0 
Promazine 839 8 95.4 29.3-161.4 
Medium to high potency antipsychoticsb 6,256 37 59.1 40.1-78.2 
Haloperidol 1,040 12 115.4 50.1-180.7 
Prochlorperazine 4,404 19 43.1 23.7-62.5 
Trifluoperazine 812 6 73.9 14.8-133.0 
Analysis restricted to patients with affective disorders  
No antipsychotic treatment 139,686 117 8.4 6.9-9.9 
Past use 199,303 164 8.2 7.0-9.5 
Any mono use 16,718 35 20.9 14.0-27.9 
Olanzapine or quetiapine 6,427 7 10.9 2.8-19.0 
Amisulpride, aripiprazole, risperidone, or 
sulpiride 
2,832 X NA NA 
Low to medium potency antipsychoticsa 2,627 6 22.8 4.6-41.1 
Medium to high potency antipsychoticsb 4,831 21 43.5 24.9-62.1 
Prochlorperazine 4,093 17 41.5 21.8-61.3 
Analysis restricted to patients with dementia  
    
No antipsychotic treatment 7,864 38 48.3 33.0-63.7 
Past use 6,326 67 105.9 80.6-131.3 
Any mono use 4,956 50 100.9 72.9-128.8 
Olanzapine or quetiapine 1,826 20 109.5 61.5-157.5 
Quetiapine 1,523 18 118.2 63.6-172.7 
Amisulpride, aripiprazole, risperidone, or 
sulpiride 
1,594 11 69.0 28.2-109.8 
Risperidone 1,063 6 56.4 11.3-101.6 
Low to medium potency antipsychoticsa 794 7 88.1 22.8-153.4 
Medium to high potency antipsychoticsb 742 12 161.6 70.2-253.1 
Haloperidol 488 10 205.0 77.9-332.0 
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Table 22 (cont.) 
Abbreviations: PYs, person-years; IR, incidence rate; CI, confidence interval; NA, not applicable; X, Cell contains <5 
patients (due to ethics regulations to preserve confidentiality, we are not allowed to display cells with a count of <5 patients). 
a This group consisted of chlorpromazine, zuclopenthixol, flupentixol, pericyazine, promazine, and thioridazine. 
b This group consisted of haloperidol, prochlorperazine, and trifluoperazine.  
Table 23: Characteristics of cases with seizures and matched controlsa, by underlying disorder 
Analysis restricted to patients with affective disorders 
Characteristics No. Cases (%)b  
(n=334) 
No. Controls (%)b 
(n=1,336) 
OR crude 95% CI 
Sex 
   
 
Male 113 (33.8) 452 (33.8) NA NA 
Female 221 (66.2) 884 (66.2) NA NA 
Age, years 
   
 
18-39 134 (40.2) 536 (40.1) NA NA 
40-59 111 (33.3) 442 (33.1) NA NA 
60-90  89 (26.7) 358 (26.8) NA NA 
Smoking status 
   
 
Nonsmoker 132 (39.5) 570 (42.7) 1 reference 
Current smoker 111 (33.2) 396 (29.6) 1.22 0.91-1.63 
Former smoker 76 (22.8) 305 (22.8) 1.08 0.78-1.49 
Unknown 15 (4.5) 65 (4.9) 0.99 0.53-1.87 
Alcohol consumption (units/week, any time prior to the index date)  
Nondrinker 156 (46.7) 620 (46.4) 1 reference 
1-14  119 (35.6) 453 (33.9) 1.04 0.80-1.36 
>14 25 (7.5) 101 (7.6) 0.98 0.60-1.59 
Unknown 34 (10.2) 162 (12.1) 0.82 0.54-1.26 
Comorbidities any time prior to the index datec  
Suicide attempt and/or suicidal ideation 49 (14.7) 129 (9.7) 1.63 1.14-2.33 
Parkinson's disease X 11 (0.8) NA NA 
Migraine 55 (16.5) 152 (11.4) 1.58 1.12-2.24 
Transient ischemic attack/ischemic stroke 45 (13.5) 44 (3.3) 7.45 4.25-13.04 
Compulsive disorders 11 (3.3) 28 (2.1) 1.59 0.78-3.24 
Concurrentd drug use     
Opioids 82 (24.6) 210 (15.7) 1.93 1.35-2.76 
Benzodiazepines 52 (15.6) 136 (10.2) 1.83 1.26-2.66 
Betalactam-Antibiotics 50 (15.0) 138 (10.3) 1.50 0.95-2.35 
Anticonvulsantse 19 (5.7) 37 (2.8) 2.30 1.26-4.18 
Any antidepressants 185 (55.4) 528 (39.5) 1.46 0.89-2.39 
Selective serotonin reuptake inhibitors 124 (37.1) 331 (24.8) 1.83 1.27-2.64 
Tricyclic antidepressants 43 (12.9) 124 (9.3) 1.45 0.98-2.15 
Other antidepressantsf 39 (11.7) 106 (7.9) 1.57 1.06-2.35 
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Table 23 (cont.) 
Analysis restricted to patients with dementia 
Characteristics No. Cases (%)b  
(n=202) 
No. Controls (%)b  
(n=773) 
OR crude 95% CI 
Sex 
   
 
Male 73 (36.1) 286 (37.0) NA NA 
Female 129 (63.9) 487 (63.0) NA NA 
Age, years 
   
 
18-39 X X NA NA 
40-59 11 (5.5) 19 (2.5) NA NA 
60-90 191 (94.5) 754 (97.5) NA NA 
Smoking status 
   
 
Nonsmoker 102 (50.5) 388 (50.2) 1 reference 
Current smoker 17 (8.4) 67 (8.7) 0.92 0.51-1.67 
Former smoker 72 (35.6) 278 (36.0) 1.01 0.71-1.45 
Unknown 11 (5.5) 40 (5.2) 1.05 0.49-2.28 
Alcohol consumption (units/week, any time prior to the index date)  
Nondrinker 110 (54.5) 433 (56.0) 1 reference 
1-14  64 (31.7) 222 (28.7) 1.13 0.79-1.60 
>14 X 33 (4.3) NA NA 
Unknown 24 (11.9) 85 (11.0) 1.12 0.66-1.91 
Comorbidities any time prior to the index datec  
Suicide attempt and/or suicidal ideation X 18 (2.3) NA NA 
Parkinson's disease 10 (5.0) 39 (5.1) 1.00 0.49-2.05 
Migraine X 29 (3.8) NA NA 
Transient ischemic attack/ischemic stroke 59 (29.2) 122 (15.8) 2.45 1.68-3.58 
Compulsive disorders X X NA NA 
Concurrentd drug use     
Opioids 28 (13.9) 113 (14.6) 0.89 0.55-1.45 
Benzodiazepines 57 (28.2) 139 (18.0) 1.80 1.22-2.66 
Betalactam-Antibiotics 28 (13.9) 101 (13.1) 1.12 0.64-1.96 
Anticonvulsantse 11 (5.5) 25 (3.2) 1.62 0.78-3.38 
Any antidepressants 67 (33.2) 250 (32.3) 1.11 0.77-1.61 
Selective serotonin reuptake inhibitors 47 (23.3) 147 (19.0) 1.30 0.87-1.93 
Tricyclic antidepressants X 28 (3.6) NA NA 
Other antidepressantsf 26 (12.9) 89 (11.5) 1.21 0.74-1.96 
Abbreviations: OR, odds ratio; CI, confidence interval; NA, not applicable; X, Cell contains <5 patients (due to ethics 
regulations to preserve confidentiality, we are not allowed to display cells with a count of <5 patients). 
a Controls were matched to cases on age, sex, index date, duration of history in the CPRD, and underlying disorder 
(schizophrenia, affective disorders, or dementia) diagnosed prior to the index date. All ORs presented are conditional on the 
matching factors.  
b Due to rounding, percentages may not total 100.  
c The reference group for the calculation of the ORs comprised patients who never had a record of the respective disorder at 
any time prior to the index date. 
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d Last prescription within 90 days prior to index date; the reference group for the calculation of the ORs comprised patients 
who had no records of the respective drug at any time prior to the index date.  
e This drug group mainly consisted of the drugs sodium valproate (38.3%), gabapentin (24.5%), carbamazepine (12.8%), and 
pregabalin (10.6%).  
f This drug group mainly consisted of the drugs venlafaxine (38.0%), mirtazapine (36.5%), and trazodone (20.4%).  
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Table 24: Odds ratios for seizures in users of different antipsychotic subclasses, by current or past use, and by underlying psychiatric disorder  
Analysis restricted to patients with affective disorders 
Antipsychotic drug group 
No. Cases (%)a 
(n=334)b 
No. Controls (%)a 
(n=1,336)b 
OR crude 95% CI OR adj.c 95% CI 
No use of antipsychotics 128 (38.3) 542 (40.6) 1 reference 1 reference 
Olanzapine or quetiapine       
Current use (last presc. ≤ 90 days ago)  10 (3.0) 38 (2.8) 1.14 0.55-2.36 0.61 0.27-1.38 
Past use (last presc. >90 days ago) 12 (3.6) 39 (2.9) 1.33 0.67-2.67 0.83 0.37-1.87 
Amisulpride, aripiprazole, risperidone, or sulpiride       
Current use (last presc. ≤ 90 days ago)  5 (1.5) 27 (2.0) 0.78 0.29-2.08 0.43 0.14-1.32 
Past use (last presc. >90 days ago) 12 (3.6) 37 (2.8) 1.41 0.71-2.81 1.10 0.48-2.49 
Low to medium potency antipsychoticsd        
Current use (last presc. ≤ 90 days ago)  6 (1.8) 21 (1.6) 1.22 0.48-3.09 1.11 0.41-2.98 
Past use (last presc. >90 days ago) 32 (9.6) 114 (8.5) 1.20 0.77-1.87 0.88 0.52-1.48 
Medium to high potency antipsychoticse       
Current use (last presc. ≤ 90 days ago)  36 (10.8) 56 (4.2) 2.76 1.72-4.43 2.51 1.51-4.18 
Past use (last presc. >90 days ago) 120 (35.9) 546 (40.9) 0.93 0.69-1.26 0.86 0.63-1.19 
Project 3: Antipsychotic drug use and the risk of seizures 
91 
 
   
 
Table 24 (cont.)       
Analysis restricted to patients with dementia       
Antipsychotic drug group 
No. Cases (%)a 
(n=202)b 
No. Controls (%)a 
(n=773)b 
OR crude 95% CI OR adj.c 95% CI 
No use of antipsychotics 46 (22.8) 290 (37.5) 1 reference 1 reference 
Olanzapine or quetiapine       
Current use (last presc. ≤ 90 days ago)  36 (17.8) 101 (13.1) 2.33 1.43-3.80 2.37 1.35-4.15 
Past use (last presc. >90 days ago) 22 (10.9) 57 (7.4) 2.66 1.47-4.80 2.66 1.33-5.30 
Amisulpride, aripiprazole, risperidone, or sulpiride       
Current use (last presc. ≤ 90 days ago)  18 (8.9) 106 (13.7) 1.08 0.60-1.94 0.92 0.48-1.75 
Past use (last presc. >90 days ago) 30 (14.9) 86 (11.1) 2.32 1.37-3.94 1.87 1.00-3.50 
Low to medium potency antipsychoticsd        
Current use (last presc. ≤ 90 days ago)  14 (6.9) 27 (3.5) 3.82 1.79-8.16 3.08 1.34-7.08 
Past use (last presc. >90 days ago) 31 (15.4) 71 (9.2) 2.99 1.75-5.12 2.97 1.55-5.69 
Medium to high potency antipsychoticse       
Current use (last presc. ≤ 90 days ago)  14 (6.9) 37 (4.8) 2.57 1.28-5.19 2.24 1.05-4.81 
Past use (last presc. >90 days ago) 50 (24.8) 154 (19.9) 2.14 1.35-3.39 2.09 1.22-3.59 
Abbreviations: OR, odds ratio; CI, confidence interval; adj., adjusted; presc., prescription. 
a Due to rounding, percentages may not total 100.  
b Cases and controls could be users of more than one antipsychotic drug group and thus be listed more than once in the table. 
c Adjusted for all other antipsychotics, alcohol status, antidepressants, anticonvulsants, benzodiazepines, opioids, compulsive disorders, Parkinson’s disease, suicidal ideation/attempts, 
and stroke and/or transient ischemic attack. 
d This group consisted of chlorpromazine, zuclopenthixol, flupentixol, pericyacine, promazine, and thioridazine. 
e This group consisted of haloperidol, prochlorperazine, and trifluoperazine.  
Project 3: Antipsychotic drug use and the risk of seizures 
92 
 
Table 25: Odds ratios for seizures in users of different antipsychotic single substances, by current or past use, and by underlying disorder 
Analysis restricted to patients with affective disorders 
Antipsychotic drug group 
No. Cases (%)a 
(n=334)b 
No. Controls (%)a 
(n=1,336)b 
OR crude 95% CI OR adj.c 95% CI 
No use of antipsychotics 128 (38.3) 542 (40.6) 1 reference 1 reference 
Quetiapine       
Current use (last presc. ≤ 90 days ago) 6 (1.8) 15 (1.1) 1.74 0.66-4.56 1.17 0.40-3.45 
Past use (last presc. >90 days ago) 9 (2.7) 18 (1.4) 2.15 0.95-4.91 1.36 0.52-3.54 
Risperidone       
Current use (last presc. ≤ 90 days ago) 5 (1.5) 18 (1.4) 1.18 0.43-3.24 0.63 0.20-1.97 
Past use (last presc. >90 days ago) 11 (3.3) 31 (2.3) 1.53 0.74-3.14 1.04 0.45-2.42 
Prochlorperazine       
Current use (last presc. ≤ 90 days ago) 28 (8.4) 52 (3.9) 2.26 1.35-3.79 1.95 1.11-3.41 
Past use (last presc. >90 days ago) 107 (32.0) 520 (38.9) 0.87 0.64-1.18 0.79 0.57-1.10 
Analysis restricted to patients with dementia 
Antipsychotic drug group 
No. Cases (%)a 
(n=202)b 
No. Controls (%)a 
(n=773)b 
OR crude 95% CI OR adj.c 95% CI 
No use of antipsychotics 46 (22.8) 290 (37.5) 1 reference 1 reference 
Olanzapine       
Current use (last presc. ≤ 90 days ago) 5 (2.5) 16 (2.1) 1.92 0.67-5.47 1.77 0.56-5.62 
Past use (last presc. >90 days ago) 9 (4.5) 24 (3.1) 2.48 1.07-5.72 1.70 0.60-4.83 
Quetiapine       
Current use (last presc. ≤ 90 days ago) 31 (15.4) 85 (11.0) 2.41 1.43-4.05 2.52 1.40-4.55 
Past use (last presc. >90 days ago) 16 (7.9) 47 (6.1) 2.39 1.23-4.63 2.75 1.29-5.85 
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Table 25 (cont.)       
Antipsychotic drug group 
No. Cases (%)a 
(n=202)b 
No. Controls (%)a 
(n=773)b 
OR crude 95% CI OR adj.c 95% CI 
Risperidone       
Current use (last presc. ≤ 90 days ago) 11 (5.5) 61 (7.9) 1.13 0.55-2.31 1.11 0.52-2.40 
Past use (last presc. >90 days ago) 23 (11.4) 65 (8.4) 2.21 1.24-3.91 2.05 1.02-4.10 
Promazine       
Current use (last presc. ≤ 90 days ago) 9 (4.5) 16 (2.1) 4.04 1.66-9.81 2.58 0.91-7.26 
Past use (last presc. >90 days ago) 13 (6.4) 25 (3.2) 3.58 1.69-7.58 3.99 1.64-9.71 
Haloperidol       
Current use (last presc. ≤ 90 days ago) 10 (5.0) 23 (3.0) 2.96 1.30-6.71 2.83 1.14-7.00 
Past use (last presc. >90 days ago) 26 (12.9) 44 (5.7) 3.80 2.15-6.73 3.82 1.91-7.65 
Abbreviations: OR, odds ratio; CI, confidence interval; adj., adjusted; presc., prescription. 
a Due to rounding, percentages may not total 100.  
b Cases and controls could be users of more than one antipsychotic drug group and thus be listed more than once in the table. 
c Adjusted for all other antipsychotics, alcohol status, antidepressants, anticonvulsants, benzodiazepines, opioids, compulsive disorders, Parkinson’s disease, suicidal 
ideation/attempts, and stroke and/or transient ischemic attack. 
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Table 26: Odds ratios for seizures in users of different antipsychotic drug groups, by current or past use, and by history of stroke or TIA prior to the index date 
Analysis restricted to patients without stroke/TIA prior 
Antipsychotic drug group 
No. Cases (%)a 
(n=465)b 
No. Controls (%)a 
(n=2,056)b 
OR crude 95% CI OR adj.c 95% CI 
No use of antipsychotic drugs 156 (27.3) 783 (35.2) 1 reference 1 reference 
Olanzapine or quetiapine       
Current use (last presc. ≤ 90 days ago)  43 (7.5) 150 (6.7) 1.67 1.11-2.49 1.30 0.83-2.01 
Past use (last presc. >90 days ago) 31 (5.4) 113 (5.1) 1.56 0.99-2.46 1.32 0.79-2.20 
Amisulpride, aripiprazole, risperidone,  
or sulpiride 
 
Current use (last presc. ≤ 90 days ago)  21 (3.7) 145 (6.5) 0.75 0.45-1.25 0.55 0.32-0.95 
Past use (last presc. >90 days ago) 40 (7.0) 128 (5.8) 1.76 1.15-2.68 1.42 0.88-2.29 
Low to medium potency 
antipsychoticsd  
      
Current use (last presc. ≤ 90 days ago)  18 (3.2) 47 (2.1) 1.99 1.10-3.60 1.69 0.91-3.14 
Past use (last presc. >90 days ago) 50 (8.8) 179 (8.0) 1.52 1.05-2.19 1.25 0.83-1.88 
Medium to high potency 
antipsychoticse 
      
Current use (last presc. ≤ 90 days ago)  43 (7.5) 94 (4.2) 2.43 1.60-3.69 2.22 1.44-3.41 
Past use (last presc. >90 days ago) 144 (25.2) 681 (30.6) 1.09 0.84-1.42 1.05 0.79-1.39 
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Table 26 (cont.) 
Analysis restricted to patients with stroke/TIA prior 
Antipsychotic drug group 
No. Cases (%)a 
(n=106)b 
No. Controls (%)a 
(n=170)b 
OR crude 95% CI OR adj.c 95% CI 
No use of antipsychotic drugs 24 (4.2) 58 (2.6) 1 reference 1 reference 
Olanzapine or quetiapine       
Current use (last presc. ≤ 90 days ago)  11 (1.9) 19 (0.9) 1.48 0.61-3.57 1.24 0.50-3.08 
Past use (last presc. >90 days ago) 8 (1.4) 10 (0.5) 1.81 0.63-5.21 1.74 0.58-5.25 
Amisulpride, aripiprazole, risperidone,  
or sulpiride 
 
Current use (last presc. ≤ 90 days ago)  6 (1.1) 11 (0.5) 1.35 0.43-4.25 1.18 0.36-3.88 
Past use (last presc. >90 days ago) 8 (1.4) 21 (0.9) 0.94 0.36-2.43 0.77 0.28-2.09 
Low to medium potency 
antipsychoticsd  
      
Current use (last presc. ≤ 90 days ago)  X 5 (0.2) NA NA NA NA 
Past use (last presc. >90 days ago) 16 (2.8) 17 (0.8) 2.45 1.06-5.66 2.30 0.96-5.53 
Medium to high potency 
antipsychoticse 
      
Current use (last presc. ≤ 90 days ago)  13 (2.3) 9 (0.4) 3.46 1.27-9.45 3.38 1.21-9.44 
Past use (last presc. >90 days ago) 34 (6.0) 48 (2.2) 1.58 0.81-3.11 1.55 0.77-3.14 
Abbreviations: OR, odds ratio; CI, confidence interval; adj., adjusted; presc., prescription; X, Cell contains <5 patients (due to ethics regulations to preserve confidentiality, we are 
not allowed to display cells with a count of <5 patients). 
a Due to rounding, percentages may not total 100.  
b Cases and controls could be users of more than one antipsychotic drug group and thus be listed more than once in the table. 
cAdjusted for all other groups of antipsychotics, alcohol status, antidepressants, anticonvulsants, benzodiazepines, opioids, compulsive disorders, Parkinson’s disease, suicidal 
ideation/attempts, and stroke and/or transient ischemic attack. 
d This group consisted of chlorpromazine, zuclopenthixol, flupentixol, pericyacine, promazine, and thioridazine. 
e This group consisted haloperidol, prochlorperazine, and trifluoperazine. 
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Table 27: Odds ratios for seizures in users of different antipsychotic drug groups, by current or past use and age, and by current use and number of prescriptions prior to the index date, and by 
underlying disorder; reference group non-users of the respective drug group 
Analysis restricted to patients with affective disorders 
Antipsychotic drug group 
No. Cases (%)a 
(n=334)b 
No. Controls (%)a 
(n=1,336)b 
OR crude 95% CI OR adj.c 95% CI 
Olanzapine or quetiapine       
No use  312 (93.4) 1,259 (94.2) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  10 (3.0) 38 (2.8) 1.07 0.52-2.18 0.66 0.31-1.43 
Past use (last presc. >90 days ago) 12 (3.6) 39 (2.9) 1.25 0.64-2.45 0.92 0.43-1.93 
Amisulpride, aripiprazole, risperidone, or 
sulpiride       
No use 317 (94.9) 1,272 (95.2) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  5 (1.5) 27 (2.0) 0.73 0.28-1.94 0.49 0.18-1.37 
Past use (last presc. >90 days ago) 12 (3.6) 37 (2.8) 1.31 0.67-2.54 1.24 0.61-2.54 
Low to medium potency antipsychoticsd       
No use 296 (88.6) 1,201 (89.9) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  6 (1.8) 21 (1.6) 1.17 0.47-2.92 1.17 0.44-3.09 
Past use (last presc. >90 days ago) 32 (9.6) 114 (8.5) 1.14 0.75-1.73 0.95 0.61-1.50 
Medium to high potency antipsychoticse       
No use 178 (53.3) 734 (54.9) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  36 (10.8) 56 (4.2) 2.71 1.70-4.30 2.60 1.58-4.28 
Past use (last presc. >90 days ago) 120 (35.9) 546 (40.9) 0.91 0.70-1.20 0.89 0.66-1.21 
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Table 27 (cont.) 
Analysis restricted to patients with dementia 
Antipsychotic drug group 
No. Cases (%)a 
(n=202)b 
No. Controls (%)a 
(n=773)b 
OR crude 95% CI OR adj.c 95% CI 
Olanzapine or quetiapine       
No use  144 (71.3) 615 (79.6) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  36 (17.8) 101 (13.1) 1.57 1.03-2.39 1.61 1.02-2.52 
Past use (last presc. >90 days ago) 22 (10.9) 57 (7.4) 1.74 1.02-2.96 1.68 0.96-2.97 
Amisulpride, aripiprazole, risperidone, or 
sulpiride       
No use 154 (76.2) 581 (75.2) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  18 (8.9) 106 (13.7) 0.63 0.37-1.06 0.63 0.36-1.12 
Past use (last presc. >90 days ago) 30 (14.9) 86 (11.1) 1.35 0.85-2.14 1.20 0.73-1.96 
Low to medium potency antipsychoticsd       
No use 157 (77.7) 675 (87.3) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  14 (6.9) 27 (3.5) 2.55 1.26-5.16 2.15 0.99-4.66 
Past use (last presc. >90 days ago) 31 (15.4) 71 (9.2) 2.01 1.25-3.21 1.86 1.12-3.08 
Medium to high potency antipsychoticse       
No use 138 (68.3) 582 (75.3) 1 reference 1 reference 
Current use (last presc. ≤ 90 days ago)  14 (6.9) 37 (4.8) 1.68 0.88-3.21 1.57 0.78-3.16 
Past use (last presc. >90 days ago) 50 (24.8) 154 (19.9) 1.40 0.95-2.04 1.41 0.93-2.13 
Abbreviations: OR, odds ratio; CI, confidence interval; adj., adjusted; presc., prescription. 
a Due to rounding, percentages may not total 100.  
b Cases and controls could be users of more than one antipsychotic drug group and thus be listed more than once in the table. 
c Adjusted for all other antipsychotics, alcohol status, antidepressants, anticonvulsants, benzodiazepines, opioids, compulsive disorders, Parkinson’s disease, suicidal ideation/attempts, and 
stroke and/or transient ischemic attack. 
d This group consisted of chlorpromazine, zuclopenthixol, flupentixol pericyacine, promazine, and thioridazine. 
e This group consisted of haloperidol, prochlorperazine, and trifluoperazine. 
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3.3.5 Discussion 
In this observational study using data from a U.K. based primary care database, we observed 
that current mono users of antipsychotics had two- to threefold higher risks of seizures 
compared to non-users of antipsychotics. Current users of medium to high potency first-
generation antipsychotics had significantly higher risks of seizures than current users of the 
second-generation antipsychotics amisulpride, aripiprazole, risperidone, or sulpiride. 
Irrespective of antipsychotic drug use, patients with dementia experienced seizures more 
frequently than patients with affective disorders. The number of patients with schizophrenia 
was too limited to estimate separate incidence rates for these patients. 
After adjusting for potential confounding and stratifying by underlying affective disorders or 
dementia, we observed that current use of medium to high potency first-generation 
antipsychotics was associated with a more than twofold increased risk of seizures compared to 
non-use of antipsychotics in patients with affective disorders. In these patients, current use of 
all other antipsychotics was not associated with seizures. In patients with dementia, current 
use of all first-generation antipsychotics and the second generation antipsychotics olanzapine 
and quetiapine, was associated with an increased risk of seizures compared to non-use of 
antipsychotics. This effect was also seen in past users of antipsychotics in those with 
dementia, suggesting that the association may be due to dementia progression or severity, 
leading to antipsychotic drug use, rather than a causal effect of antipsychotics. Notably, 
current use of amisulpride, aripiprazole, risperidone, or sulpiride, was not associated with the 
occurrence of seizures in patients with dementia. 
Our results do not corroborate existing evidence for a higher seizure risk in association with 
strongly sedating low-potency first-generation drugs (especially aliphatic phenothiazines) 
compared with less sedating high-potency first-generation drugs.55,57,121,123,132 However, this 
evidence is based mainly on one observational study conducted between 1960 and 1965, 
which reported a higher seizure incidence among phenothiazine (especially chlorpromazine) 
users compared to non-users.91 As the group of non-users in that study comprised patients 
who used other first-generation antipsychotics as well as those who did not use any 
antipsychotics, a comparison of seizure risk associated with different first-generation 
antipsychotics was not possible.91 Additionally, in contrast to our study, patients with major 
direct risk factors for seizures were not excluded from this study.91 We observed slightly 
higher incidence rates of seizures in users of medium to high potency first-generation 
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antipsychotics (mainly haloperidol and prochlorperazine) than in users of low to medium 
potency first-generation antipsychotics (mainly flupenthixol, chlorpromazine, and 
promazine), although differences did not reach statistical significance. After adjusting for 
potential confounding, current use of medium to high potency, but not low to medium potency 
first-generation antipsychotics, was associated with an increased risk of seizures compared to 
non-use of antipsychotics in patients with affective disorders.  
In contrast to the available literature that describes a higher risk of seizures associated with 
clozapine, olanzapine, and quetiapine (three structurally related antipsychotics) compared to 
other second-generation antipsychotics,92–94 our rates of seizures were not significantly 
different between users of olanzapine or quetiapine and users of other second-generation 
antipsychotics. However, we could not investigate the risk of seizures associated with 
clozapine use, the second-generation antipsychotic reported to be most strongly associated 
with seizures,93,122,124 because treatment with clozapine in the U.K. takes place almost 
exclusively in secondary care and there was little use captured in the CPRD. Yet, among 
patients with dementia, we did observe an increased risk of seizure with current use of 
olanzapine or quetiapine compared to non-use. This effect was not present for current use of 
other second-generation antipsychotics.  
To our knowledge, no other study to date has investigated the risk of first-time seizures 
associated with use of antipsychotics in such a large population of patients over such a long 
observation period. The available studies on the risk of seizures in association with 
antipsychotics had no control group and were prone to bias and confounding,91,92,94 or had 
only a very small control group.93 Moreover, these studies did not assess the risk of seizures in 
association with antipsychotics separately for each underlying disorder.  
In this study, we observed that patients with dementia were at a significantly increased risk of 
seizures compared to patients with affective disorders, irrespective of whether they used 
antipsychotics or not. This finding is consistent with the results of another observational study 
from our group based on data from the CPRD that reported that dementia is a major risk 
factor for developing seizures.86 Notably, current use of drugs of the subclass amisulpride, 
aripiprazole, risperidone, and sulpiride (especially the single drug risperidone), was not 
associated with the development of seizures in patients with dementia. Thus, with regard to 
seizure risk, our results support that risperidone has so far been the only antipsychotic in the 
U.K. licensed for short-term use in patients with dementia.133 
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In this study, we aimed to minimize confounding by excluding patients with major risk factors 
for seizures. Additionally, we controlled for further confounding by matching controls to 
cases on age, gender, calendar time, and underlying disorder which presumably led to the 
prescription of antipsychotics. Lastly, we adjusted our analyses for additional potential 
confounders such as alcohol consumption, relevant comorbidities or concomitantly used 
drugs. However, there may still be some residual confounding by unmeasured risk factors for 
seizures such as disease severity. Non-users of antipsychotics could potentially have been at a 
less severe disease stage than current users of antipsychotics. However, the sensitivity 
analysis in which we redefined the reference group as non-users of the respective drug 
subclass did not yield considerably different results than the main analysis.  
We were not able to investigate a potential relationship between antipsychotic dose and the 
development of seizures, although the risk of seizures in association with antipsychotic drugs 
has been reported to be dose dependent.91,124,134 However, antipsychotics were prescribed 
almost exclusively in doses equal to or lower than the defined daily dose, irrespective of the 
drug subclass. Therefore, the increased risk of seizures associated with current use of medium 
to high potency antipsychotics in patients with affective disorders could not be due to higher 
doses prescribed in this subclass compared to other subclasses. Due to limited numbers of 
current users of antipsychotics, we could not assess whether seizure risk was dependent on 
exposure duration. Additionally, some antipsychotic drugs, especially prochlorperazine, could 
have been prescribed for nausea rather than psychosis. However, excluding prochlorperazine 
users from the group of medium to high potency antipsychotic users led to an even higher risk 
estimate of seizures than the main analysis.  
There may have been some outcome misclassification in this study, either if the seizure was 
missed by the GP or by the patient, or if a patient had a medical condition other than a seizure 
that was misreported as a seizure. However, potential misclassification of seizures was most 
likely not related to the antipsychotic drug used. Also, our algorithm to define a first-time 
seizure was developed by reviewing a random sample of 120 patient profiles, in which we 
assessed the likelihood of a seizure taking into account codes of antiepileptic drug 
prescriptions or codes of suspected seizures preceding the actual seizure code. Thus any 
misclassification was unlikely to materially affect our results. In addition, the validity of 
affective disorders diagnoses has not formally been investigated in the CPRD, but the 
database has proven to be of high validity with regard to many acute or chronic diseases in 
numerous previous studies.34,35 
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Conclusion 
In conclusion, we observed that the risk of seizures associated with use of antipsychotics 
strongly differed according to the underlying disorder of the patient: It was considerably 
higher in patients with dementia than in patients with affective disorders, irrespective of 
antipsychotic drug use. In patients with affective disorders, current use of medium to high 
potency first-generation antipsychotics was associated with a more than twofold increased 
risk of seizures compared to non-use of antipsychotics, while current use of other 
antipsychotics was not associated with seizures. In patients with dementia, current use of 
amisulpride, aripiprazole, risperidone, and sulpiride, was not associated with an altered risk of 
seizures, while current use of all other antipsychotics was associated with an increased risk of 
seizures, compared to non-use of antipsychotics. 
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4. Discussion 
It has long been suspected that patients suffering from neuropsychiatric disorders exhibit an 
increased risk of developing new-onset seizures. However, to this date, little real-world 
evidence on specific risk factors provoking new-onset seizures in patients with 
neuropsychiatric disorders exists. The primary aim of this thesis was set to identify and 
analyze such risk factors for new-onset seizures in patients with affective disorders, 
schizophrenia, or dementia, thereby focusing on antidepressant and antipsychotic drug use.  
The first project suggested that patients with depression exhibit similar risk factors for new-
onset seizures as those reported from the general population.27,51,54,67,86,103–105 Patients with 
depression who abused drugs, had alcoholism, a history of cerebrovascular disease or recent 
head trauma, comorbid dementia, and psychiatric comorbidities such as schizophrenia or 
bipolar disorder, were at an increased risk of seizures compared to patients with depression 
without these features. Patients who currently used cephalosporin antibiotics or 
antiarrhythmics were at an increased risk of seizures than non-users of these drug classes. 
The subsequent project was able to demonstrate that new-onset seizures among adult patients 
with depression were rare. We found that for patients treated with certain antidepressants (i.e., 
SSRIs, SNRIs, or mirtazapine, bupropion, reboxetine and trazodone), the incidence rate of 
seizures was higher than for non-users of antidepressants. However, absolute risk differences 
between exposed and non-exposed study groups were small.  
Different types of antidepressants exhibited different relative risk estimates of seizures 
compared to non-use. Use of SSRIs and SNRIs was found to be associated with a twofold 
increased risk of seizures compared to non-use, while use of TCAs at low doses (as prescribed 
in this primary care setting) was not associated with seizures. It is important to note that these 
results do not challenge the evidence on the epileptogenic potential of TCAs in high 
doses.57,88–90 Nevertheless, the results obtained support the current evidence that 
antidepressant-induced seizures are dose-dependent rather than just class-specific.26,55,135  
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The final project could demonstrate that the association between antipsychotic drugs and new-
onset seizures is strongly modified by the underlying neuropsychiatric indication. 
First of all, patients with dementia were at a considerably higher risk of seizures than those 
with affective disorders, irrespective of the use of antipsychotics. Secondly, we found that use 
of haloperidol, prochlorperazine, or trifluoperazine, was associated with a more than twofold 
increased risk of seizures compared to non-use of antipsychotics in patients with affective 
disorders. Finally we could show that in patients with dementia, use of all antipsychotic 
subclasses, except amisulpride, aripiprazole, risperidone or sulpiride, was associated with an 
increased risk of seizures. However, antipsychotic drug use could not be studied separately 
among patients with schizophrenia. Additionally, we were not able to further explore any 
potential dose-effect relationship of antipsychotics and seizures because in the care setting 
analyzed, antipsychotics were used at low doses only. 
The subsequent paragraphs will discuss the following two factors that I found to have a major 
impact on the results: i) the data source and ii) the observational approach used to address the 
research questions.  
4.1 Strengths and limitations of the data source 
4.1.1 Sample size limitations 
All studies carried out were based on primary care observational data provided by the U.K. 
CPRD, one of the world’s largest and best validated medial record databases.31,35,136 The 
CPRD currently encompasses anonymized data of roughly 12 million patients (about 6% of 
the U.K. population) and 64 million person-years of prospective follow-up.33,34 Due to its size 
and long history this database is suitable for studying rare outcomes and outcomes with long-
term latency periods.136  
The main topic of this thesis was the study of the occurrence of new-onset seizures, a rare 
outcome with an incidence of 0.06% per year.44,45 All studies were carried out based on a 
strongly restricted study population. Thus, despite the vast amount of data available in the 
CPRD, our analyses were limited by low sample sizes of patients who fulfilled the inclusion 
criteria. 
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The primary aim of the initial study was to describe risk factors for new-onset seizures rather 
than generate or test specific hypotheses. Including the entire population of adult patients with 
depression, the sample size for this study was not as limited as the sample sizes of the follow-
up investigations. The negative impact of small sample sizes was found to be significant in 
the second and third project, thus limiting the precision of the results.  
In the second project, the cohort of patients with depression who met the inclusion criteria 
comprised about 150,000 patients, however only 619 patients had a new-onset seizure during 
follow-up. We were only able to formally assess effect modification by a history of 
stroke/TIA, or prevalent dementia for SSRIs users. The low sample sizes in sub-analyses of 
single antidepressant drugs and potential dose-effect relationships led to low precision of the 
results.  
In the final project the cohort of patients with neuropsychiatric disorders included about 
60,000 patients, of whom as little as 583 patients experienced a new-onset seizure during 
follow-up. 
Initially we wanted to study the risk of seizures associated with antipsychotics separately for 
patients with affective disorders, schizophrenia, or dementia. The limited number of cases 
with schizophrenia however prevented the separate study of patients suffering from this 
disorder. 
Finally, most single antipsychotic drugs were too infrequently used in order for them to be 
analyzed individually and additionally, potential effects associated with the duration of 
treatment were not possible. 
4.1.2 Validity of drug exposures and medical diagnoses 
4.1.2.1 Validity of drug exposures 
Validity and completeness of recorded drug prescriptions in the CPRD is reported to be high, 
as GPs issue prescriptions directly with the computer.34,137 
However, several caveats need to be kept in mind when working with data of any medical 
records database. Firstly, prescription data are only a proxy for drug exposure, as drugs 
prescribed are not always used by the patients. Secondly, whether patients took their 
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prescribed medication as prescribed is unknown. Thirdly, although regular prescriptions at 
appropriate time intervals indicate adherence to drugs, accidental or intentional use of drugs 
in overdose cannot be ruled out.  
Medication adherence has been reported to be a problem in patients with neuropsychiatric 
disorders.138,139 However, multiple interacting factors appear to be associated with adherence 
to antidepressants and antipsychotics, reaching beyond drug tolerability.139,140  Factors 
reported to affect drug adherence include patient education, positive attitude to medication, 
illness insight, collaborative management by GPs and psychiatrists and perceived risk of 
adverse events.108,139,141 
In light of these earlier reports, non-differential non-adherence of patients prescribed different 
neuropsychiatric drug classes in the second and third project cannot be ruled out. For 
example, second-generation antidepressants have been found to be generally better tolerated 
than TCAs.142 It is thus possible that patients using second generation antidepressants exhibit 
a higher drug adherence than patients with prescribed TCAs, and thus are at a higher risk of 
adverse events such as seizures. However, no significant difference in prescription patterns of 
patients using either type of antidepressant was found. Additionally, in the study population 
analyzed, most antidepressants were prescribed on a medium to long-term basis, reducing 
potential problems with medication adherence even further. Finally, a review of randomly 
selected patient profiles revealed that for those patients who received several prescriptions, 
prescriptions were regularly noted at the appropriate times, suggesting proper use of 
medication. 
The chance that the results of the final study were altered due to differences in medication 
adherence between patients using different antipsychotic subclasses is small, as antipsychotic 
drug type does not seem to affect drug adherence.139 Additionally, while it cannot be ruled out, 
it is highly unlikely that patients suffering from dementia were adherent to every 
antipsychotic drug subclass analyzed except amisulpride, aripiprazole, risperidone, or 
sulpiride (the only drug subclass not associated with increased seizure risk in patients with 
dementia), and that patients with affective disorders were only adherent to medium to high 
potency antipsychotics (the only drug class associated with an increased seizure risk in 
patients with affective disorders). 
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Thus, it can be said that prescription data does not prove drug exposure. However, for any of 
the projects carried out during this thesis, we assumed non-adherence to drugs to be randomly 
distributed between different groups of drug users. Therefore, while randomly distributed 
non- adherence may have introduced a small bias towards the null hypothesis (i.e., no 
association between psychotropic drugs and seizures), the overall interpretation of the results 
would remain unaffected.3 
4.1.2.2 General validity of medical diagnoses 
Especially for chronic diseases, the validity of medical diagnoses recorded in the CPRD is 
regarded to be high.34,35 For example for diagnoses of schizophrenia or dementia, the positive 
predictive value (i.e., the proportion of diagnoses recorded that are confirmed by the GP to be 
correctly recorded) was estimated at 80%.86,143,144 
However, to this day, validity of diagnoses of depression, other affective disorders, and 
seizures, has not been estimated. 
For example, the positive predictive value of a depression diagnosis in primary care in general 
has reported to be only 42%.145 Moreover, only 50% of patients suffering from depression are 
identified in general practice and only about 15% of these patients receive proper 
antidepressant treatment.145 While no formal validation study of depression has been carried 
out so far with data of the CPRD, integration between primary and secondary care (a key 
feature of this database), has been shown to improve diagnostic validity of depression.141 
In our second study, we resorted to a narrow definition of depression in order to avoid 
inclusion of non-depressed persons or depressed patients with various depression severities 
(see 4.2.3). Patients with codes related to dysthymia or bipolar disorders were thus excluded 
from our analysis. These measures increased homogeneity of the study population with 
respect to the underlying disease and its degree of severity. However, since dysthymia or 
bipolar disorder can exhibit similar features as unipolar depression,146 and might not always 
be correctly distinguished from unipolar depression, a proper separation of these different 
disorders cannot be assured in this project.  
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Alternatively, to increase statistical power, one could have included patients with dysthymia 
and bipolar disorder, and perform sensitivity analyses to explore whether associations 
between antidepressants and seizures changed with different definitions of depression.34 
4.1.2.3 Validity of seizure diagnosis 
Based on the definition of epilepsy by the International League Against Epilepsy, antiepileptic 
treatment after a first seizure is justified only if the risk of seizure occurrence is ≥60% within 
the next 10 years.38,82   
Throughout this thesis new-onset seizures were defined by first-ever recorded codes of 
seizure or epilepsy in a patient’s profile, regardless of any subsequent antiepileptic treatment. 
The approach that one seizure code was sufficient for a patient to be classified as having 
experienced a seizure could have produced false positive cases.  
However, in our studies we wanted to investigate the occurrence of first ever seizures in 
association with drugs. Thus, although the requirement of a formal epilepsy diagnosis (i.e., at 
least two seizures occurring more than 24 hours apart, or at least one seizure followed by 
antiepileptic drug therapy38) could have increased the positive predictive value of seizure 
diagnoses, we would have missed persons with only one acute symptomatic seizure. 
It is well known that not all seizure types are equally well identified by patients and observers 
(see 1.2.6). Thus, although individuals who presented to secondary care or the emergency 
department after a seizure should be linked back to the CPRD, we expect not all seizures were 
captured in the patient records. Additionally, it is likely that not all seizures classified as 
newly onset were in fact first-ever seizures. 
However, we found the validity of seizure diagnosis in our studies supported by the finding 
that the incidence rate of seizure among patients with depression in remission was comparable 
with the reported incidence rate of unprovoked seizures in the general population.44,45 
Finally, any potential misclassification of seizures was likely to be distributed randomly 
across users of antidepressants or antipsychotics under investigation, introducing a bias 
towards the null hypothesis (i.e., no difference in seizure risk associated with different 
drugs).3 
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4.2 Strengths and limitations of the observational approach 
4.2.1 Chance 
All studies carried out during this thesis are based on a CPRD dataset comprising 6% of the 
U.K. population (i.e., >10 million individuals).34 Due to its large size statistically significant 
associations can be observed frequently.2,4,8 
The likelihood of false positive associations (i.e., type I error) increases however when 
multiple sub-analyses are performed on the same dataset.147,148 Adjustments can be performed 
for multiple comparisons to reduce the type I error in statistical analyses. However, 
conventional methods appear to be a poor choice since they only decrease the α-level and 
thereby the power of the study.149,150 Thus, rather than merely manipulating the cut-off that 
decides whether a finding is statistically significant or not it is considered better practice to 
disclose which analyses were carried out and discuss the reasoning underlying this 
choice.149,150  
In line with these arguments all analyses carried out throughout this thesis were of type 
hypothesis generating rather than testing. All sub-analyses (e.g., stratified analyses by age, 
sex, comorbidities) were disclosed and limitations associated with the analysis of small 
subgroups discussed. Finally, no statistical adjustment for multiple comparisons was applied.  
4.2.2 Bias 
Collected CPRD patient data are representative of the  U.K. population with regard to age, 
sex, and geographical distribution.136 
Selection bias due to non-representative sampling is limited as no segment of the U.K. 
population is excluded from being enrolled with GPs contributing data to the CPRD. Also, 
cases and controls analyzed in our studies originated from the same well-defined cohort and 
thus were comparable in many important aspects associated with underlying seizure risk.  
It is unlikely that upon usage of CPRD data information bias (e.g., measurement bias, recall 
bias, or interviewer bias) would have negatively impacted on our results, as the records were 
computerized prospectively in the context of daily clinical practice without any ulterior 
motive of answering specific research questions.  
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4.2.3 Confounding 
Unlike bias we found confounding by indication to be a limiting factor in the interpretation of 
our studies. 
In our first study we provided a coarse description of factors associated with new-onset 
seizures among patients suffering from depression. However, we did not adjust for 
confounding factors other than age, gender, calendar time, duration of history on the database 
and a proxy for depression severity. It is thus possible that associations between drug use and 
seizures were confounded by underlying indication (e.g., use of antibiotics by underlying 
infection/fever). 
Similarly, in our second project, severity of depression might have been a predictor of seizure 
risk as well as antidepressant prescription. Direct adjustment for diseases severity was not 
possible as depression severity and quantity of depression symptoms are not recorded in the 
CPRD. 
A means to validate our findings would have been to investigate association between 
antidepressants and seizures in patients with other underlying disorders (e.g., chronic pain 
disorders, obsessive compulsive disorder, anxiety disorders). This would have allowed us to 
ascertain that association patterns observed for different antidepressant classes remained 
stable across the different indications studied. However, depression is often a comorbidity of 
patients with named disorders.146 Thus it is unlikely that a sufficient number of individuals 
with records of just one of these disorders would have been available for statistical analyses. 
In our final study we assessed seizure risk associated with antipsychotics separately among 
patients with affective disorders or dementia to account for different underlying seizure risks 
correlated with these disorders.  
Our findings indicate that in patients with dementia seizure risk was similarly increased for 
patients currently using antipsychotics as for those who had used antipsychotics in the past 
compared to patients diagnosed with dementia but not yet using antipsychotics.  
It is thus possible that not actual use of antipsychotics but dementia severity leading to 
antipsychotics prescription predicted seizure occurrence. 
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4.2.4 Causality 
Causality cannot be proven based solely on observational studies. There exists however a 
series of criteria that allow assessing the likelihood of causality in studies investigating the 
association between drug use and seizures.12,56 In Table 28 these criteria are discussed with 
regard to the studies carried out in this thesis. 
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Table 28: Discussion of the criteria used to assess the likelihood of causality 12,56 with regard to the associations observed in projects 3.1-3.3 of the thesis 
Project 
Criterion Project 3.1 Project 3.2 Project 3.3 
Strength Absolute risk differences: not available 
 
Crude odds ratios: 
Strongly increased for: 
 intracerebral bleeding (OR 8.2) 
 ischemic stroke/TIA (OR 6.1) 
 dementia (OR 6.8) 
Moderately increased for: 
 alcoholism (OR 3.0) 
 drug abuse (OR 2.5) 
 schizophrenia/bipolar disorder (ORs around 
2.0) 
 current use of antiarrhythmics (OR 1.6) 
 current use of cephalosporins (OR 2.5) 
Absolute risk differences: small 
 
Adjusted odds ratios: 
Moderately increased for: 
 current use of SSRIs/SNRIs (ORs 2.0) 
 current use of mirtazapine, bupropion, 
reboxetine, or trazodone (OR 2.3) 
Not increased for: 
 current use of TCAs (OR 1.0) 
 
Absolute risk differences: moderate 
 
Adjusted odds ratios: 
Moderately increased for: 
 current use of high potency first generation 
antipsychotics in patients with affective 
disorders (OR 2.5) 
 current use of all first-generation 
antipsychotics (ORs 2.2 to 3.1) and 
olanzapine or quetiapine (OR 2.4)  in 
patients with dementia  
Not increased for: 
 current use of amisulpride, aripiprazole, 
risperidone, or sulpiride in patients with 
affective disorders (OR 0.4) or dementia 
(OR 0.9) 
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Table 28 (cont.) 
Criterion Project 3.1 Project 3.2 Project 3.3 
Consistency Similar associations reported in studies among the 
general population 51,54,56,67,85,86,103–105 
 Similar associations reported in an 
observational study among depressed 
patients aged 65 or over, using a different 
database and study design.26 
 Different associations reported in a meta-
analysis of clinical trials (decreased risk of 
seizures associated with SSRIs or SNRIs 
compared to placebo).93 
 Studies among patients with epilepsy mostly 
reported a decrease in seizure frequency 
associated with use of SSRIs or SNRIs. 151 
 Very little post-marketing evidence exists on 
seizure risk associated with antipsychotics, 
results are not comparable with ours.91,92,94 
 Meta-analysis of clinical trials reported 
supported some findings (increased risk of 
seizures in users of second generation drugs 
olanzapine or quetiapine, but not risperidone, 
compared to placebo).93  
Temporality  Reverse causality not an issue as data collection occurred prospectively and as seizures have a clearly determinable onset 
 By study design it was ascertained that exposure happened prior to the seizure 
Temporal relationship between certain comorbidities 
and seizures was evident. Temporal relationship 
between drugs and seizures not assessed (no study 
aim).  
Temporal relationship between antidepressant use and 
seizures suggested that seizures happened at treatment 
initiation. 
Temporal relationship between antipsychotic use and 
seizures could not be investigated because of low 
statistical power. 
Dose-effect 
relationship 
Not investigated in this study. Tendency for increased seizure risk with increasing 
doses of antidepressants, but low statistical power 
yielded imprecise results. 
Could not be investigated because drugs were 
generally used at low doses. 
Plausibility Most associations observed make sense, taking into 
account the evidence from the literature on risk factors 
for seizures in the general population. 
Difficult to assess: 
 Scarce evidence exists on the association between therapeutic dose ranges of psychotropic drugs as 
used in general practice settings and new-onset seizures.  
 The epileptogenic potential of psychotropic drugs is likely dose-dependent,55,56 thus studies reporting a 
high seizure risk associated with certain drug classes in overdoses are not comparable to our study. 
 The mechanisms by which drugs change excitability of neurons remain largely unknown56,57,59,135  
Abbreviations: OR, odds ratio; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin norepinephrine reuptake inhibitors; TCAs, tricyclic antidepressants; PYs, person-years.
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Many questions remain regarding a potential causal association between use of psychotropic 
drugs and seizures (see Table 28 for details).  
Well-conducted RCTs provide the strongest evidence for cause-effect relationships.8 
However, data on adverse events collected in this type of analysis is often incomplete since 
randomized control trials mostly study efficacy of drugs rather than adverse events.152  
The sole available meta-analysis of clinical trials studying the association between 
psychotropic drugs and seizures confirmed this limitation.93 In this study data on occurrence 
of seizures were not as rigorously recorded among patients assigned to placebo as patients 
assigned to active drugs rendering the results of the study questionable. 
In summary, despite its inherent limitations, observational studies can provide new insight 
when studying adverse effects of drugs as demonstrated in the different studies carried out in 
this thesis which assessed in-depth the occurrence and determinants of new-onset seizures in a 
population of patients with neuropsychiatric disorders.  
Studying this rare event as well as adjusting for important confounders was only possible 
since we were able to make use of the existing large data set, detailed patient information, and 
long follow-up data available from the CPRD. 
However, additional large pharmacoepidemiologic studies conducted by different 
investigators, using different data and study designs, assessing temporal and dose-response 
relationships in more detail are warranted to corroborate our findings.  Finally, in light of the 
results obtained it would be interesting to understand in more detail the molecular mechanism 
of how psychotropic drugs alter neuron excitability.  
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5. Outlook 
The work of this thesis provides important insight on the epidemiology of incident seizures in 
patients with neuropsychiatric disorders. Based on the results obtained in the different studies 
important follow-up questions arise.  
A key criterion of cause-effect relationships is a decline in outcome frequency once exposure 
stops.12 Results of the two follow-up studies of my thesis suggest an association between use 
of different psychotropic drug classes and an increased risk of incident seizures. In light of 
these findings it would be important to analyze the number of cases in projects 3.2 and 3.3 
who experienced recurrent seizures and/or were diagnosed with epilepsy after the incident 
seizure. Additionally, it would be important to investigate a potential association between 
recurrent seizures and/or epilepsy diagnosis and the continuation of psychotropic drug use. 
If incident seizures observed in projects 3.2 and 3.3 were causally associated with the use of 
psychotropic drugs, one would expect to observe a lower seizure recurrence rate in patients 
who stopped the drug after the first seizure compared to those who continued with it. As GPs 
participating in the CPRD are encouraged to record each event causing significant morbidity 
and each significant diagnosis,34 recurrent seizure leading to an epilepsy diagnosis or 
antiepileptic drug prescription should be recorded in the database.  
Further, it is unclear to which extend antidepressants and antipsychotics are safe with respect 
to seizure exacerbation in patients with epilepsy and psychiatric disorders.153,154 Several small 
prospective open-label trials reported no increase or even a decrease in seizure frequency 
among patients with epilepsy and comorbid depression after treatment start with SSRIs 
(mainly citalopram or sertraline) compared to prior treatment start.155–158 However, no large 
cohort studies on this topic have been conducted so far. Furthermore, no significant evidence 
on safety of antipsychotics with regard to seizure exacerbation in patients with epilepsy is 
available.154 
Thus it would be very important to assess the safety of an antidepressants and antipsychotics 
in patients with epilepsy and comorbid neuropsychiatric disorders with regard to seizure 
exacerbation. A potential challenge is that any cohort study investigating psychotropic drug 
safety in association with seizure frequency in patients with epilepsy would require a large 
number of patients with epilepsy and comorbid depression or indications requiring 
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antipsychotics therapy (e.g., schizophrenia, bipolar disorder, or dementia). Moreover, seizure 
frequency at baseline as well as each seizure frequency after drug initiation would have to be 
recorded rigorously. GPs participating in the CPRD are not required to computerize each 
recurrent event associated with a diagnosis, such as each recurrent seizure in a patient with 
diagnosed epilepsy, which makes this database unsuitable for a study like this. 
Additional drugs or drug classes acting on the CNS have been reported to have epileptogenic 
potential, such as opioids and drugs used to treat ADHD.55,56 Both drug classes have not yet 
been studied with regard to seizure risk in large population-based observational studies, but it 
would be important to know how safe they are with regard to seizure risk. 
Drugs used to treat ADHD have for example been associated with seizures when ingested in 
overdose.159 Moreover, ADHD patients have been reported to exhibit a higher risk of 
undergoing seizures compared to age-matched controls without ADHD.160 To my knowledge 
however, no evidence exists on a potential association between therapeutic use of 
methylphenidate or atomoxetine and a further increased risk of seizures in patients with 
ADHD.161,162 A study like this could potentially be conducted using CPRD data since this 
database at this moment comprises information on almost 25,000 patients with diagnosed 
ADHD, 3,600 atomoxetine users, and 22,300 methylphenidate users.  
Unlike ADHD-related drugs, an association with seizures has been reported for therapeutic 
use of different opioids, including meperidine (buprenorphine), morphine, fentanyl, and 
tramadol.55,56 An observational study published 15 years ago used CPRD data to investigate 
the association between use of tramadol, other opioids, or non-opioid analgesics, and incident 
idiopathic seizures.100 While use of all analgesic drug classes was associated with an 
increased risk of seizures compared to non-use, numbers of seizure cases analyzed were small 
rendering relative risk estimates imprecise.100 Larger study groups as provided by the CPRD 
today would facilitate to study the association between opioids and incident seizures.  
Finally, the relationship between use of antiepileptic drugs and depression in patients with 
epilepsy remains unclear. It has been reported that depressed patients develop seizures more 
frequently compared to the general population.66,67 However, patients with epilepsy also more 
often develop depression than the general population.27,66,67 This bidirectional relationship 
suggests common neurobiological features of epilepsy and depression that reach beyond the 
idea that depression merely represents a stress reaction associated with epilepsy.84,163–165 
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In line of this argument a number of risk factors for developing depression in patients with 
epilepsy have been suggested, including use of antiepileptic drugs with negative effects on 
mood.166–170 However most data on risk of  depression associated with antiepileptic drugs 
come from clinical trials,82,166–168,170–172 in which mood disorders were not the primary 
outcome measured and might not have been reported systematically. CPRD based data are 
well suited to study the relationship between antiepileptic drug use in patients with epilepsy 
and new-onset depression. In a further project we will thus study this potential relationship.
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“Our greatest weakness lies in giving up.  
The most certain way to succeed is always to try just one more time” 
Thomas A. Edison 
 
 
 
 
 
 
 
 
 
 
